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II Abstract 
 
Background:  
Angiogenesis is the process of new blood vessel formation, and is regulated by 
angiogenic growth factors including vascular endothelial growth factor (VEGF). 
Angiosarcomas are rare, aggressive vascular tumours. Studies were performed to 
investigate the expression of angiogenic growth factors in angiosarcoma, and to 
assess vascular targeted agents for the treatment of angiosarcoma.  
Methods:  
In vitro studies compared two human cutaneous angiosarcoma cell lines (ASM and 
ISO-HAS) with human dermal microvascular endothelial cells (HuDMECs). The cell 
lines were compared in functional assays, including cell viability, cell differentiaiton and 
cell migration assays, and protein expression profiled using antibody arrays.  
Cell responses to vascular targeted agents were compared, including response to 
bevacizumab an anti-VEGF antibody, axitinib a VEGF receptor (VEGFR) tyrosine 
kinase inhibitor, selumetinib a MEK inhibitor, and DMXAA a vascular disrupting agent.  
Immunohistochemistry studies measured the expression of angiogenic growth factors 
in angiosarcoma tumour specimens using benign vascular lesions for comparison, and 
assessed canine angiosarcoma as a model of human angiosarcoma.  
Results:  
ASM and ISO-HAS demonstrated accelerated growth kinetics, chaotic tubule 
formation, and increased cell migration compared to HuDMECs.  
ASM and ISO-HAS expressed significantly increased VEGF compared to HuDMECs. 
Only minor responses were observed to VEGF targeted agents in functional assays 
 
 
despite western blot studies that showed target inhibition of VEGFR2 phosphorylation,. 
Striking responses were seen however to selumetinib and DMXAA.   
Immunohistochemistry studies demonstrated benign and malignant vascular tumours 
expressed a range of pro-angiogenic growth factors, however analysis did not 
distinguish malignant from benign vascular tumours.  
The morphology of canine angiosarcoma was similar to human angiosarcoma. VEGF 
and VEGFR2 expression was significantly increased in canine angiosarcoma 
compared to benign vascular lesions. 
Conclusion:  
These studies predict limited in vivo angiosarcoma tumour response to VEGF targeted 
agents. Selumetinib and DMXAA are suggested for further study. Canine 
angiosarcomas represent a potential model of human angiosarcoma to be explored in 
future studies.  
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1 Introduction 
1.1 Angiogenesis 
Angiogenesis is the process of new blood vessel formation from existing 
vasculature[1]. It maintains vascular homeostasis, and is stimulated during 
menstruation, in wound healing, and in skeletal muscles in response to exercise. 
Physiological angiogenesis is tightly regulated by exquisite control across a spectrum 
of pro and anti-angiogenic growth factors.  
Angiogenesis is also important in a variety of pathological processes. Angiogenesis is a 
critical step in cancer progression and is one of the Hallmarks of Cancer[2]. Tumours 
are unable to grow beyond 2-3mm3 without a vascular supply, and the tumour 
vasculature also provides passage for tumour dissemination. Genetic abnormalities, 
including mutations in p53, Ras and von Hippel-Lindau (VHL), or changes within the 
tumour micro-environment, particularly tissue hypoxia, stimulate a shift to a pro-
angiogenic state. A switch to uncontrolled release of pro-angiogenic growth factors 
results in dysregulated angiogenesis and the formation of chaotic, immature, leaky 
vessels. Tumour angiogenesis is initiated early in cancer progression, and is up-
regulated even in pre-malignant conditions[3]. Numerous studies have correlated 
increasing tumour angiogenesis with a poorer prognosis[4].  
The main signalling components regulating angiogenesis are: 
 Vascular Endothelial Growth Factors (VEGF)  
 Angiopoietins 
 Platelet Derived Growth Factors (PDGF) 
 Fibroblast Growth Factors (FGF) 
 Notch 
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1.1.1 Vascular Endothelial Growth Factors 
Vascular endothelial growth factors are a family of five glycoproteins, VEGF A, B, C, D 
and placental growth factor (PlGF), with VEGFA the most important member (hereafter 
referred to as VEGF)[5]. The VEGF gene, located at chromosome 6p12, consists of 
eight exons. mRNA splice variants involving exons 6 and 7 result in different VEGF 
isoforms, including VEGF121, VEGF165, VEGF189. These isoforms have distinct matrix 
binding properties that modify their solubility and biological activity, of which VEGF165 is 
the most abundant and biologically active[6]. Exon 8 splice variants with anti-
angiogenic properties have also been described (e.g. VEGF165b)[7].  
VEGF expression may be induced in all cell types however basal expression is usually 
low. In contrast, VEGF is over-expressed in tumours. Tumour cells secrete VEGF in 
response to hypoxia, other growth factors including epidermal growth factor (EGF), 
fibroblast growth factor (FGF), platelet derived growth factor (PDGF), transforming 
growth factor (TGF)-β, interleukin (IL)-6 and oestrogen, and mutations of Ras, Src, p53 
and phosphatase and tensin homolog (PTEN)[6].  
VEGF stimulates angiogenesis through the tyrosine kinase receptors VEGFR1-3 
(figure 1.1). VEGFR1 is the most abundant VEGF receptor, and also binds VEGFB and 
PlGF. VEGFR1 is expressed by endothelial cells as both a transmembrane receptor 
and in a soluble truncated form (sVEGFR1). VEGFR1 is also expressed by monocytes, 
and stimulates macrophage infiltration of tumours. VEGF binding to VEGFR1 induces a 
weak intracellular signal, and the receptor’s primary function appears to be to trap 
circulating VEGF to limit binding to VEGFR2[8]. However, tumour secretion of VEGFB 
and PlGF displaces VEGF from VEGFR1 and so increases VEGFR2 signalling[9].  
VEGFR2 is principally expressed on endothelial cells, and is the main receptor 
mediating VEGF signalling[8]. VEGFR2 also forms complexes with neuropilin (NRP) 
co-receptors, enhancing the response to VEGF[10]. VEGFR2 activation induces 
endothelial cell survival, proliferation, migration and invasion[11]. Cell surface 
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expression of VEGFR2 is not static, but cycles within endocytic compartments[12], and 
VEGF binding to VEGFR2 also stimulates receptor ubiquitination and degradation[12]. 
VEGFR2 processing is therefore an important mechanism regulating endothelial cell 
sensitivity to VEGF. 
VEGFR3 is chiefly expressed by lymphatic endothelial cells, and is the main receptor 
for VEGFC and D. VEGFR3 is not expressed on mature vascular endothelial cells, but 
is expressed by tip endothelial cells of angiogenic sprouts[13].  
 
Figure 1.1: VEGF receptors and their ligands. 
1.1.2 Angiopoietins 
Four angiopoietin ligands have been identified (Ang1-4). Ang-1 and Ang-2 are the most 
important isoforms[14]. The angiopoietins signal through the Tie tyrosine kinase 
receptors, with Tie2 the primary receptor[14]. Tie2 receptors are principally found on 
endothelial cells, although they are also expressed on haemopoetic cells and are 
required for normal haematopoeisis[15].  
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Ang-1 is constitutively produced by pericytes[15]. Ang-1 stabilises the vasculature by 
promoting endothelial cell survival, and maintaining tight intercellular junctions between 
endothelial and perivascular cells[14, 16]. Ang-2 is produced by endothelial cells. It 
binds to, but does not activate Tie2, and antagonises Ang-1 signalling[14]. The effect of 
Ang-2 is to increase endothelial cell plasticity[14]. In the presence of VEGF this results 
in endothelial cell proliferation, but in the absence of VEGF leads to vascular 
regression[16]. Ang-2 is therefore intimately involved in vascular re-modelling[14]. 
A meta-analysis of pathology studies comparing tumour expression of Ang-1 and Ang-
2 concluded that angiopoietin expression was increased in tumours compared to 
benign controls, and that tumour expression of Ang-2 was higher than Ang-1. Ang-1 
was principally expressed by tumour cells, whilst Ang-2 was expressed by both tumour 
and tumour endothelial cells[17].   
1.1.3 Platelet Derived Growth Factors 
PDGFs consist of four homodimeric ligands, AA, BB, CC and DD, which signal through 
two tyrosine kinase receptors, PDGFRα and β[18]. The PDGFRs are closely related to 
the VEGFR family, and have a wide range of cellular functions. PDGF-BB and 
PDGFRβ are involved in the regulation of angiogenesis; PDGF-B is secreted by 
vascular endothelial cells, whilst PDGFRβ is expressed by pericytes[19]. PDGF-B 
stimulates pericyte migration and proliferation, and recruits pericytes to blood vessels 
during the process of vessel maturation[19]. 
Pericyte coverage of the tumour vasculature may protect tumour endothelial cells from 
VEGF targeted agents. Co-inhibition of VEGF signalling with agents to target PDGFRβ 
may therefore enhance the anti-angiogenic response[20].  PDGFRβ expression is not 
limited to pericytes however, and it is also expressed by stromal cells throughout the 
tumour, suggesting PDGFRβ inhibition may have broader anti-tumour effects[18]. 
Specific pathogenic abnormalities of PDGF signalling have been identified in a number 
of different tumours: a translocation between chromosomes 17 and 22, 
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t(17:22)(q22:q13.1), results in synthesis of a collagen type 1 alpha 1 (COL1A1)-PDGF-
BB fusion protein which causes dermatofibrosarcoma protuberan (DFSP) tumour 
formation[21], and activating mutations in PDGFRα have been demonstrated in a third 
of c-kit wild-type gastrointestinal stromal tumours (GISTs)[22].  
1.1.4 Fibroblast Growth Factors 
FGF stimulated angiogenesis mediates tumour resistance to VEGF targeted 
agents[23]. FGFs are a family of 22 growth factors which signal through four tyrosine 
kinase receptors (FGFR1-4). They are secreted by a variety of cell types, including 
tumour cells, and have a wide range of effects beyond promoting angiogenesis[24]. 
Endothelial cells express FGFR1 and FGFR2 through which the pro-angiogenic FGFs, 
acidic FGF (aFGF, also known as FGF-1) and basic FGF (bFGF, also known as FGF-
2), promote degradation of the extracellular matrix, and endothelial cell proliferation 
and migration[24]. As well as directly stimulating endothelial cells, FGFs also promote 
angiogenesis through the up-regulation of other pro-angiogenic pathways, including 
increased expression of VEGF and Ang-2[24]. As growth factors that stimulate a broad 
range of cellular processes, including proliferation, survival, migration and invasion, it is 
unsurprising that aberrant FGF signalling has been identified in a wide range of 
tumours[25]. Drugs to target FGF signalling are in development, including tyrosine 
kinase inhibitors (TKIs) such as Brivanib and BIBF1120, however these agents also 
inhibit VEGF and PDGF receptors[26]; newer agents under investigation including 
AZD4547 are more potent and selective inhibitors of FGFRs [27].  
1.1.5 Notch 
The Notch signalling system is an evolutionary conserved system that controls 
branching morphogenesis[28]. Notch consists of five distinct ligands, Delta-like ligand 
(DLL) 1, 3 and 4, Jagged 1 and 2, and four Notch receptors. The endothelial specific 
signalling components of Notch are DLL-1, DLL-4, Jag-1, Jag-2 and Notch 1 and 4[29]. 
Unlike other angiogenic growth factors which are secreted, both the Notch ligand and 
its receptor are bound to the cell membrane. This restricts the effects of Notch 
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signalling to cells immediately adjacent to each other. In response to endothelial cell 
stimulation with VEGF, DLL-4, expressed on the surface of the leading tip endothelial 
cell, binds to the Notch receptor in neighbouring stalk endothelial cells. This releases 
the Notch intracellular domain (NICD), which translocates to the cell nucleus to 
stimulate transcription of Notch target genes such as Hey and Hes[29]. Notch 
stimulation decreases stalk endothelial cell expression of VEGFR2, 3 and NRP1, and 
increases their expression of VEGFR1. Different receptor expression results in different 
functional responses to VEGF stimulation, with endothelial tip cells guiding angiogenic 
sprout formation and stalk endothelial cells proliferating behind[30]. 
Notch signalling is important in the development of the vasculature including tumour 
angiogenesis, but is also considered to play an important role in cancer by maintaining 
cancer stem cells. Together with Wnt and Heghehog, Notch signalling pathways form 
an inter-linked signalling network which controls stem cell differentiation and is 
dysregulated in a wide range of cancers[31]. Therapeutic agents to target Notch are 
currently in development, particularly inhibitors of γ-secretase which cleaves the Notch 
receptor to release the NCID[32].     
1.1.6 VEGF targeted therapy 
The importance of VEGF in tumour angiogenesis has led to a focus on the 
development of drugs that target VEGF. Key therapeutic agents include the humanised 
monoclonal antibody to VEGF bevacizumab (Avastin), and TKIs such as sunitinib 
(Sutent) and axitinib (Inlyta). 
1.1.6.1 Bevacizumab 
The feasibility of VEGF targeted therapy was confirmed in studies using the anti-VEGF 
antibody A4.6.1 (a bevacizumab prototype), which demonstrated no direct effect on 
tumour growth in vitro, but reduced tumour micro-vessel density (MVD) and tumour 
growth in vivo[33]. The precise mechanism through which bevacizumab exerts its anti-
angiogenic effects has yet to be fully elucidated. Suggested mechanisms include 
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inhibition of new blood vessel formation, pruning of existing immature tumour vessels, 
and functional normalisation of the tumour vasculature[34, 35]., An imaging study of 
tumour xenografts, using ex vivo micro-computed tomography and in vivo dynamic 
contrast-enhanced (DCE) ultrasound, showed anti-VEGF antibody reduced tumour 
perfusion and tumour blood volume within 24 and 48 hours of administration 
respectively[36]. In patients with colorectal liver metastasis, DCE magnetic resonance 
imaging (MRI) showed a similarly rapid reduction in tumour blood volume within just 4 
hours of bevacizumab infusion. In phase III clinical trials, in combination with standard 
chemotherapy, bevacizumab improved progression free survival in metastatic breast 
cancer and improved overall survival in metastatic colorectal cancer, advanced non 
small cell lung cancer, and advanced ovarian cancer (table 1.1). 
1.1.6.2 Tyrosine kinase inhibitors 
Protein kinases are enzymes that transfer a phosphate group from adenosine tri-
phosphate (ATP) on to tyrosine, serine or threonine residues of substrate molecules, 
which are themselves often other protein kinases[37]. Tyrosine kinases are essential 
for translating extracellular signals into an intracellular response including signals that 
promote angiogenesis. Ligand binding to the extracellular domain of tyrosine kinase 
receptors causes receptor dimerisation and phosphorylation of tyrosine residues on the 
intracellular domain. This leads to the sequential recruitment and activation of a 
cascade of intracellular signalling proteins, finishing with an end biological effect. For 
example, VEGF binding to VEGFR2 triggers receptor dimerisation and subsequent 
auto-phosphorylation of tyrosine residues including tyrosine1175. Phosphorylated 
tyrosine1175 activates phospholipase-Cγ (PLCγ) and, through protein kinase C (PKC), 
stimulates the mitogen-activated protein kinase (MAPK) pathway, Raf-MEK-ERK, 
inducing endothelial cell proliferation[38]. 
TKIs are small molecules that readily diffuse through the cell surface membrane to 
inhibit protein kinase activity and thus inhibit signal transduction. Most TKIs are 
competitive inhibitors of ATP binding. There are a number of different TKIs in clinical 
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development, each with a different profile of kinases they inhibit[39]. Sunitinib is a 
broad spectrum TKI, inhibiting VEGFR1-3, PDGFRs, KIT, FLT3, CSF-1R and RET[40]. 
Sunitinib extends overall survival in patients with renal cell carcinoma and GISTs (table 
1.2). Axitinib is more selective and principally inhibits VEGFR1-3, PDGFRs and 
KIT[41]. Axitinib has shown benefit in renal cell carcinoma, and is currently under study 
in a national phase II clinical trial for advanced soft tissue sarcoma. 
TKIs have a potential therapeutic advantage over bevacizumab, as their broad 
spectrum of activity inhibits angiogenic pathways beyond VEGF which are implicated in 
anti-angiogenic drug resistance mechanisms. Furthermore TKIs that inhibit 
angiogenesis may also inhibit tumour progression by directly targeting aberrant 
signalling pathways within the tumour cell. A broad spectrum of activity however also 
increases the potential for side effects. 
There is debate about how anti-angiogenic therapy should be integrated with standard 
treatment regimens. Vessel normalisation as a consequence of anti-angiogenic therapy 
may improve tumour oxygenation and reduce interstitial pressure, improving the 
delivery and efficacy of combined cytotoxic therapy[42]. In addition, radiation or 
chemotherapy-induced tumour cell death releases pro-survival signals, including pro-
angiogenic cytokines, which would be inhibited by concurrent anti-angiogenic therapy. 
It has also been hypothesised however that anti-angiogenic therapy could reduce the 
efficacy of concurrent cytotoxic therapy as vasoconstriction and destruction of the 
tumour vasculature, as a consequence of anti-angiogenic therapy, would decrease 
tumour perfusion with cytotoxic chemotherapy, and increase tumour hypoxia inducing 
radiation resistance[42].  
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Reference Trial Trial Design Comparison 
Patient 
Numbers 
Median PFS, 
Bz vs Control p 
Median OS, 
Bz vs Control p 
Metastatic Colorectal Cancer 
[43] Study 2107 Randomised placebo-controlled phase III IFL +/- Bz 813 10.6 vs 6.2 mths` <0.001 20.3 vs 15.6 mths <0.001 
[44] NO16966 Randomised placebo-controlled phase III XELOX or FOLFOX 
+/-Bz 
1401 9.4 vs 8.0 mths 0.002 21.3 vs 19.9 mths 0.077 
Advanced Non Small Cell Lung Cancer 
[45] E4599 Randomised open-label phase III PC +/- Bz 878 6.2 vs 4.5 mths <0.001 12.3 vs 10.3 mths 0.003 
[46, 47] AVAiL Randomised placebo-controlled phase III CG +/- Bz  
(15 or 7.5mg/kg) 
1043 6.5 or 6.7 vs 6.1 mths 0.03 or 
0.003 
13.4 or 13.6 vs 13.1 mths 0.761 or 0.420 
Ovarian Cancer 
[48] ICON7 Randomised open-label phase III 
High risk (FIGO III/IV) cohort 
Carbotaxol +/- Bz 1528 
465 
19.0 vs 17.3 mths 
16.0 vs 10.5 
0.004 
0.002 
NA 
36.6 vs 28.8 mths 
NA 
0.002 
Metastatic Breast Cancer 
[49] E2100 Randomised open-label phase III P +/- Bz 722 11.8 vs 5.9 mths <0.001 26.7 vs 25.2 mths 0.16 
[50] AVADO Randomised placebo-controlled phase III D +/- Bz 
(15 or 7.5mg/kg) 
736 10.1 or 9.0 vs 8.2 mths 0.006 or 
0.12 
NA NA 
[51] RIBBON-1 Randomised placebo-controlled phase III Cape +/- Bz or 
Tax/Anthra +/- Bz 
1237 8.6 vs 5.7 mths 
9.2 vs 8.0 mths 
<0.001 
<0.001 
      1 yr OS:   81% vs 74% 
                  81% vs 83% 
0.27 
0.83 
Metastatic Renal Cancer 
[52, 53] CALGB 90206 Randomised open-label phase III IFNα +/- Bz 732 8.5 vs 5.2 mths <0.001 18.3 vs 17.4 mths 0.097 
[54] AVOREN Randomised placebo-controlled phase III IFNα +/- Bz 649 5.4 vs 10.2 mths <0.001 23.3 vs 21.3 mths 0.336 
Recurrent Glioblastoma Multiforme 
[55]  Open-label phase II Bz 85 NA NA 9.3 mths NA 
Advanced Pancreatic Cancer 
[56] CALGB 80303 Randomised placebo-Controlled phase III Gem +/- Bz 602 3.8 vs 2.9 mths 0.07 5.8 vs 5.9 mths 0.95 
Table 1.1: Clinical trials of bevacizumab 
PFS – progression free survival; OS – overall survival; Bz – Bevacizumab; p – p value presented from hazard ratio analysis; IFL – irinotecan + fluorouracil + leucovorin; XELOX – oxaliplatin + 
capecitabine; FOLFOX – oxaliplatin + fluorouracil/folinic acid; PC – paclitaxel + carboplatin; P – paclitaxel; D – docetaxol; Cape – Capecitabine; Tax/Anthra – Taxane/Anthracycline; IFNα – interferon 
alpha; Gem – Gemcitabine; NA – not available. 
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Tumour Trial Design Comparison 
Patient 
Numbers 
Median PFS, 
 Drug vs Control p 
Median OS, 
Drug vs Control p 
Sunitinib        
Metastatic Renal 
Cancer[57, 58] 
Randomised open-label phase III Sunitinib vs IFNα 750 11 vs 5 mths <0.001 26.4 vs 21.8 mths 0.051 
GIST[59] Randomised placebo-controlled phase III Second-line Sunitinib vs 
Placebo 
312 24.1 vs 6.0 weeks <0.0001 NA 0.007 
Metastatic Breast 
Cancer[60] 
Randomised  open-label phase III P + Sunitinib vs P + Bz 485 7.4 vs 9.2 mths 0.999 NA NA 
Sorafenib        
Metastatic Renal 
Cancer[61] 
Randomised placebo-controlled 
phase III 
Second-line Sorafenib vs 
Placebo 
903 5.5 vs 2.8 mths <0.001 NA vs 14.7 mths 0.02 
Hepatocellular 
Cancer[62] 
Randomised placebo-controlled 
phase III 
Sorafneib vs placebo 602 5.5 vs 2.8 mths <0.001 10.7 vs 7.9 mths <0.001 
Advanced NSCLC[63] Randomised placebo-controlled 
phase III 
PC +/- Sorafenib 926 4.6 vs 5.4 mths 0.433 10.7 vs 10.6 mths 0.915 
Axitinib        
Advanced Pancreatic 
Cancer[64] 
Randomised placebo-controlled 
phase III 
Gem +/- Axitinib 632 4.4 vs 4.4 mths 0.520 8.5 vs 8.3 mths 0.544 
Pazopanib        
Metastatic Renal 
Cancer[65] 
Soft Tissue Sarcoma[66] 
Randomised placebo-controlled 
phase III 
Randomised placebo-controlled 
phase III 
Pazopanib vs Placebo 
 
Pazopanib vs Placebo 
 
435 
 
369 
9.2 vs 4.2 mths 
 
4.6 vs 1.6 mths 
<0.0001 
 
<0.0001 
NA 
 
12.5 vs 10.7 mths 
NA 
 
0.25 
Vandetanib        
Advanced NSCLC[67] Randomised placebo-controlled phase III Second-line  
D +/- Vandetanib 
1391 4 vs 3.2 mths <0.0001 10.3 vs 9.9 mths 0.371 
Table 1.2: Clinical trials of tyrosine kinase inhibitors 
PFS – progression free survival; OS – overall survival; p – p value presented from hazard ratio analysis;  GIST – gastro-intestinal stromal tumour; NSCLC – non small cell lung cancer; IFNα – interferon 
alpha; P – paclitaxel; Bz – Bevacizumab; PC – paclitaxel + carboplatin; Gem – Gemcitabine; D – docetaxol 
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1.2 Angiosarcoma 
Angiosarcomas are a subtype of soft tissue sarcoma, which are rare aggressive 
tumours derived from malignant endothelial cells of vascular or lymphatic origin[68]. 
Angiosarcomas are included within the spectrum of vascular tumours which ranges 
from benign capillary haemangioma and pyogenic granuloma, through intermediate 
grade haemangioendotheliomas, to the malignant Kaposi’s sarcoma and 
angiosarcoma[69]. 
1.2.1 Epidemiology 
Angiosarcomas represent 2% of all soft tissue sarcomas[70] and 5.4% of cutaneous 
soft tissue sarcomas[71]. They can arise in any soft tissue structure or viscera but 
cutaneous disease predominates (table 1.3). Clinically, angiosarcomas can be sub-
divided into primary cutaneous, breast or soft tissue disease, and secondary  
lymphoedema-associated or radiation-induced tumours[69]. Genetic analysis has 
shown that primary and secondary angiosarcoma have distinct molecular profiles[72], 
and there is clinical evidence to suggest behaviour may differ dependent on site of 
origin[73, 74]. Typically however study numbers are too small to allow extensive 
subgroup analysis, and it is not clear to what extent differences between angiosarcoma 
subgroups are due to primary biological differences, or to differences in their clinical 
presentation and subsequent treatment.  
Angiosarcomas can develop in any age group, but are more frequent in older patients. 
Classically, angiosarcomas present as cutaneous disease of the head and neck in 
white elderly men. Breast angiosarcomas however are the second most common 
tumour group, and therefore overall the distribution of disease is similar between 
sexes. 
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Table 1.3: Distribution of angiosarcoma; pooled data from 534 cases was used to 
compile this table (Fury et al[73], Mark et al[75], Abraham et al[76], Naka et al[77] and 
Fayette et al[78]).   
1.2.2 Aetiology 
Most angiosarcomas arise de novo, though there are a few reports of malignant 
transformation within a pre-existing benign vascular lesion[79]. Chronic lymphoedema 
of any origin is associated with the development of angiosarcoma, a phenomenon 
known as Stewart-Treves Syndrome[80]. Lymphoedema after treatment for breast 
cancer is one aetiological factor in the development of breast angiosarcoma. 
Radiotherapy is an independent aetiological factor with a peak incidence 10 years after 
treatment[81]. There are also case reports suggesting mutations in the DNA repair 
proteins, BRCA 1 and BRCA 2, predispose to the development of angiosarcoma 
following breast cancer therapy[82].  
Hepatic angiosarcomas are associated with occupational exposure to vinyl chloride[83] 
and thorium dioxide (Thorotrast), used in the 1930-40’s as a radiology contrast 
medium[84]. Other chemical carcinogens include arsenic, radium and anabolic 
steroids[85].  
Site Number Percentage 
Head and neck 144 27.0 
Breast 105 19.7 
Extremities 82 15.3 
Trunk 51 9.5 
Liver 32 6.0 
Heart 25 4.7 
Bone 19 3.6 
Spleen 14 2.6 
Other or unknown 62 11.6 
 
Total 534 100 
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There are reports of angiosarcoma in association with foreign bodies, including 
accidentally retained surgical gauzes[86, 87], vascular[88, 89], and orthopaedic 
prostheses[90, 91] and even in association with a gouty tophus[92].  
1.2.3 Clinical presentation 
Cutaneous angiosarcoma may initially resemble a bruise, or a purplish-red raised 
papule (figure 1.2). With increasing size these lesions are associated with marked 
tissue infiltration, surrounding oedema, tumour fungation and areas of ulceration and 
haemorrhage [69]. Deeper soft tissue lesions present as an expanding mass 
associated with pain or discomfort (figure 1.3). Tissue infiltration and multi-focal 
disease are particular features, and positive microscopic margins despite radical 
surgery are common[76, 78, 93, 94]. 
Angiosarcomas principally disseminate haematogenously and in keeping with this the 
lung is the most common site for metastases to develop. This may manifest as pleural 
disease, haemorrhagic pleural effusion or pneumothorax. Other common metastatic 
sites include liver, bone, soft tissue structures and lymph nodes[73, 75-77, 93, 95, 96].  
 
Figure 1.2: Cutaneous angiosarcoma arising in a mastectomy scar 5 years after 
surgery and radiotherapy for a primary breast cancer. 
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Figure 1.3: Hepatic angiosarcoma. CT scan showing multifocal tumour in the right lobe 
of liver (arrowed). 
1.2.4 Pathology 
Abnormal pleomorphic malignant endothelial cells are the hallmark of angiosarcoma 
(figure 1.4). They are infiltrative tumours and do not have a capsule or clear 
demarcating border separating them from normal tissue. In well differentiated areas the 
abnormal endothelial cells form functioning vascular channels, but in poorly 
differentiated areas they form continuous sheets with areas of haemorrhage and 
necrosis, and may be difficult to differentiate from anaplastic carcinoma or 
melanoma[69, 97, 98]. 
Angiosarcomas typically express endothelial markers including von Willebrand factor 
(vWF), cluster of differentiation 31 (CD31), CD34, ulex europaeus agglutinin-1 (UEA-1) 
and VEGF. vWF, UEA-1 and CD31 are most useful in poorly differentiated cases, 
although progressive tumour de-differentiation can lead to loss of these markers[99]. 
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Figure 1.4: Haematoxylin and eosin stained sections of angiosarcoma. (A) shows the 
neoplastic vascular structures dissected by collagen bundles (CB) (magnification x20); 
(B) contrasts the varied shapes of the large malignant endothelial cells (AS) with the 
endothelial cells a normal capillary vessel below (EC) (magnification x40). 
1.2.5 Treatment 
Most of the published reports of angiosarcoma treatment describe retrospective case 
series.  There are no randomised trials, and few prospective studies. To date, their 
treatment has been encompassed by management guidelines for other soft tissue 
sarcomas such as those published by ESMO[100] and NCCN[101]. 
AS 
CB 
CB 
AS 
EC 
EC 
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As rare tumours angiosarcomas present specific challanges to their study. Currently 
there are no established in vitro or in vivo models of angiosarcoma, and archived 
tumour material for molecular analysis is limited. Typically two or three patients per 
year present to the Sheffield Sarcoma Network with angiosarcoma and their rarity limits 
the feasibility of performing adequately powered randomised clinical trials. National and 
international collaborations are therefore necessary to progress clinical studies of 
angiosarcoma. Angiosarcomas have been included in larger studies of soft tissue 
sarcomas, such as the PALETTE study (Pazopanib for metastatic soft tissue 
sarcoma)[66], however patient numbers restrict sub-group analysis of trial results by 
histology. Furthermore, tumour response to therapeutic agents is usually assessed 
using Response Evaluation Criteria in Solid Tumours (RECIST)[102]. RECIST employs 
radiological measurements (CT or MRI) to assess disease response. Angiosarcomas 
however often present as superficial, cutaneous lesions and radiological assessment 
may not be helpful to assess disease. Criteria other than RECIST may be more 
appropriate including use of clinical photographs.  
1.2.5.1 Local disease 
Radical surgery with complete (R0) resection is the primary treatment of choice. 
Involved margins (R1 or R2 resection) are common due to the invasive and often multi-
focal nature of angiosarcomas[73, 76, 78, 93]. Because of the high risk of local 
recurrence, adjuvant radiotherapy is recommended using large doses (>50Gy) and 
wide treatment fields[75, 93].   
1.2.5.2 Advanced disease 
Cytotoxic chemotherapy using anthracyclines or taxanes is the primary treatment 
option for metastatic disease, although supporting evidence is limited (table 1.4). 
Taxanes have anti-angiogenic activity and have been of particular interest in the 
management of angiosarcoma.  A retrospective study of 32 patients with angiosarcoma 
reported an overall response rate of 20/32 (63%), with progression free survival of 7.6 
months[74]. The only prospective phase II study of taxane for advanced disease 
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demonstrated responses in 5/30 (17%), though two were deemed a pathological 
complete response[103]. A retrospective analysis comparing the response of 
metastatic angiosarcoma to doxorubicin with the response to weekly paclitaxel 
suggested similar efficacy[104]. 
1.2.5.3 Biological agents 
Vascular-targeted biological therapies have led to a renewed interest in 
angiosarcomas. The results from phase II clinical trials are summarised in table 1.5.   
Preliminary results from a phase II study of single agent bevacizumab in 29 patients 
with angiosarcoma showed 3 partial responses and 13 with stable disease[105].  
Tyrosine kinase inhibitors for the treatment of soft tissue sarcomas have been 
assessed in several phase II studies. The largest study, using sorafenib, included a 
cohort of 37 angiosarcomas within a larger study of 122 advanced soft tissue 
sarcomas[106]. 4 partial responses and 1 complete response were seen within the 
angiosarcoma group, giving an overall response rate of 14%.  In contrast, only one 
partial response was seen in the other sarcoma patients. Another phase II study of 
sorafenib in 41 patients with angiosarcoma reported responses in 4 (10%)[107]. Final 
results from a phase II study of sunitinib in 48 patients with metastatic soft tissue 
sarcomas included 2 patients with angiosarcoma; one partial response and 10 stable 
disease were reported, but none in angiosarcoma[108]. 
There are also scattered case reports of angiosarcoma responses to thalidomide, 
which has documented anti-angiogenic properties[109]. 
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Reference Study          
design 
Patient 
Numbers 
Chemotherapy         ORR Median 
PFS 
Median 
OS 
Comments 
[110] Review of 
RCTs 
33 Doxorubicin regimens 33% NR NR Pooled data from AS patients in four 
prospective RCTs in advanced STS 
[104] Case series 117 Doxorubicin vs 
Weekly paclitaxel 
29% vs 53% 3.0 vs 5.8 
mths  
(p>0.05) 
5.5 vs 
10.3 mths 
(p=0.002) 
On multivariate analysis performance 
status was the only factor associated with 
survival 
[73] Case series 71 Doxorubicin regimens vs 
Paclitaxel 
NR 3.7-5.4 mths 
4.0 months 
NR Taxane response for disease above and 
below the neck (6.8 vs 2.8 mths) 
[111] Case series 9 Paclitaxel 89% 5 mths NR  
[112] Case series 9 Docetaxel 67% 9.5 mths NR  
[74] Case series 32 Paclitaxel 63% 7.6 mths NR ORR 75% (PFS 9.5 mths) for face & scalp, 
ORR 58% (PFS 7 mths) for other sites 
[103] Single arm 
phase II 
30 Weekly Paclitaxel 17% 4 mths 7.6 mths  
Table 1.4: Studies of palliative chemotherapy for locally advanced or metastatic angiosarcoma  
ORR - overall response rate; PFS - progression free survival; OS - overall survival; AS - angiosarcoma; NR - not reported; RCT - randomised controlled trial; STS - soft tissue sarcoma 
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Author Evaluable Patient Numbers Treatment ORR Median PFS Median OS 
Ryan CW et al. [113] 38 STS 
Including 9 AS 
Sorafenib 
 
2 PR/ 14 SD (ORR 5%) overall 
1 PR/ 6 SD (ORR 11%) in AS 
3 months overall 
4.7 months in AS 
13 months overall 
13.5 months in AS 
Maki RG et al.[106] 122 STS 
Including 37 AS 
Sorafenib 
 
1 CR/ 5 PR/ 62 SD (ORR 5%) overall 
1 CR/ 4 PR/ 21 SD (ORR 14%) in AS 
3.2 months overall 
3.8 months in AS 
14.9 months overall 
14.2 months in AS 
Ray-Coquard et al.[107] 26 cutaneous AS 
15 visceral AS 
Sorafenib 1 CR/ 1 PR/ 4 SD (ORR 8%) 
0 CR/ 2 PR/ 4 SD (ORR 13%) 
1.8 months 
3.8 months 
12.0 months 
9.0 months 
George et al. 2009.[108] 48 STS 
Including 2 AS 
Sunitinib 1 PR/ 10 SD (ORR 2%) overall 
No responses in AS 
NR NR 
Agulnik et al. 2009.[105] 26 AS Bevacizumab 3 PR/ 13 SD 
(ORR 12%) 
NR NR 
Table 1.5: Phase II trials of biological therapies in soft tissue sarcoma, including angiosarcoma  
ORR - overall response rate; PFS - progression free survival; OS - overall survival; STS - soft tissue sarcoma; AS - angiosarcoma; CR - complete response; PR - 
partial response; SD - stable disease; NR - not reported  
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1.3 The Molecular Pathology of Angiosarcoma 
Published reports of the molecular changes in angiosarcoma typically explore the 
expression of one or two markers in a small series of tumours, with limited correlation 
to clinical or pathological features, and are usually insufficient to compare subgroups 
such as cutaneous, visceral or radiation-induced disease. Recently however, several 
studies have highlighted differences between angiosarcoma subgroups. An RNA array 
analysis of 22 angiosarcomas demonstrated, in keeping with their endothelial nature, 
up-regulated genes for VEGFR1, VEGFR2, TIE-1, and TIE-2, as well as other 
endothelial markers such as CD31 and vWF[72]. Cluster analysis suggested two 
groups of angiosarcoma – primary disease with over expression of VEGFR1 and the 
protein kinase AKT3, and radiation-induced or lymphoedema-associated secondary 
disease with increased expression of the protein kinases LYN and PKCθ. Other studies 
have confirmed differences between the genetic abnormalities of primary and 
secondary angiosarcoma, with amplifications of MYC in secondary but not primary 
disease[114].  
 
Cancer cells are characterised by a set of molecular abnormalities, the “Hallmarks of 
Cancer”[2]. These abnormalities include insensitivity to programmed cell death 
(apoptosis), aberrant growth, a propensity towards invasion and metastasis, and the 
stimulation of angiogenesis. Angiosarcomas demonstrate a variety of molecular 
abnormalities in keeping with their malignant phenotype. None of these abnormalities 
however are unique to angiosarcoma, and they have also been described in other 
cancers, including other soft tissue sarcomas[115].  
1.3.1 Chromosomal abnormalities 
Cytogenetic analysis of angiosarcomas has been published for nine cases[116]. Most 
of these samples were derived from metastases, poorly differentiated angiosarcomas 
or radiation induced tumours. In keeping with this, a wide range of disparate 
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chromosomal abnormalities have been identified, none of which are specific to 
angiosarcoma. Common themes include trisomy 5, deletions on the short arm of 
chromosome 7, varied abnormalities on chromosomes 8, 20 and 22, and loss of 
chromosome Y. 
1.3.2 Immortality 
p53 has a central role in controlling cell growth and programmed cell death. 
Abnormalities in p53 are frequently described in tumours, including angiosarcomas. 
Naka et al showed half of human angiosarcomas (17/33) had at least one mutation 
involving the p53 gene[117]. An immunohistochemistry study by Zietz et al 
demonstrated high levels of sequestered defective p53 tetramers in 10/19 (53%) of 
angiosarcomas, and p53 inactivation by increased levels of MDM2 in 13/19 (68%)[118]. 
In this study p53 and MDM2 expression did not correlate with tumour site or grade, 
although benign vascular controls demonstrated lower levels of p53 accumulation. In 
contrast, a recent study by Italiano et al found p53 mutations in only 2/52 (4%) of 
angiosarcomas. Despite this, p53 accumulation was observed in 23/46 (50%) of 
tumours, and was associated with a significantly worse prognosis[119]. 
In a genetic study of vascular abnormalities, 5/6 head and neck angiosarcomas 
demonstrated loss of heterozygosity at p53 (17p13), 4/6 at the RB allele (13q14) and 
3/5 at WT-1 (11p13)[120]. Similar abnormalities, although less frequent, were also 
identified in benign hemangiomas (3/5, 3/5, 1/5 respectively). 
1.3.3 Abnormal growth signals 
Myc is a key transcription factor, stimulating cell growth and proliferation, and is 
important in tumourigenesis. MYC amplifications have been reported in secondary but 
not primary angiosarcomas. Combined results from four studies using fluorescence in 
situ hybridisation (FISH) have shown MYC amplification in 0/54 primary angiosarcomas 
and 74/90 (82%) secondary angiosarcomas (range 55 – 100%)[114, 121-123]. 
Secondary angiosarcomas with MYC amplification were not histologically 
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distinguishable from other tumours, but were associated with co-amplification of 
VEGFR3 in 8/55 (15%)[114, 121]. 
Abnormalities in Ras, an intracellular growth signal, have been found in many different 
cancers. K-ras-2 mutations have been found in 5/19 (26%) sporadic and 2/5 (40%) 
Thorotrast induced liver angiosarcomas[124]. Liver angiosarcomas induced by vinyl 
chloride have shown similar K-ras-2 mutations (8/15)[125]. A small study of primary 
cardiac angiosarcomas demonstrated K-ras mutations in 3/5 (60%)[126].  
In vitro human umbilical vein endothelial cells (HUVECs) with inducible H-RAS 
demonstrated up-regulation of ERK and Akt signalling pathways. Functionally this was 
associated with increased HUVEC cell survival, proliferation and reduced tube 
formation in co-culture assays with fibroblasts. Up-regulated ERK controlled increased 
proliferation whilst Akt controlled vascular morphogenesis. Both ERK and Akt 
contributed to increased endothelial cell survival[127]. 
SVR cells, an immortalised murine endothelial cell line over expressing H-ras, form 
angiosarcoma tumours in vivo[128]. In vitro studies with SVR cells showed that down-
regulation of MEK (MAPKK), by using clones with dominant negative MEK or by 
inhibition of MEK with the drug PD98059, resulted in a significant reduction in colony 
formation[129]. Despite this, inhibition of MEK had no effect on in vivo tumour 
development. Wortmannin inhibition of the phosphatidylinositol-3-kinase (PI-3-kinase) 
pathway in SVR cells did result in significantly smaller angiosarcoma tumours in 
vivo[128], although independent over expression of Akt1 in murine endothelial cells 
resulted in benign vascular malformations distinct from angiosarcomas[130]. The viral 
oncogene v-p3k, of the avian sarcoma virus ASV16, codes for a gene homologous to 
the catalytic subunit of PI-3-kinase. This oncogene is implicated in the pathogenesis of 
haemangiosarcomas in chickens[131]. However, whilst mutations in the PI-3-KCA gene 
have been described in 13/33 (39%) human angiosarcomas, the PI-3KCA mutations 
 23 
 
identified were not manifest in the transcriptome, and thus were unlikely to be 
biologically relevant[119]. 
Activating transcription factor 2 (ATF2) and signal transducer and activator of 
transduction 3 (STAT3) are important downstream transcription factors involved in cell 
growth and proliferation. A study by Chen et al demonstrated over expression of 
phosphorylated ATF2 and STAT3 in cutaneous angiosarcoma (13/14 and 14/14 
respectively) compared to normal blood vessels[132]. However this study also 
demonstrated over expression in benign vascular proliferations, suggesting these 
factors were simply a measure of increased cellular proliferation rather than of 
malignancy.  
Yamamoto et al showed an increased number of mast cells in cutaneous 
angiosarcoma lesions[133]. Angiosarcoma tumour cells were shown to express stem 
cell factor and thus to recruit mast cells. Mast cells produce various cytokines including 
VEGF and FGF-2 which may in turn stimulate endothelial cells. Because of the 
success of KIT inhibitors in treating other sarcomas, particularly GISTs, investigators 
have studied KIT expression in angiosarcoma. Results pooled from three separate 
series showed KIT positivity in 38/76 (50%), with diffuse KIT expression in 18/38 
(47%)[134-136]. KIT mutation analysis has been performed for a handful of 
angiosarcomas, none of which identified activating mutations in the key juxtamembrane 
and tyrosine kinase domains, exon 11 and 17 respectively[134].  
Finally a study of epidermal growth factor receptor (EGFR) expression in soft tissue 
sarcomas included a small subset of angiosarcomas, with 3/4 (75%) demonstrating 
increased EGFR expression[137].  
1.3.4 Invasion and metastasis 
Disruption of the extracellular matrix releases sequestered growth factors, promoting 
malignant growth and facilitating tumour invasion and migration. The matrix is digested 
by a variety of different proteases, including matrix metalloproteinases (MMPs), and the 
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urokinase plasminogen activator system (uPAS). A comparative immunohistochemistry 
study of different cutaneous vascular lesions by Thewes et al, showed no evidence of 
inhibitors or activators of uPAS in 15 normal skin controls. In contrast, activators of 
uPAS were found in both benign and malignant vascular lesions. 4/4 (100%) cutaneous 
angiosarcomas showed diffuse expression of uPA, and its corresponding receptor 
uPA-R. uPAS inhibitors (PAI-1 and PAI-2) however were found only in benign vascular 
proliferations[138].  
Synthesis of the Ets-1 transcription factor is stimulated through VEGF and bFGF 
activation of ERK. Ets-1transcription factor promotes the expression of matrix 
metalloproteinases, including MMP1, MMP3, and uPA[139]. A study by Naito et al 
showed Ets-1 and MMP1 expression were increased in 7 cutaneous angiosarcomas, 
compared to hemangioma and pyogenic granuloma controls[140].   
Decreased levels of the major basement membrane components (laminin, collagen 
type IV, fibronectin and heparin sulfate proteoglycan) were also shown in 
angiosarcomas compared to benign vascular proliferations such as capillary 
hemangioma[141].  
Finally the actin bundling motility protein fascin was uniformly over expressed in a 
study of 20 angiosarcomas compared to a small control group of benign 
hemangiomas[142].  
1.3.5 Angiogenesis 
Immunohistochemistry studies have investigated the expression of VEGF and its 
receptors in angiosarcoma, but there is little data on the expression of other angiogenic 
cytokines such as angiopoietins.  
Several studies have shown VEGFA is expressed at higher levels in angiosarcomas 
compared to benign vascular or normal tissue controls. A study by Tokuyama et al 
showed VEGFA was expressed in 13/17 (76%) cutaneous angiosarcomas compared to 
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2/34 (6%) of benign vascular tumours[143], and a study by Zietz et al showed 
expression in 18/19 (95%) of angiosarcomas compared to 1/10 (10%) of benign 
vascular lesions[144]. 
The study by Tokuyama et al also reported that tumour endothelial expression of 
VEGFR2 and R3 correlated significantly with Ki-67 expression, with VEGFR2 and R3 
expression significantly increased in angiosarcomas compared to the benign vascular 
tumour controls[143]. A study of 34 cutaneous and soft tissue angiosarcomas by 
Itakura et al however demonstrated increased expression of VEGFR2 was associated 
with an improved survival, whilst VEGFR1 and R3 expression were not related to 
outcome[145].  A study by Yonemori et al in a separate panel of 34 angiosarcomas 
confirmed VEGFR2 expression correlated with survival, whilst PDGFRβ expression 
was inversely related to survival; VEGFR1, R2, R3, and PDGFRα and PDGFRβ 
expression were not associated with tumour site or size[146]. These studies suggest 
tumour cell expression of VEGFR2 in angiosarcoma is a marker of endothelial 
differentiation, rather than a pathogenic feature. 
Murine endothelial cells (MS1) transfected with VEGF 121 over-expressed VEGFR1 
and VEGFR2 in comparison to the parent cell line[147]. Inoculation of the MS1-VEGF 
cell line into nude mice produced slow growing well-differentiated angiosarcomas 
similar to, although less rapidly growing than those formed by the Ras modified MS1 
(SVR) cell line.  
No evidence of increased copy numbers of VEGFR2 were observed by FISH in 9 
angiosarcoma patients studied by Antonescu et al[72]. Point mutations were identified 
in 4/39 (10%) angiosarcoma patients; 2 primary breast angiosarcoma had point 
mutations in the transmembrane domain of VEGFR2 (exon 16 T771R) and 2 radiation-
induced breast angiosarcoma had mutations, one in the extracellular domain (exon 15 
D717V) and one in the kinase domain (exon 24 A1065T). Transfection of COS-7 cells 
with D717V or A1065T mutated VEGFR2 demonstrated constitutive phosphorylation in 
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the absence of VEGF stimulation. VEGFR2 autophosphorylation was sensitive to 
tyrosine kinase inhibition with either sorafenib or sunitinib.  
The expression of angiopoietins in angiosarcoma is less well studied. The Tie2 kinase 
inhibitor 4-(6-methoxy-2-naphthyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1 H-
imidazole inhibited SVR and MS1-VEGF cell viability in vitro, and inhibited 
angiosarcoma tumour growth in vivo[148]. In this study, sunitinib also inhibited SVR 
and MS-1 tumour growth in vivo, and combination therapy with the Tie2 kinase inhibitor 
was more effective than either agent alone[148].     
Wang et al investigated the effects of introducing a point mutation into the Tie2 kinase 
domain (a glycine to aspartic acid substitution at residue 833 found in 22% (8/37) of 
human intramuscular haemangiomas) of the murine endothelial cell line MSS31[149]. 
Compared to wild type MSS31, endothelial cells with the Tie2 mutation showed no 
significant difference in Tie2 protein expression, but demonstrated an increase in Tie2 
phosphorylation and increase in VEGF expression. Interestingly, in vivo the Tie2 
mutant cell line produced angiosarcomas rather than haemangiomas.  
There is minimal evidence for the role of other pro-angiogenic factors in the 
development of angiosarcomas. An immunohistochemistry study of 7 cutaneous 
angiosarcomas by Yamamoto et al identified increased expression of FGF-2 and its 
receptor compared to normal skin controls, with serum FGF-2 also elevated in 4/7 
(57%)[150]. DNA abnormalities in the Notch signalling pathway have been identified in 
a small series of angiosarcoma patients[151]. Interestingly, pan inhibition of Notch 
signalling resulted in liver sinusoidal endothelial cell proliferation, intussusceptive 
angiogenesis, and the formation of hepatic vascular abnormalities, including 
angiosarcomas, in vivo[152, 153]. 
In summary, angiosarcomas are rare aggressive tumours of endothelial cells. A variety 
of molecular abnormalities have been described, none of which are specific to 
angiosarcoma.  
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1.4 Hypothesis 
It was hypothesised that angiogenic growth factors drive the biology of angiosarcomas, 
and represent targets for the treatment of angiosarcoma. 
1.5 Aims 
A series of laboratory studies were planned to investigate this hypothesis: 
 To characterise established angiosarcoma cell lines, and tumour cell 
isolates derived from fresh angiosarcoma tumour samples, and to compare 
them with primary cell cultures of dermal microvascular endothelial cells. 
 To profile endothelial cell expression of angiogenic cytokines, and to 
compare their behaviour in functional assays including cell differentiation 
and cell migration assays.  
 To assess the in vitro response to vascular targeted therapies in functional 
assays including cell viability, cell differentiation and cell migration assays. 
 To compare the expression of angiogenic growth factors and their receptors 
in a panel of angiosarcoma tumour samples using a series of benign 
vascular tumours as a control.  
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2 Methods 
2.1 Cells 
The online catalogues of the American Type Culture Collection (ATCC), the Health 
Science Research Resources Bank (Japanese Collection of Research Bioresources – 
JCRB) the German Collection of Microorganisms and Cell Cultures (Deutsche 
Sammlung von Mikroorganismen und Zellkulturen – DSMZ), and the published 
literature were searched to identify malignant endothelial cell lines as potential in vitro 
models of angiosarcoma. 
The cell lines subsequently obtained were: 
i) ASM – provided courtesy of Professor V Krump-Konvalinkova, Institute of 
Pathology, Johannes Gutenburg University Mainz, Germany. The cell line 
was developed from an 80 year old male with primary cutaneous 
angiosarcoma of the scalp[154]. ASM cells were cultured in Endothelial Cell 
Growth Media (ECGM; PromoCell) with ECGM Supplement Pack 
(PromoCell) plus 10% fetal calf serum (FCS; Gibco), 0.5% v/v penicillin, 
0.5% v/v streptomycin and 0.5% v/v amphotericin. 
ii) ISOS-1 – provided courtesy of Professor M Masuzawa, Cell Resource 
Centre for the Biomedical Research Institute of Development, Aging and 
Cancer, Tohoku University, Japan. This cell line was developed from an 84 
year old male with locally metastatic cutaneous angiosarcoma of the scalp 
by subcutaneous implantation of tumour fragments into severe combined 
immunodeficient (SCID) mice[155]. The cell line derived from the resultant 
growth, designated ISOS-1, expressed murine major histocompatibility 
complex (MHC) class I antigens and murine telocentric chromosomes. 
ISOS-1 cells were cultured in Dulbecco’s modified Eagle’s media (DMEM; 
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Lonza) plus 10% FCS, 0.5% v/v penicillin, 0.5% v/v streptomycin and 0.5% 
v/v amphotericin. 
iii) ISO-HAS – provided courtesy of Professor M Masuzawa. The cell line was 
developed concurrently with ISOS-1 from the patient described above[156]. 
As per its developmental protocol ISO-HAS was initially grown in ISOS-1 
conditioned media: ISOS-1 cells were grown to confluency in DMEM media, 
and this media was collected at 72 hours and passed through a 0.2μm filter. 
Complete ISO-HAS media consisted of 50% ISOS-1 conditioned media in 
combination with 50% fresh DMEM supplemented with 10% FCS, 0.5% 
penicillin, 0.5% streptomycin and 0.5% amphotericin to total volume. After 
initial passages, flasks of ISO-HAS cells were conditioned for four weeks in 
100% DMEM with 10% FCS, 0.5% penicillin, 0.5% streptomycin and 0.5% 
amphotericin, or ECGM as described for ASM. ISO-HAS growth was poor in 
100% DMEM, and cell morphology altered to a spindle shape. ISO-HAS 
grown in ECGM remained healthy with similar growth kinetics. Therefore, 
following initial studies, ISO-HAS was grown in ECGM media, 
supplemented as described for ASM. ISO-HAS cells were well-maintained 
under these conditions and this allowed for direct cell comparisons in 
subsequent studies. 
iv) SVR – purchased from ATCC. The SVR cell line was developed from a 
primary murine endothelial cell line (MS-1) transfected with retrovirus 
encoding SV40 large T antigen and H-Ras[128]. In vivo SVR produces 
haemorrhagic tumours consistent with well differentiated angiosarcomas. 
SVR was grown in DMEM media supplemented with 10% FCS, 0.5% v/v 
penicillin, 0.5% v/v streptomycin and 0.5% v/v amphotericin. 
v) EAhy926 – provided courtesy of Dr Edgell, University of North Carolina, 
USA. EAhy926 was formed by fusion of the lung cancer cell line A549 with 
human umbilical vein endothelial cells (HUVECs)[157]. In vitro these 
transformed cells express vWF, CD31, VEGFR1, VEGFR2, and form cord-
 30 
 
like structures on the extracellular matrix Matrigel, consistent with an 
endothelial phenotype[158]. EAhy926 cells were cultured in DMEM media 
with 10% FCS, 0.5% v/v penicillin, 0.5% v/v streptomycin and 0.5% v/v 
amphotericin. 
Adult human dermal micro-vascular endothelial cells (HuDMECs) were sourced as 
experimental controls. HuDMECs were purchased from Promocell and grown in ECGM 
media and ECGM Supplement Pack. Human dermal fibroblasts (HDFs) and human 
umbilical vein endothelial cells (HuVECs) were used in several studies. HDFs were 
kindly donated by Dr Canton, Kroto Research Institute, University of Sheffield, who 
purchased them from ATCC (PCS-201-010). HDFs were grown in DMEM media with 
10% FCS, 0.5% v/v penicillin, 0.5% v/v streptomycin and 0.5% v/v amphotericin. 
HuVECs were kindly provided by Dr Holmes, Microcirculation Research Group, 
University of Sheffield who sourced them from Promega. HuVECs were grown in 
endothelial basal media (EBM-2; Lonza) with 10% FCS. 
Unless otherwise stated, all cells were cultured in T75 flasks (Nunc) within a humidified 
incubator (SANYO), in 21% O2, 5% CO2, at 37
oC. Flasks were regularly monitored to 
assess cellular health.  Media was changed every 2 or 3 days; the old media was 
discarded, cells washed with phosphate buffered saline (PBS; Lonza), and 10mls of 
fresh growth medium applied. Cells were passaged as they approached confluency. 
Old media was removed and the cells washed with PBS. 2mls of trypsin 0.05% (Lonza) 
were added and the flask returned to the incubator for 1 – 2 minutes. Flasks were 
viewed under a microscope and cell detachment assisted if necessary with a gentle 
tap. Trypsin was neutralised with an equal volume of growth media and the cells 
divided, typically 1:3, between new flasks with 10mls of fresh growth media added.  
For primary endothelial cell cultures (HuDMECs and early cell passages from 
angiosarcoma tumour samples), cells were passaged using Promocell trypsin solution 
and trypsin neutralising solution. Cell suspensions were transferred to a 15ml tube and 
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centrifuged at 1000 x g for 3 minutes. The supernatant was tipped off, and cells re-
suspended in fresh media, and split (1:3) into new flasks. 
2.2 Characterisation Studies 
2.2.1 Immunocytochemistry characterisation 
Immunocytochemistry studies were performed to demonstrate the expression of 
endothelial cell markers including CD31, CD34 and vWF. CD31, also known as platelet 
endothelial cell adhesion molecule (PECAM-1), is a transmembrane glycoprotein cell 
adhesion molecule expressed by endothelial cells, platelets and inflammatory 
cells[159]. CD34 is a transmembrane glycoprotein and a haematopoietic stem cell and 
endothelial progenitor cell marker[159]. vWF is stored in Weibel-Palade bodies of 
endothelial cells and also expressed by platelets. It stabilises factor VIII and is 
important for thrombus formation[159]. 
2.2.1.1 Slides 
Slides of each cell line were created for immunocytochemistry profiling. Semi-confluent 
flasks of cells were trypsinised, centrifuged and then re-suspended in 10mls of full 
media. Clean glass slides were placed in large petri dishes and 1ml of cell suspension 
pipetted on to each slide. Slides were incubated overnight, washed briefly in PBS and 
fixed in ice-cold methanol at –20oC for 10 minutes. Slides were air dried and stored in 
cardboard racks covered in aluminium foil at –20oC until used. 
2.2.1.2  Immunocytochemistry protocol 
Slides prepared as above were washed for 3 minutes in PBS. 10% blocking serum in 
PBS was applied to each slide and incubated at room temperature for 1 hour. Primary 
antibodies in 2% serum were applied and incubated at 4oC overnight (Table 2.1). 
Following this, slides were washed twice for 5 minutes in PBS, 0.1% Tween (PBST). 
Secondary antibodies in 2% serum were applied and slides incubated at room 
temperature for 1 hour (Table 2.1). Slides were again washed twice for 5 minutes in 
PBST before ABC Elite solution (Vector Laboratories) was applied for 40 minutes. 
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Slides were washed twice for 5 minutes in PBST and then DAB solution (Vector 
Laboratories) was applied for 3 minutes. Slides were washed in tap water for 5 
minutes, stained with Gills Haematoxylin for 1 minute, and then washed in running tap 
water for 3 minutes. Finally slides were dehydrated in successive ethanol baths using 
70%, 90%, 95% and 100% ethanol, 2 minutes each, followed by a xylene bath for 5 
minutes. Coverslips were affixed using DPX. Pilot studies were performed to optimise 
the procedure and determine the final antibody concentration for each antigen until a 
working protocol was finalised. 
Slides of ASM and ISO-HAS cells were stained and scored for the expression of 
endothelial cell markers. Slides of HuDMEC cells were used as a positive control and 
slides of HDF cells as a comparison. Slides of HuDMEC cells incubated with PBS 
rather than the primary antibody were used as a negative control. Each slide was 
studied to calculate a staining score: a score for the proportion of stained cells (0 = 
<1%, 1 = 1-10%; 2 = 11-50%; 3 = >50%) was summed with a score for the staining 
intensity (1 = weak, 2 = moderate, 3 = strong) to provide a total score (range 0-6). 
Immunocytochemistry studies were performed three times using slides of cells from 
different passages, and a mean staining score for each marker was calculated.  
 
Antibody Primary Secondary 
CD31 (sc-0.N.100) 1:50 1:250 
CD34 (sc-19587) 1:50 1:250 
vWF (sc-53466) 1:50 1:250 
αSMA (ab5694) 1:300 1:500 
VEGF (sc-152) 1:100 1:200 
VEGFR1 (ab2350) 1:50 1:200 
VEGFR2 (ab39256) 1:100 1:200 
Table 2.1: Concentration of antibodies used in immunocytochemistry characterisation 
studies 
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2.2.1.3 Permanox slides 
ASM and ISO-HAS exhibited a mixed morphology in tissue culture, and 
immunocytochemistry studies suggested a mixed pattern of staining. Cell morphology 
however was not maintained on glass slides. In order to correlate cell morphology with 
immuno-staining, cells were grown on plastic 4-chambered Permanox slides (Lab-Tek). 
These slides permitted cells to be grown directly on the slides, and the four chamber 
system allowed concurrent staining with four different antibodies on one slide. 30,000 
cells in 0.75mls full growth media were seeded into each chamber and incubated at 
37oC. Permanox slides of ASM, ISO-HAS, and HuDMECs were established. Growth 
was observed over several days and the media replenished at 48 hours. Cell growth 
was very slow however, and the majority of cells were non-adherent. Permanox slides 
were fixed in ice-cold methanol for 10 minutes after 72 hours. Fixed cells were stained 
for CD31, CD34, vWF and αSMA as per the protocol in 2.2.1.2. Staining quality was 
also poor and this methodology was not pursued further.  
2.2.2 Flow cytometry 
Flow cytometry studies were performed to investigate the expression of CD31, VEGF, 
VEGFR1 and VEGFR2 in ASM and ISO-HAS in order to demonstrate the presence of 
cell sub-populations indicated in the immunocytochemistry studies. 
Flow cytometry measures the scatter of light directed through a stream of cells to 
quantify their attributes. Light detectors collect data on forward scatter (FSC), a 
measure of cell size, and side scatter (SSC), a measure of cell granularity. 
Flurochromes excitated by light present distinct emission spectra, and so antibodies 
labelled with different fluorochromes are used to simultaneously assess the expression 
of different cellular antigens[160]. Data collected can be presented as a dot plot (also 
known as a cytogram) (Figure 2.1), or as a histogram (Figure 2.2). 
 
 
 34 
 
 
 
Figure 2.1: Cytogram of unstained ISO-HAS cells plotting forward scatter (FSC) 
against side scatter (SSC). Subsequent results were gated to a main study population 
(shown in red) to reduce signal noise, particularly from non-viable cells. 
 
Figure 2.2: Histogram showing a population shift in fluorescence intensity from a 
median of 432 to 1,104 demonstrating the presence of bound PE-Cy7 labelled antibody 
(in this case CD31). 
Prior to their use in flow analysis, primary antibodies were prepared by conjugating 
them to a fluorochrome (table 2.2) using the Lightning Link Conjugation Kit (Innova 
Biosciences).  As per manufacturer instructions, 1µl of Lightning Link Modifier reagent 
was added per 10µl of antibody and mixed gently. 10µgs of Lightning Link Mix were 
added to the antibody and incubated for 3 hours in the dark at room temperature. 1µl of 
Lightning Link Quencher was added per 10µl of antibody and the vials of conjugated 
antibodies were wrapped in aluminium foil and stored at 4oC until used.  
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Semi-confluent T175 flasks of cells were washed in PBS twice, trypsinised, centrifuged, 
and re-suspended in flow cytometry buffer solution (PBS with 1% FCS). 500,000 viable 
cells were aliquoted into tubes, centrifuged and re-suspended in 200µls of buffer 
solution. Separate tubes were established to analyse cells without the addition of 
antibody, with each individual antibody, and with a combination of the four conjugated 
primary antibodies (table 2.2). Tubes were incubated on ice for 30 minutes following 
the addition of antibody. Then, cells were washed twice, re-suspended in 300µls of 
buffer solution, and transferred to flow cytometry tubes for analysis. Flow cytometry 
was performed using a BD LSR II analyser and BD FACS Diva Software (version 6.0). 
Preliminary studies were performed using a series of increasing antibody 
concentrations to optimise the protocol, including antibody concentrations beyond that 
which induced a maximum cell population shift, indicating antigen-antibody specific 
binding. 
Antibody Fluorochrome Emission 
Spectra 
Volume of antibody 
per 500,000 cells (µl) 
CD31 (sc-0.N.100) PE-Cy7 Blue 780/60-A 2.5 
VEGF (sc-152) PerCP-Cy5.5 Blue 695/40-A 2.5 
VEGFR1 (ab2350) RPE (R-Phycoerythrin) Blue 575/26-A 5 
VEGFR2 (ab2349) APC (Allophycocyanin) Red 660/20-A 5 
Table 2.2: Fluorochromes and volume of antibody used. 
2.2.3 Dil-Ac-LDL 
Dil-Ac-LDL is an acetylated-low density lipoprotein labelled with the fluorescence 1,1’-
dioctadecyl-3,3,3’,3’-tetramethyl-indocarbocyanine perchlorate, and is selectively taken 
up by macrophages and endothelial cells via the receptor-mediated scavenger cell 
pathway. Dil-Ac-LDL is metabolised in lysosomes, and the fluorescent probe 
accumulates in the lysosome intracellular membrane[161].  ASM and ISO-HAS uptake 
of Dil-Ac-LDL was compared with HuDMEC and HDF cells to confirm their endothelial 
nature. 
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Semi-confluent flasks of cells were washed in PBS twice. 2mls of growth media with 
Dil-Ac-LDL (Biomedical Technologies Inc) 10µg/ml were added and cells were 
incubated at 37oC for 4 hours. The Dil-Ac-LDL media was removed and flasks were 
washed twice in PBS. 2mls of normal growth media (Dil-Ac-LDL free) were added and 
fluorescent cells were observed through a Leica DM IL microscope.    
2.3 Functional Assays 
In vitro studies were performed to compare ASM and ISO-HAS cells with HuDMECs in 
functional assays: 
2.3.1 Growth kinetics 
Preliminary studies were performed with HuDMECs, ASM, and ISO-HAS to compare 
their growth curves: 30,000 viable cells in 1ml were seeded in 12-well plates in full 
growth media. Viable cell counts were calculated at 24, 48, 72 and 96 hours. 
Supernatant from the wells were collected in individual 15ml tubes. Wells were washed 
with PBS, trypsin applied, and the wells monitored until the cells had detached. Cells 
were collected, the wells rinsed twice and these washes collected. The tubes were 
centrifuged at 1000 x g for 3 minutes, the media was tipped off and the cells re-
suspended in 1ml of fresh media. Cells were counted using the Beckman Coulter Vi-
CELL, and the %viability, viable and total cell count recorded.  3 wells were assessed 
at each time point and a mean cell count calculated. At 48 hours uncounted wells were 
washed and replenished with equal volumes of fresh media.   
2.3.2 Differentiation 
Endothelial differentiation assays were used to model the angiogenic process in vitro, 
including endothelial cell attachment, migration, alignment and tubule formation[162]. 
For these studies, semi-confluent T75 flasks of cells were starved overnight in EBM-2 
media with 1% FCS. Meanwhile, a 96-well plate and cassette of 200µl pipette tips were 
chilled at -20oC, and aliquots of growth factor reduced basement membrane matrix 
(Matrigel; BD Biosciences) defrosted overnight on ice at 4oC. Then, 40µls of matrigel 
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were added to wells of the 96-well plate and incubated at 37oC for half an hour. 10,000 
viable cells in 100µls media +/- 50ng/ml carrier free recombinant VEGFA165 (R&D 
Systems) were added to wells, a minimum of 3 wells per condition. Tubule formation 
was assessed at 6 hours. The well centres were imaged, and the number of tubules 
formed and the tubule length counted manually. 
Pilot studies were performed to establish the optimum conditions for endothelial tubule 
formation. Studies were performed with cells in full growth media using cell seeding 
densities of 15,000, 20,000 and 25,000 cells per well with serial images taken at 4, 6, 
8, 12 and 24 hours. These preliminary studies showed analysis of HuDMEC 
differentiation at seeding densities greater than 15,000 cells per well was limited by 
large islands of proliferating cells. In contrast, optimum ASM and ISO-HAS tubule 
formation in these preliminary studies required 25,000 cells per well. The number of 
tubules formed peaked after 6 – 8 hours, and rapidly regressed thereafter (figure 2.3).  
 
Figure 2.3: Number of tubules formed in the differentiation assay using ASM cells at 
25,000 cells per well in full media. Data shown represents mean of 3 wells (n=1). 
Preliminary studies to compare tubule formation between cell lines and investigate 
response to the TKI axitinib were performed using 15,000 HuDMECs per well and 
25,000 cells per well of ASM and ISO-HAS, +/- 20ng/ml VEGF, with cell differentiation 
assessed at 8 hours. These preliminary studies showed no evidence of increased 
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tubule formation in response to VEGF stimulation and no significant effects of axitinib 
50ng/ml (figure 2.4). Repeat assays were performed to validate these findings, and to 
extend the doses of axitinib up to 250ng/ml with VEGF increased to 50ng/ml. These 
studies were performed using ASM and ISO-HAS cells recovered from a different vial 
of cryo-preserved cells frozen down at an earlier passage. These, and subsequent 
cells, formed extensive islands of proliferating cells at 25,000 cells per well, and the 
protocol was modified to 10,000 cells per well of HuDMECs, ASM and ISO-HAS, with 
tubule formation assessed at 6 hours and these conditions were maintained in all 
subsequent differentiation assays.             
 
Figure 2.4: Number of tubules formed in preliminary endothelial differentiation studies 
with HuDMECs 15,000 cells/well, ASM and ISO-HAS 25,000 cells/well, axitinib 50ng/ml 
and VEGF 20ng/ml. Data shown represents mean +/- SEM; n=3. 
2.3.3 Migration 
Cell migration may be assessed in vitro by several different methods[163]. The scratch 
assay requires a monolayer of cells to which a ‘wound’ (scratch) is applied. Serial 
images to measure gap closure are used to assess migration. Addition of an anti-
proliferative drug such as Mitomycin-C is used to exclude gap closure due to cell 
proliferation. Problems with this assay include difficulties in consistently producing a 
uniform scratch, the absence of a chemokine gradient, and toxicity from adding the 
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anti-proliferative agent. Alternatively, both cell migration and cell invasion (which also 
requires digestion of an extracellular matrix) can be assessed using a chamber system 
such as the Boyden chamber. This assay measures the movement of cells from an 
upper to a lower chamber, across a matrix coated porous membrane. 
Chemoattractants may be added to the lower chamber to mimic migration in vivo along 
a chemokine gradient. The assay is fiddly to set up however, and laborious to quantify.  
The Boyden chamber was used in these studies: Cells were starved overnight in EBM-
2, 1% FCS. The Boyden chamber was washed, thoroughly dried and placed in an 
incubator at 37oC. Polycarbonate porous membranes (25 x 80mm, 8μm pores; 
NeuroProbe) had the bottom right hand corner clipped for orientation. 20μls of 1mg/ml 
collagen IV (Sigma Aldrich) were mixed in 2mls PBS. The membrane was immersed in 
this collagen IV solution for 10 minutes each side and allowed to air dry. The 
membrane was then immersed in EBM-2, 1% FCS media, for 10 minutes each side, 
and again allowed to dry. Meanwhile, cells were trypsinised and re-suspended to form 
a suspension of 300,000 viable cells/ml in EBM-2, 1% FCS media. 30μls of EBM-2, 1% 
FCS media +/- 20ng/ml recombinant VEGF were then added to lower wells. The dry 
porous membrane was carefully placed across the lower wells, and the top plate 
secured in place. 50μls (15,000 cells) of cell suspension were added to the upper wells 
with a minimum of 6 wells established for each condition. The chamber was incubated 
for 4 hours, then the Boyden chamber plates were separated and the membrane 
carefully removed. The upper surface of the membrane was scraped and washed in 
PBS to remove adherent cells that had not migrated through. The membrane was fixed 
in methanol for 5 minutes, stained with Gills Haematoxylin for 5 minutes and washed in 
PBS for a further 5 minutes. The membrane was placed on glass slides and a coverslip 
affixed using DPX. Once dry, migration was assessed. The lower surface of the 
membrane was viewed at x4 magnification to locate the well centres and then imaged 
at x20 magnification. Cells were counted manually. Those with a complete nucleus 
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visible at the photograph margins were included in the count. An average migration 
count from 3 wells was calculated for each condition.  
Initial assays were performed with 10,000, 15,000, 20,000 and 25,000 ASM and ISO-
HAS cells/well to optimise the assay conditions. 
2.3.4 In vivo tumour formation 
Preliminary studies were performed to assess ASM and ISO-HAS tumour formation in 
vivo. These studies were performed by Sapna Lunj under the Home Office Project 
Licence PPL40/3531. Female CD1 nude mice were purchased from Charles River 
Laboratories. 5 x 106 viable ASM or ISO-HAS cells in 0.5mls PBS, were injected 
subcutaneously into the mammary fat pads of the nude mice, six animals for each cell 
line. The animals were then followed over 8 weeks. Their general health and weight 
were monitored, and the inoculation sites checked for cutaneous tumour formation. 
Macroscopic tumours did not develop, and the animals remained healthy and active 
throughout. They were culled after 8 weeks with no evidence of gross pathology.    
2.4 Protein Expression Profiling 
2.4.1 Protein arrays 
R&D Systems protein arrays (ARY 001, 003, 007) were used to investigate the 
expression of 55 angiogenesis related proteins, 42 phosphorylated receptor tyrosine 
kinases (pRTK) and 46 phosphorylated tyrosine/serine/threonine kinases (pTK) in cell 
lysates. The expression of angiogenic proteins was also investigated in cell 
supernatants. The arrays were similar in principle to the sandwich enzyme-linked 
immunosorbent assay (ELISA). Briefly, they consisted of nitrocellulose membranes 
with duplicate spots of antibody for each individual protein. Study samples were added, 
followed by a second antibody with a horseradish peroxidise (HRP) tail. 
Chemiluminescence was applied and the membranes then imaged. Spot densities 
subsequently developed in proportion to the quantity of bound protein. 
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These studies were performed according to supplied manufacturer instructions; the 
method for the angiogenesis array is described below, but pTK and pRTK array 
methods were similar. First, the membranes were washed in array buffer (supplied) for 
1 hour at room temperature during which time equivalent quantities of study sample 
proteins were incubated at room temperature with array buffer and biotinylated 
detection antibody mix (supplied). The membranes were then incubated overnight at 
4oC with the study sample/antibodies, and subsequently washed for 10 minutes three 
times in wash buffer (supplied). Streptavidin-HRP (supplied) was diluted in array buffer 
and added to the membrane and then incubated for 30 minutes at room temperature. 
The membranes were again washed in wash buffer for 10 minutes three times, and 
then incubated with Immobilon Western Chemiluminescent HRP substrate (Millipore) 
for 3 minutes in a dark room. The arrays were arranged in a Hypercassette and 
exposed to Amersham Hyperfilm ECL (GE Healthcare) for up to 10 minutes and the 
film developed.  The film was scanned and peak density measured for each antibody 
spot on the protein array using a GS-710 Callibrated Imaging Densitometer (Bio-Rad) 
and Quality One (version 4.6.8) 1-D image analysis software. An average peak density 
for each protein was calculated from the paired duplicate spots, a background reading 
was subtracted, and the density then presented as a ratio of the averaged peak 
densities from the positive control spots. An example image of a protein array study is 
shown in figure 2.5. 
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Figure 2.5: Example image of an array to assess the expression of angiogenesis 
related proteins in HuDMEC, HDF, ISO-HAS and ASM cell lysates.   
To generate the cell lysate samples for analysis, T75 flasks of semi-confluent cells 
were starved overnight in EBM-2 media with 1% FCS.  Lysis buffer was created 
according to 1% NP-40, 20mM Tris-HCL (pH 8.0), 137 mM NaCl, 10% glycerol, 2mM 
EDTA, Complete Mini EDTA-free protease inhibitor cocktail tablets (Roche) +/- 
PhosSTOP phosphatase inhibitor cocktail tablets (Roche) for the pRTK arrays. The 
lysis buffer was mixed, aliquoted and stored at -20oC until use. Lysis buffer supplied 
with ARY 003 was used for the pTK array.  
Flasks were washed in PBS, 500µls of lysis buffer were added, and the flasks gently 
rocked on ice for 20 minutes. Flasks were scraped and the lysate collected and 
transferred to 1.5ml eppendorf tubes. The lysate was agitated through a 22 gauge 
needle and then centrifuged at 4oC for 5 minutes at 14,000 rpm. Lysates were stored at 
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-80oC until use. Prior to use, quantification of protein content in the cell lysates was 
performed using protein standards of 0.0, 0.05, 0.25, 0.5, 0.75 and 1.0mg/ml from 
Bovine Serum Albumin (BSA) 2mg/ml (Sigma-Aldrich) diluted with lysis buffer. 20µl’s of 
standard or sample were aliquoted in triplicate in a 96 well plate and absorbance 
measured at 570nm using a FLUOstar Galaxy plate reader after 30 minutes incubation 
at 37oC following the addition of 200µl of bicinchoninic acid and copper II sulphate 
solution (8mls BCA to 200µl CuSO4; Sigma-Aldrich). Absorbance readings from the 
BSA standards were used to plot a standard absorbance curve from which the protein 
concentration in the study samples was calculated. 
The expression of angiogenic proteins in hypoxic conditions was also investigated in 
cells starved overnight in EBM-2, 1% FCS in a hypoxic chamber (1% O2). Cell lysates 
were generated as described above. For investigating angiogenic protein expression in 
cell supernatant, T175 flasks of semi-confluent cells were washed in PBS and 
incubated overnight at 370C following the addition of 20mls of EBM-2 with 1% FCS. 
The supernatant was removed, filtered using a 0.2µm filter (Sarstedt), and 
concentrated [x20] using Amicon Ultra-15 10K Centrifugal Filter Units (Millipore) 
centrifuged at 4oC for 20 minutes at 4000 x g.  
2.4.2 VEGF ELISA 
T75 flasks of semi-confluent cells were washed in PBS and starved overnight in 10mls 
EBM-2 media with 1% FCS. The cell supernatant was collected, filtered (0.2µm) and 
stored at -80oC until use. Cell lysates were prepared on ice following the addition of 
triple lysis buffer (section 2.4.3) and protein quantification performed as previously 
described. Samples were also prepared from flasks of cells starved overnight in 1% 
FCS EBM-2 media in a hypoxic chamber (1% O2). VEGF ELISA (R&D Systems) was 
performed according to manufacturer instructions. VEGF protein standards were re-
constituted in calibrator diluent (supplied) and serially diluted. 50µls of assay diluent 
were added to each well of a 96-well plate pre-coated with a monoclonal antibody 
specific for all VEGF isoforms, followed by 200µls of sample. Duplicate wells were used 
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for the measurement of VEGF in cell supernatant. The plate was covered and 
incubated at room temperature for 2 hours. The wells were then washed three times 
with wash buffer (supplied) using a squirter bottle. 200µls of VEGF conjugate (supplied) 
were added, the plate covered, and again incubated at room temperature for a further 2 
hours. The plate was washed three times with wash buffer and then 200µls of substrate 
solution added (supplied). The plate was covered with aluminium foil and incubated for 
20 minutes before 50µls of stop solution were added (supplied). Colour developed 
relative to the proportion of bound VEGF. Colour intensity was measured using a 
FLUOstar Galaxy plate reader at 450nm and corrected using absorbance readings at 
520nm. A standard curve was calculated from the VEGF protein standards and used to 
estimate VEGF concentrations in the study samples. VEGF secretion in to the cell 
supernatant was expressed relative to the total protein concentration in cell lysates.  
2.4.3 Western blot 
Protein expression of VEGF, VEGFR1, VEGFR2, phosphorylated VEGFR2 
(pVEGFR2) and phosphorylated extracellular signal-regulated kinase (pERK) was 
investigated by western blot.  
To investigate VEGF expression, semi-confluent T175 flasks of cells were starved 
overnight in 10mls of EBM-2, 1% FCS. The supernatant was collected, filtered (0.2µm) 
and concentrated [x10] (Centrifugal Filter Units, Millipore). Cell lysate samples were 
derived concurrently. To create these lysates, 500µl of triple lysis buffer per T75 flask 
was added on ice. This lysis buffer comprised of 50mM Tris-HCl (pH 8.0), 150mM 
NaCl, 0.02% sodium azide, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate and 
Complete Mini EDTA-free protease inhibitor cocktail tablets +/- PhosSTOP 
phosphatase inhibitor cocktail tablets. The lysis buffer was mixed, aliquoted and stored 
at -20oC until use. Following addition of the lysis buffer, flasks were gently agitated for 
10 minutes and scraped. The lysate was transferred to an eppendorf and aspirated 
through a 22 gauge needle ten times. The lysate was incubated on ice for 20 minutes 
and then centrifuged for 10 minutes at 15,000rpm at 4oC.The lysate was transferred to 
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a fresh eppendorf, leaving behind any residual cell debris that had settled during 
centrifugation, and stored at -80oC until use. Prior to use protein quantification was 
performed as previously described. 
To investigate baseline expression of VEGFR1, VEGFR2, pVEGFR2 and to quantify 
the effects of axitinib (0ng/ml, 50ng/ml and 250ng/ml) and bevacizumab (0mg/ml, 
0.25mg/ml) on pVEGFR2, semi-confluent T75 flasks of cells were starved overnight in 
EBM-2, 1% FCS. Flasks were washed in PBS and then incubated for 1 hour at 37oC 
with 2mls of EBM-2 media plus VEGF targeted agent, with DMSO or bevacizumab 
control vehicle (see section 2.5) added as necessary to ensure equal quantities 
throughout. 50ng/ml recombinant VEGF was added and flasks were incubated for a 
further 3 minutes at 37oC before cells were lysed. pVEGFR2 expression was also 
investigated in hypoxia following incubation of semi-confluent T75 flasks of cells 
overnight in EBM-2, 1% FCS in a hypoxic chamber (37oC, 1% O2). Lysates were 
generated as described above. 
The effect of axitinib (0ng/ml, 50ng/ml and 250ng/ml) and bevacizumab (0mg/ml, 
0.25mg/ml) on pERK expression was investigated. Semi-confluent T75 flasks of cells 
were starved overnight in EBM-2, 1% FCS. Flasks were washed in PBS and then 
incubated for 1 hour at 37oC with 2mls of media and VEGF targeted agent, with 
DMSO/control vehicle quantities added as necessary. 50ng/ml recombinant VEGF was 
added and separate flasks of cells lysed at 0, 5, 10 and 20 minutes.  Lysates were 
generated as described above. 
For the western blot procedure, the gel apparatus was constructed using a 1.5mm 
plate. Separating gels were prepared for each plate according to the quantities shown 
in table 2.3. 12% gels were used for the VEGF studies, the 10% gels for VEGF and 
pERK studies and 7.5% gels for the VEGFR studies. Butanol was layered on top of the 
separating gel and then washed off once this had set (40 minutes). Stacking gel was 
prepared from 6.1ml distilled water, 2.5ml 0.5M Tris-HCl (Geneflow), 100µl 10% 
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sodium dodecyl sulphate (SDS; Geneflow), 1.3ml 30% Acrylamide (Geneflow), 100µl 
10% ammonium persulphate (APS; Sigma-Aldrich) and 10µl 
Tetramethylethylenediamine (TEMED; Sigma-Aldrich), added and a 9 well comb 
inserted.  
% Acrylamide 12% 10% 7.5% 
Distilled Water 3.35ml 2.5ml 2.5ml 
1.5M Tris-HCl 2.5ml 2.5ml 2.5ml 
10% SDS 100µl 100µl 100µl 
30% Acrylamide 4ml 3.3ml 2.5ml 
10% APS 50µl 50µl 50µl 
TEMED 5µl 5µl 5µl 
Table 2:3: Separating gel preparation.  
Whilst the stacking gel was setting (20 minutes) the samples for running were prepared 
from 4µl NuPAGE sample reducing buffer [10x] (Invitrogen), 10µl NuPAGE sample 
buffer [4x] (Invitrogen), sample and distilled water 26µl; sample volumes were varied to 
ensure equivalent protein loads were used.  Samples were heated at 70oC for 10 
minutes using a Techne DRI-Block DB-2A. The gel cassette was placed in the running 
apparatus and the tank filled with running buffer (100ml UltraPure [10x] 
Tris/Glycine/SDS (Geneflow), 900ml distilled water). The combs were removed and 
each well flushed with running buffer using a 25 gauge needle. 10µl of Precision Plus 
Protein Standards Kaleidoscope (Bio-Rad) molecular weight marker was loaded into 
the first well and subsequent wells loaded with sample. The gel was then run at 100V 
using a Bio-Rad PowerPac Basic. Once the samples had passed through the stacking 
gel the voltage was increased to 150V. Running time was approximately 2 hours. Once 
the samples had run off the gel, the apparatus was disassembled, the plates prised 
open and the bottom right hand corner of the gel sliced off for orientation. The gel was 
then washed in transfer buffer (100ml UltraPure [10x] Tris/Glycine, 200ml methanol, 
700ml distilled water) on a shaking platform (Luckham Shaker R100) for 10 minutes 
twice. Polyvinylidene fluoride (PVDF) membrane was cut to size and activated in 
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methanol for 5 minutes before being washed in transfer buffer during which time Bio-
Rad Extra Thick filter paper was soaked in transfer paper. The transfer plates (Trans-
Blot SD Semi-Dry Tansfer Cell, Bio-Rad) were cleaned with methylated spirit and the 
blotter stacked with filter paper, membrane, gel, filter paper. Air bubbles were rolled out 
following the addition of each layer to ensure an even transfer of proteins. The BioRad 
PowerPac HD was set at 15V and the Transfer Cell run for 20 minutes for 1 gel, 33 
minutes for 2 gels. After transfer the bottom right hand corner of the membrane was cut 
for orientation and placed in blocking solution. 
The protocol describing blocking conditions, washes and concentration of antibodies 
were adjusted independently for each antibody to optimise the blots produced. The 
final protocols are described here.  
For VEGF, VEGFR1, VEGFR2 and pERK studies, membranes were blocked in PBS, 
0.1% Tween (PBST) with 5% powdered milk (Marvel) for 1 hour at room temperature 
and then overnight at 4oC with the primary antibody in blocking solution (table 2.4). 
Membranes were then washed for 10 minutes, 3 times with PBST and the secondary 
antibody applied (ECL anti-mouse/anti-rabbit IgG horseradish peroxidise linked whole 
antibody; GE Healthcare) also in blocking solution, for 1 hour at room temperature. The 
membrane was again washed in PBST for 10 minutes, 3 times and then covered with 
1ml of Immobilon Western Chemiluminescent HRP substrate (Millipore) for 3 minutes 
in a dark room. The membranes were arranged in a Hypercassette and exposed to 
Amersham Hyperfilm ECL (GE Healthcare) for up to 10 minutes and the film 
developed.   
For pVEGFR2 studies, membranes were blocked in TBST (TBS [x10] – TrisHCl 
24.23g, 80.06g NaCl, 800ml distilled water, pH to 7.6 with HCl and top with distilled 
water to 1L. For [1x] – 100ml TBS[x10], 900ml distilled water, 0.1% Tween), 5% bovine 
serum albumin (Sigma-Aldrich) overnight at 4oC. Primary antibody was applied in 
blocking solution for 2 hours at room temperature and the membranes then washed in 
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TBST for 15 minutes, 4 times and secondary antibody then applied for 1 hour at room 
temperature. Membranes were again washed in TBST for 15 minutes, 4 times and then 
covered with 1ml of Pierce ECL Western Blotting Substrate (Thermo Scientific) for 3 
minutes. The membranes were arranged in a Hypercassette and exposed to 
Amersham Hyperfilm ECL (GE Healthcare) for up to 20 minutes and the film 
developed.   
 Primary 
Antibody 
Secondary 
Antibody 
VEGF (sc-152) 1:500 1:1000 
VEGFR1 (Cell Signalling #2893) 1:500 1:1000 
VEGFR2 (Cell Signalling #2479S) 1:1000 1:2000 
pVEGFR2 (Cell Signalling #2478) 1:1000 1:2000 
pERK (Sigma M8159) 1:10,000 1:15,000 
β-actin (Sigma A5441) 1:10,000 1:15,000 
Table 2.4: Antibody concentrations used in western blotting 
To demonstrate equivalent protein loading of wells membranes for pVEGFR2 probing 
were run concurrently with VEGFR2 studies. Following probing for VEGF and pERK, 
membrane was immersed in Restore Western Blot Stripping Buffer (Thermo Scientific) 
for 20 minutes at room temperature and washed for 10 minutes, 3 times in PBST. 
Primary antibody to β–actin was added and incubated for 20 minutes, the membranes 
were washed again 3 times in PBST for 10 minutes, secondary antibody was applied 
for 30 minutes, washed again for 10 minutes, 3 times in PBST. Finally the membranes 
were covered with 1ml of Immobilon Western Chemiluminescent HRP substrate 
(Millipore) for 3 minutes in a dark room. The membranes were arranged in a 
Hypercassette and exposed to Amersham Hyperfilm ECL (GE Healthcare) for up to 5 
minutes and the film developed. 
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2.5 Drug Studies 
A series of studies were performed to investigate the effects of vascular targeted 
agents on ASM and ISO-HAS, with HuDMECs as a comparison.  
Doxorubicin (D1515, Sigma Aldrich) and paclitaxel (T7402, Sigma Aldrich) were 
purchased. Axitinib (AG-13736) and sunitinib (SU-11248) were provided by Pfizer. Akt 
inhibitor (MK2206, Selleck), Chk2 inhibitor (C3742, Sigma Aldrich) and mTOR inhibitor 
everolimus (RAD001, Selleck) were purchased. 1mg of each drug was dissolved in 1ml 
DMSO prior to use and stored in 10µl aliquots at -20oC. Prior to use, a fresh aliquot 
was re-constituted in 10mls of media to provide a working solution of 1µg of drug/ml of 
media. 10µls of DMSO were dissolved in another 10mls of media to provide a control 
solution. Quantities of each were used to provide different drug concentrations with 
equal quantities of DMSO as illustrated in table 2.5.  
The MEK inhibitor selumetinib (S1008, Selleck) was purchased, 1mg of drug was 
dissolved in 50µls of DMSO, and 10µl aliquots stored at -20oC. DMXAA (ASA404) was 
initially provided by Novartis with additional supplies purchased from Santa Cruz (sc-
207592). 25mgs DMXAA were dissolved in 1.25mls DMSO and stored at 4oC until use. 
DMSO was added as required in studies of selumetinib and DMXAA to control for 
DMSO concentration.  
Bevacizumab (Roche, Avastin) was purchased and supplied in a control vehicle at 
25mg/ml. Additional control vehicle was prepared according to 51 mM sodium 
phosphate and 60 mg/ml trehalose dihydrate (pH 6.2) and 0.04% Tween[164], and 
added as necessary to ensure equal volumes throughout. Both bevacizumab and 
control vehicle were stored at 4oC until use. 
2.5.1 Chemosensitivity assays 
A series of studies were performed to investigate the effects of vascular targeted 
agents on endothelial cell proliferation and cell viability. The principal assays available 
to measure this were[165]: 
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Clonogenic assay – these assays are considered the gold standard approach for 
determining chemosensitivity. Cells are first exposed to the drug of interest, plated, and 
then colonies that subsequently develop are counted. This assay measures cell 
proliferation and can be used to distinguish cytostatic from cytotoxic drug effects. 
Colonies must grow sufficiently large to be visualised for counting, and thus this assay 
may overestimate drug response. These assays are also tedious, labour intensive and 
are impractical for screening a large number of samples. 
DNA synthesis – these assays measure the uptake of a DNA precursor (e.g. 3H-
thymidine) to assess cell proliferation. These assays do not distinguish between viable, 
non-replicating cells and cells that have died, and do not distinguish DNA replication 
from repair. 
Cell membrane integrity assays – or dye exclusion assays, use the differential uptake 
of a dye to distinguish viable from dead cells. Trypan blue is excluded by viable cells 
but not by those that have died. This is used to estimate a viable cell count. Trypan 
blue may underestimate drug toxicity as dying cells may still exclude the dye, and fully 
lysed cells will not appear. A Beckman Coulter Vi-CELL haemocytometer was available 
within the laboratory and provided consistent, reproducible results. The Vi-CELL uses 
trypan blue staining, a microscope and image analysis to calculate % viability, viable 
and total cell count.  
Metabolic assays – including the MTS assay, measures the mitochondrial reduction by 
metabolically active cells of the yellow tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), in the presence of 
phenazine ethosulphate (PES), to a formazan compound. Plate reader measurement 
of colour change (absorbance) is used as a surrogate measure for the number of viable 
cells. Comparing absorbance measurements from plates analysed at different time 
points (e.g. 24 and 48 hrs) provides an estimate of drug effects on cell proliferation, 
assuming mitochondrial activity (and MTS metabolism) remains constant over time.  
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The MTS assay is easy to replicate but only measures viable cells, and the results may 
be affected by chemical composition of the media including its pH. 
Studies of drug effects on ASM and ISO-HAS were performed with a cell membrane 
integrity assay, using the Vi-CELL to produce semi-automated cell counts. It was not 
practical to perform these assays using HuDMECs, as the assay demanded a large 
number of cells and HuDMECs required stringent conditions to maintain growth. The 
MTS assay was therefore used to assess drug effects on HuDMEC viability and cell 
proliferation. Supplementary MTS studies were performed with ASM and ISO-HAS to 
ensure comparisons of drug effects were fair. 
Initial drug viability studies were performed with ASM cells. 100,000 viable cells in 1 ml 
of full growth media were seeded in 12-well plates and incubated at 37oC. After 60 
hours for cultures to establish, wells were washed in PBS and chemotherapy drugs 
added in fresh growth media. A different drug concentration was used for each 12-well 
plate. Viable cell counts were performed using the Beckman Coulter Vi-CELL 0, 48, 72 
and 96 hours after drug addition. 3 wells were assessed at each time point and results 
averaged. The protocol described in 2.5.1.1 was subsequently used to assess drug 
effects on cell viability. 
2.5.1.1 Cell membrane integrity assay  
100,000 viable cells in 1ml were seeded in 12-well plates in full growth media. At 48 
hours the wells were washed with PBS and any residual PBS aspirated. Solutions of 
drug and fresh growth media were added to each well, 3 wells for each condition 
(tables 2.5). Following a further 120 hours, cells were counted as previously described. 
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Drug Concentration 
(ng/ml) 
Drug (μls) 
(@1μl(1µg)/ml media) 
DMSO (μls) 
(@1μl/ml media) 
Growth 
Media (μls) 
0 0 250 750 
25 25 225 750 
50 50 200 750 
100 100 150 750 
150 150 100 750 
200 200 50 750 
250 250 0 750 
Table 2.5: Example doses used in vascular targeted drug studies. 
2.5.1.2 MTS assay 
Semi-confluent flasks of cells were starved for 4 hours in EBM-2 with 1% FCS. Cells 
were trypsinised, centrifuged, and re-suspended in EBM-2 with 1% FCS, and a viable 
cell count calculated using the Vi-Cell. Tubes of different drug concentrations were 
established containing 50,000 viable cells/ml in EBM-2, 1% FCS. 100µls (5,000 cells) 
were pipetted into wells of a 96-well plate, 6 wells per condition. 6 wells held media 
only (no cells) to provide a background reading. 3 hours prior to the assessment of cell 
viability, 20µls of MTS (Promega) were added per well. The plate was then covered in 
aluminium foil and incubated at 37oC. Colour intensity developed proportional to 
mitochondrial activity (a surrogate marker for cell viability), and absorbance measured 
using a FLUOstar Galaxy plate reader at 420nm. A background reading from the blank 
wells was subtracted from the absorbance measurements, and an average reading 
calculated for each condition. A preliminary study with serial plates read at 24, 48 and 
72 hours showed minimal change in absorbance measurements between 48 and 72 
hours, and thus the subsequent studies assessed proliferation at 24 and 48 hours only.  
A study of drug concentrations in the absence of cells was performed to control for any 
direct chemical effects of the study drugs on the tetrazolium salt. Figure 2.6 shows the 
drugs did not have a direct chemical effect.  
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Figure 2.6: Absorbance measurements from an MTS study performed in the absence 
of cells. Axi - axitinib (0-250ng/ml), BzCV - bevacizumab control vehicle, Bz - 
bevacizumab (0.25mg/ml), DMXAA (0-100µg/ml). Data is represented as mean of 5 
wells ±SEM; n=1. 
2.5.2 Functional studies 
Studies were performed to investigate the effects of vascular targeted agents on 
endothelial cell function in differentiation, migration and invasions assays. 
2.5.2.1 Differentiation 
The effects of axitinib, bevacizumab, selumetinib and DMXAA on endothelial cell tubule 
formation were studied. The differentiation assay protocol described in 2.3.2 was 
followed. After plating the Matrigel, tubes of 100,000 viable cells per ml were prepared, 
in different drug concentrations, +/- 50ng/ml recombinant VEGF. Volumes of DMSO or 
bevacizumab control vehicle were added to ensure equal quantities were used 
throughout. 
2.5.2.2 Migration 
The effects of axitinib and bevacizumab on endothelial cell migration were studied. The 
Boyden chamber assay protocol described in 2.3.3 was followed. Tubes of different 
drug concentrations with 300,000 viable cells/ml were prepared for the upper chambers 
and tubes of drug concentrations +/- 20ng/ml recombinant VEGF were prepared for the 
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lower chambers. Volumes of DMSO or bevacizumab control vehicle were added to 
tubes to ensure equal volumes throughout. 
2.5.2.3 Invasion 
Endothelial cell invasion was investigated using the CULTREX 96-well Basement 
Membrane Extract (BME) Cell Invasion Assay (Trevigen), a modified trans-well assay. 
The assay was prepared as per manufacturer instructions: The supplied reagents were 
first prepared. 500µls of [10x] Coating Buffer were diluted in 4.5mls of distilled water. 
50µls of growth factor reduced basement membrane extract (BME) purchased 
separately (Trevigen) were reconstituted in 450µls of [x1] Coating Buffer to produce a 
working BME solution of [x0.1]. 3mls of [x10] Cell Dissociation Solution were diluted in 
27ml of distilled water, and 30µls of dimethyl sulfoxide (DMSO) were used to form a 
Calcein-AM solution. 50µls of [x0.1] BME were then pipetted into the top chambers of 
the supplied 96-well plate. The plate was covered and incubated overnight at 37oC to 
allow the matrix to set and a semi-confluent flask of cells were starved overnight in 
EBM-2, 1% FCS. Tubes were prepared of 1 x 106 viable cells/ml of EBM-2, 1% FCS +/- 
axitinib, and 50µls (50,000 cells) pipetted into upper chambers, 3 wells per condition, 3 
wells containing media only. Tubes of EBM-2, 1% FCS +/- axitinib +/- recombinant 
VEGF 20ng/ml were prepared, and 150µls aliquoted into lower chambers. The plate 
was covered and incubated for 24 hours at 37oC. Following incubation the lower plate 
was exchanged for a black 96-well base-plate (supplied). 100µls of [x1] Cell 
Disassociation + Calcein-AM (1.2µls/ml) were pipetted into chambers of the black 
base-plate. The reconstructed plates were then covered and incubated at 37oC for a 
further hour. The base-plate was gently tapped at 30 and 60 minutes to release 
adherent cells. Calcein fluorescence of cells released into the lower chambers was 
measured at 1 hour using the FLUOstar Galaxy plate reader at 485nm excitation, 
520nm emission.  A background measurement from the 3 wells of media only was 
subtracted from readings, and an average measurement calculated for each drug 
condition from the wells prepared in triplicate. 
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A preliminary study was performed using BME [x1] supplied (not growth factor 
reduced). Fluorescence measurements were not increased above baseline readings 
from the blank wells of media only, suggesting the absence of cell invasion. As per kit 
instructions, a subsequent study was performed using serial BME concentrations (x0.1 
– x1.0) diluted with coating buffer, 3 wells per condition (figure 2.7). These studies 
showed no increase in fluorescence measurements above a BME concentration of 
0.25. A 10% concentration [x0.1] BME was therefore used in all the subsequent studies 
as described above. 
 
Figure 2.7: Mean fluorescence from invasion assay using serial dilutions of basement 
menbrane extract (BME); n=1. 
Initial studies were then performed using BME extract [x0.1] supplied, to compare ASM 
and ISO-HAS invasion in control media +/- axitinib, +/- VEGF 20ng/ml (figure 2.8). 
These studies showed no significant change in fluorescence readings, indicating no 
increase in cell invasion following the addition of the chemotractant VEGF, and no 
difference in cell invasion in the presence of axitinib 50ng/ml. The BME supplied with 
the invasion assay kit however was not growth factor reduced. As growth factors 
contained within the BME may have influenced these results subsequent studies were 
performed, as described in the protocol above, using growth factor reduced BME 
purchased separately, comparing endothelial cell invasion with axitinb concentrations 
of 0, 50 and 250ng/ml.      
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Figure 2.8: Mean fluorescence measurements from invasion assays using basement 
membrane extract [x0.1] supplied, in 1% EBM (control), plus 20ng/ml VEGF, axitinib 
50ng/ml, and axitinib 50ng/ml plus VEGF. Data shown represents mean ± SEM; n=3.  
Calcein-AM is absorbed and cleaved by viable cells to produce AM and fluorescent 
free Calcein. Fluorescence measured in this invasion assay was therefore proportional 
to the number of viable cells in the lower chamber. These viable cells had invaded from 
the upper chambers through the BME, remained adherent to the underside of the 
upper chamber, to then be released into the lower chamber by the Cell Disassociation 
solution.  Baseline studies were performed to convert the fluorescence readings into 
estimated cell numbers (figure 2.9): Semi-confluent T75 flasks of cells were starved 
overnight in EBM-2, 1% FCS. Cells were trypsinised, centrifuged at 1000 x g for 3 
minutes, and re-suspended to form a suspension of 1 x 106 viable cells/ml in [1x] Cell 
Disassociation Solution. 0-50µls of cell suspension were pipetted into wells to produce 
wells of 0, 1,000, 2,500, 5,000, 10,000, 25,000 and 50,000 cells per well, 3 wells per 
condition. Volumes of [1x] Cell Disassociation Solution were added to produce equal 
volumes of 50µls per well. A solution of [1x] Cell Disassociation Solution + Calcein-AM 
(2.4µl/ml) was prepared and 50µls pipetted into each well. The plate was covered and 
incubated at 37oC for 1 hour. The plate was read with a FLUOstar Galaxy plate reader 
at 485nm excitation, 520nm emission. Background readings were subtracted and the 
0 
25 
50 
75 
100 
125 
150 
Control +VEGF Axi50 Axi50 
+VEGF 
M
e
an
 f
lu
o
re
sc
e
n
ce
 
ASM 
ISO-HAS 
 57 
 
average readings plotted to produce a standard curve used to transform fluorescent 
reading from the invasion assay into an estimate of cell numbers. 
 
 
 
Figure 2.9: Mean fluorescence for (A) ASM, (B) ISO-HAS and (C) HuDMECs for 
known cell concentrations. Trendline equations shown were used to estimate the 
number of invaded cells from fluorescence readings in subsequent assays.    
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2.6 Tumour Samples 
2.6.1 Cell line development   
I obtained approvals from the Research Ethics Committee (REC), and the Sheffield 
Teaching Hospital’s (STH) Research department for obtaining intra-operative tumour 
tissue samples from patients undergoing a planned surgical procedure for soft tissue 
sarcoma including angiosarcoma (REC number: 09/H1313/52; STH project number: 
15394; Appendix I). Potential research participants were identified from clinical review 
at the local sarcoma multi-disciplinary team meeting. Patients were approached by 
their treating physician during an outpatient assessment and provided with a patient 
information sheet. A signed consent form was obtained from the patient by a study 
investigator at a follow-up visit. At resection the surgical specimen was transferred on 
ice to histopathology for tumour sampling. Samples were obtained by blind biopsy of 
the tumour specimen by the collaborating histopathologists. Fresh samples were taken 
for cell line development and other samples stored in RNAlater (Ambion) at -80oC, or 
fixed in formaldehyde and embedded in paraffin wax for later molecular analysis. 
Samples were pseudo-anonymised with a soft tissue sarcoma (STS) study number. 
Multiple methods were simultaneously trialled to isolate malignant endothelial cells 
from fresh tumour biopsies. Protocols 3 and 4 detailed below were based on methods 
described by Krump-Konvalinkova et al[154] and Masuzawa et al[156], yielding ASM 
and ISO-HAS respectively.   
Protocol 1: 
A 2mm3 sample of tumour was finely minced with a scalpel in a small petri dish, and 
transferred to T25 Nunc flasks containing full growth media (ECGM, ECGM 
Supplement Pack, plus 10% FCS, 0.5% v/v penicillin, 0.5% v/v streptomycin and 0.5% 
v/v amphotericin). 
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Protocol 2: 
A 2mm3 sample of tumour was minced with a scalpel and incubated in trypsin 0.04% 
(PromoCell) for 30 minutes at 37oC. After 10 minutes the supernatant was removed 
and centrifuged at 1000 x g for 5 minutes, and plated in a T25 flask in full growth 
media. Additional trypsin 0.04% was added to the residual minced tumour tissue and 
the process repeated 3 times.    
Protocol 3: 
A 2mm3 sample of tumour was minced with a scalpel and then digested with the 
collagenase dispase (Sigma Aldrich), 2mg, at 4oC for 4 hours. Cells were centrifuged at 
1000 x g for 5 minutes and re-suspended in trypsin 0.04% and incubated at 37oC 
degrees for 2 hours. Cells were again centrifuged at 1000 x g for 5 minutes, re-
suspended in full growth media and plated in T25 flasks.  
Protocol 4: 
A 2mm3 sample of tumour was minced with a scalpel and incubated in 0.04% trypsin at 
37oC for 15 minutes. The cell solution was centrifuged at 1000 x g for 5 minutes and 
plated in T25 flasks in full growth media. 
To encourage endothelial cell adhesion some T25 flasks were first coated with gelatin 
0.2%: 1ml of 2% gelatin (Sigma Aldrich) was warmed at 37oC until the solution became 
clear (approximately 1 hour) and then diluted in 9mls PBS. 1ml of 0.2% gelatin was 
aliquoted into T25 flasks, and incubated at 37oC for 1 hour. Excess gelatin in the flask 
was then pipetted off prior to use. 
Flasks were regularly monitored to observe for cell adherence and subsequent growth.  
Small aliquots of fresh growth media were added every 72 hours. 2 to 3 weeks were 
typically required before any growth was seen. Cells were then trypsinised, centrifuged, 
and re-plated as a monolayer in a T75 flask. Once semi-confluent, T75 flasks of cells 
were split gently (ratio of 1:2 – 1:3) and early cell passages used for in vitro studies. 
Protocol 3 proved the most effective method at yielding cells for further study. 
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Tumour samples from four patients were obtained (STS0510, 2110, 2210 and 1011). 
Tumour details are presented in the relevant section of the results chapter (see section 
3.5). 
STS0510 
MACS microbeads (Miltenyi Biotec) were used to isolate CD31 positive cells. As 
previously described CD31 is a transmembrane glycoprotein cell adhesion molecule 
expressed on the surface of endothelial cells, platelets and monocytes[166], as well as 
by tumour cells of angiosarcoma[99]. The protocol used to isolate CD31 positive cells 
was followed as per manufacturer instructions: A semi-confluent flask of cells were 
washed in PBS, trypsinised and centrifuged for 3 minutes at 1000 x g. Cells were re-
suspended in 60µls of full growth media. 20µls of Fc receptor Blocking Reagent 
(supplied) were added, the sample was briefly vortexed, 20µls of CD31 microbeads 
added, and the sample incubated on ice for 15 minutes. 1ml of media was added, 
centrifuged again for 3 minutes at 1000 x g and re-suspended in 1 ml of media. 
Meanwhile, an LS Column (Miltenyi Biotec) was placed in the Midi-MACS Separator – 
a magnetic retainer, and rinsed with 3 mls of media. The cell suspension was added 
and the column again rinsed with 3 mls of media 3 times. Cells that bound to the 
magnetic CD31+ microbeads were held within the LS Column and were flushed out 
using 5mls of full growth media into a T25 flask once the Column was removed from 
the magnetic Midi-MACS Separator. 
Glass slides of cells were prepared for immunocytochemistry staining (as per 2.2.1). 
Early cell passages were stored in liquid nitrogen for subsequent recovery and study in 
functional assays: Flasks were trypsinised, centrifuged at 1000 x g for 3 minutes, re-
suspended in 1ml full growth media with 10% DMSO and transferred to a cryo-vial, 
placed in -80oC freezer for 24 hours, and then to liquid nitrogen. For cell recovery the 
vials were extracted, warmed in a water bath at 37oC for 1 minute and rapidly 
transferred to a flask with full growth media. Unfortunately none of the vials cryo-
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preserved were successfully recovered, despite also using flasks coated in 0.2% 
gelatin or 50ng/ml fibronectin (Sigma Aldrich).     
STS2110, STS2210 
Insufficient cells grew from these tumour samples for immunocytochemistry and 
functional studies. 
STS1011 
CD31 extraction was not performed with cells grown from STS1011 in order to study 
the whole tumour cell population in functional assays. Slides of an early cell passage 
were prepared for immunocytochemistry staining (as per section 2.2.1). Functional 
assays were performed on early cell passages (P2 – P7) to investigate the effects of 
axitininb and bevacizumab on proliferation and differentiation as per the protocols 
described in section 2.5.  
2.6.2 Angiogenesis related protein array of human tumours 
Human angiosarcoma specimens were obtained from two sources: 
i) Peri-operative tumour sampling described in section 2.6.1. 
ii) Baseline biopsies of angiosarcoma lesions from patients who participated in 
the national cancer research network (NCRN) multi-centre study of axitininb 
for advanced soft tissue sarcoma (Axi-STS; International Standard 
Randomised Controlled Trials Number (ISRCTN): 60791336). 
All biopsies were placed in RNAlater immediately after sampling. Samples from the 
Axi-STS study were sent to the University of Sheffield at room temperature. Samples 
were stored in RNAlater at -80oC until analysis. Samples were analysed using the 
angiogenesis related protein array (R&D Systems). Tumour samples from two de-
differentiated liposarcomas collected peri-operatively (STS1711, STS1810) were also 
analysed using the angiogenesis related protein array  
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2.6.2.1 Protein extraction 
Tumour samples were minced in 15 second bursts, in 500µls of Cell Disruption Buffer 
(Ambion), using an Ultra-Turrax T8 (IKA Labortechnik). Samples were then incubated 
for 2 hours on ice, and then centrifuged at 15,000rpm for 12 minutes at 4oC. Cell 
supernatant was transferred to a fresh eppendorf, leaving behind residual cell debris 
settled during centrifugation, and stored at -20oC overnight until analysis. 
2.6.2.2 Protein array 
Methods described in section 2.4.1 were followed for performing the array studies. 
Prior to analysis, total protein quantification of study samples was performed as 
previously described. Identical quantities of protein (120µg/ml) were used for each 
array. 
2.6.3 Immunohistochemistry study of human vascular tumours 
I obtained REC and STH Research department approvals for retrieving archived 
formalin-fixed paraffin embedded (FFPE) pathology specimens for analysis (REC 
number: 09/H1313/30; STH project number: 15355; Appendix I). The STH pathology 
archive was searched for angiosarcoma and benign vascular tumours processed 
between1999 – 2009. Archived haematoxylin and eosin (H&E) slides of identified 
vascular tumours were reviewed for quality control, to confirm the underlying histology, 
and to ensure adequate material for further study. Angiosarcoma tumour samples 
collected prospectively (see section 2.6.1) were also included in these studies. Basic 
clinical parameters from angiosarcoma specimens were recorded including the 
patient’s age, sex, and disease site. 
Slides were cut from FFPE tumour blocks by University of Sheffield technical staff. 
Tumour blocks were first chilled on ice, and 6µm sections cut onto glass slides with a 
Biocut 2035 (Leica). The slides were dried at 37oC for 24 hours before use.  
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2.6.3.1 Immunohistochemistry protocol   
Slides were stained simultaneously for each antibody to enable direct comparison 
across the tumour groups. Preliminary studies were performed to optimise the study 
protocol for each antibody. Slides were racked and rehydrated for 5 minutes in xylene 
twice, then 3 minute baths of 100%, 100%, 95%, 90% and 70% ethanol, then washed 
in distilled water. Antigen retrieval was performed using citric acid (0.01M citric acid, 
pH6.0 with 0.1% Tween). Slides were immersed in citric acid, covered and heated on 
high in a 700W microwave (Panasonic NN6308) for 3 minutes and then 7 minutes on 
medium. During heating the bath was regularly topped up with additional citric acid to 
ensure the slides remained submerged. Slides were then allowed to cool on ice in the 
citric acid bath for 20 minutes. Slides were washed briefly in distilled water and 
endogenous peroxidase was blocked with 0.3% hydrogen peroxidase (270mls 
methanol and 30mls of 3% hydrogen peroxidase (Sigma Aldrich)) at 37oC for 30 
minutes.  Slides were again washed with distilled water and the tumour sections edged 
with an ImmEdge wax pen. Blocking solution was applied (9mls PBS, 1ml serum, 1ml 
[10x] casein) at room temperature for 1 hour. Primary antibody as per table 2.6 was 
applied in 2% serum and incubated overnight at 4oC. Slides were then washed in PBST 
(0.1% Tween) for 5 minutes, twice. Secondary antibody was applied for 1 hour at room 
temperature, during which time ABC solution (Elite) was prepared (5mls PBS, 2 drops 
tube A, 2 drops tube B). Slides were again washed in PBST for 5 minutes, twice. ABC 
solution was applied for 40 minutes. Slides were washed again, and then stained with 
DAB (Elite; 5mls distilled water, 2 drops buffer, 4 drops DAB, 2 drops hydrogen 
peroxide) for up to 3 minutes. Slides were washed in tap water and stained in Gills 
Haematoxylin for 1.5 minutes and allowed to ‘blue’ in running tap water for 3 minutes. 
Slides were then dehydrated in sequential baths of 70%, 90%, 95%, 100% and 100% 
ethanol for 3 minutes each and then immersed in xylene for 5 minutes twice. Finally 
coverslips were affixed using DPX and allowed to dry before immuno-scoring.  
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As in the immunocytochemistry staining studies, slides were scored for the number of 
cells stained (0 = <1%, 1 = 1-10%; 2 = 11-50%; 3 = >50%) combined with a score for 
staining intensity (1 = weak, 2 = moderate, 3 = strong). Slides of placental tissue were 
used as a positive control. Tumour slides processed with the primary antibody 
substituted with PBS were used as a negative control. Staining of normal tissue 
adjacent to the vascular tumour was used to assess endothelial specific staining. 
 
Antibody Primary Secondary 
VEGF (sc-152) 1:100 1:200 
VEGFR1 (ab2350) 1:50 1:200 
VEGFR2 (ab39256) 1:100 1:200 
NRP1 (ab81321) 1:250 1:500 
bFGF (ab106245) 1:250 1:500 
FGFR1 (ab71928) 1:250 1:500 
Ang-1 (ab8451) 1:250 1:500 
Ang-2 (ab65835) 1:75 1:250 
Tie2 (AF-313) 1:50 1:250 
HGF (AF-294-NA) 1:250 1:500 
MET (ab51067) 1:250 1:500 
Table 2.6: Concentration of primary and secondary antibodies used in the 
immunohistochemistry studies 
2.6.4 Immunohistochemistry study of canine vascular tumours 
In contrast to human disease, angiosarcomas represent 10% of all canine 
tumours[167]. FFPE tumour samples of benign canine vascular tumours and 
cutaneous and visceral angiosarcomas were obtained through collaboration with the 
Animal Health Trust (Cambridge, UK). The Animal Health Trust pathology archive was 
searched for vascular tumours and retrieved tumour blocks sent to the University of 
Sheffield for analysis. Canine specific antibodies are not available commercially and 
therefore the immunohistochemistry protocols used to study the human tumour 
samples were folowed, as described in section 2.6.3.1. 
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2.7 Statistical Methods 
The biological characteristics of ASM, ISO-HAS and HuDMEC cells, as assessed by 
cell differentiation and cell migration functional assays, were compared using the 
independent t test. Proteins of interest were selected from the protein array expression 
profiles, by comparing the size of the protein peak densities between cell lines (a more 
than two fold difference in protein peak density was considered of interest), and by 
identifying statistically significant differences between peak densities using the one-way 
ANOVA test. ASM, ISO-HAS and HuDMEC expression of VEGF, as quantified by 
ELISA, were compared using the independent t test. Responses to vascular targeted 
agents were analysed using the paired t test, by comparing cell response to increasing 
drug exposure in cell viability, cell differentiation or cell migration assays, with or 
without the presence of VEGF stimulation. The immuno-staining of the vascular tumour 
samples were compared between tumour groups using the Kruskall-Wallis or Mann-
Whitney test.  
All statistical analysis was performed using PASW Statistics 18; p values less than 0.05 
were considered significant. 
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3 Results 
3.1 Characterisation of Angiosarcoma Cell Lines 
ASM and ISO-HAS have been identified as malignant endothelial cell lines[154, 156, 
158]. Characterisation studies were performed to confirm that ASM and ISO-HAS cells 
were endothelial. As ASM and ISO-HAS cells were derived from cutaneous vascular 
tumours, dermal microvascular endothelial cells (HuDMECs) were selected as a 
positive control. As angiosarcomas are classified with mesenchymal tumours, dermal 
fibroblasts (HDFs), cells of mesenchymal origins that do not usually express 
endothelial cell markers, were selected as a negative control. The morphology of ASM 
and ISO-HAS cells were compared to HuDMECs and HDFs, immunocytochemistry 
studies quantified the expression of endothelial cell markers, and uptake of the 
fluorescent endothelial cell specific marker Dil-Ac-LDL was assessed.  
3.1.1 Cell morphology 
Images of cultured cells are presented in figure 3.1. Images were taken using phase 
contrast microscopy (x4 magnification). HuDMECs had a cobblestone morphology 
typical of endothelial cells in culture. HuDMEC morphology was maintained up to 
passage 6, beyond which an increasing proportion of cells demonstrated a spindle 
morphology. HuDMECs were therefore utilised up to passage 6 for these experiments. 
HDFs demonstrated a spindle morphology typical of fibroblasts, which was maintained 
by cells up to passage 8 used for these experiments. ASM and ISO-HAS cells 
exhibited a mixed morphology. A proportion of cells appeared polygonal, whilst others 
were spindle shaped. ASM and ISO-HAS cells were studied in experiments up to 
passage 20. ASM cells passaged beyond this adopted a homogenous spindle 
morphology, and were negative for endothelial cell markers including CD31.  
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Figure 3.1: Cell morphology in full growth media (x4 magnification). 
3.1.2 Immunocytochemistry studies 
Immunocytochemistry studies were performed to compare the expression of 
endothelial cell markers by ASM and ISO-HAS cells with HuDMEC and HDF cells. The 
results are summarised in table 3.1. HuDMECs stained strongly for the endothelial cell 
markers CD31, CD34 and vWF, and also for VEGF, VEGFR1 and VEGFR2. 
Unexpectedly HuDMECs also showed staining for αSMA. Pericytes and vascular 
smooth muscle cells would be expected to stain for αSMA but not endothelial cells. 
HuDMEC expression of aSMA may have been induced, perhaps as a consequence of 
in vitro culture on glass slides, or show contamination of the HuDMEC cell line with 
pericytes; alternatively this staining may represent a false positive finding. In contrast 
HDFs did not stain for the endothelial cell markers CD31, CD34 or vWF, but stained 
strongly for αSMA. HDFs also showed staining for VEGF, VEGFR1 and VEGFR2. 
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Whilst VEGF and VEGFR1 are not endothelial specific markers, VEGFR2 is principally 
expressed on endothelial cells. HDF expression of VEGFR2 was not predicted and 
suggests a false positive result. 
ASM and ISO-HAS cells showed staining for the endothelial cell markers. However, in 
contrast to HuDMECs which showed a uniform staining pattern, ASM and ISO-HAS 
cells demonstrated a range of staining intensities to CD31 and vWF (figure 3.2). ASM 
and ISO-HAS cells also stained for VEGF, VEGFR1, VEGFR2 and αSMA.  
Pilot studies of other putative endothelial cell lines found EAhy926 stained for CD31 but 
not vWF, whilst SVR and ISOS-1 stained for neither CD31 nor vWF. EAhy926, SVR 
and ISOS-1 stained for both VEGF and VEGFR2. 
 HuDMEC ASM ISO-HAS HDF 
CD31 6.0 4.0 4.7 0.0 
CD34 4.3 2.7 2.7 0.0 
vWF 6.0 4.3 4.3 0.0 
αSMA 4.3 4.0 4.7 6.0 
VEGF 4.7 5.3 5.0 5.0 
VEGFR1 5.7 5.7 5.3 5.3 
VEGFR2 5.0 4.7 5.7 4.0 
Table 3.1: Immunocytochemistry studies of HuDMEC, ASM, ISO-HAS and HDF cells. 
Immunocytochemistry staining was semi-quantified using a composite score for the 
number of stained cells and the staining intensity (see section 2.2.1.2). Data shown 
represents mean score; n=3. 
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HuDMEC CD31 ASM CD31 ISO-HAS CD31 HDF CD31 
    
HuDMEC vWF ASM vWF ISO-HAS vWF HDF vWF 
Figure 3.2A: Images from immunocytochemistry studies (x20 magnification). HuDMECs stained strongly for the endothelial cell markers CD31 and 
vWF. ASM and ISO-HAS cells in contrast showed a mix of staining intensity (arrows indicate ASM and ISO-HAS cells that stained weakly for CD31, 
and cells that stained strongly for vWF). HDFs did not stain for either CD31 or vWF.  
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HuDMEC VEGF ASM VEGF ISO-HAS VEGF HDF VEGF 
    
HuDMEC VEGFR2 ASM VEGFR2 ISO-HAS VEGFR2 HDF VEGFR2 
Figure 3.2B: Images from immunocytochemistry studies (x20 magnification). HuDMEC, ASM, ISO-HAS and HDF cells stained for VEGF and 
VEGFR2.  
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3.1.3 Dil-Ac-LDL 
Consistent with other endothelial cells, ASM and ISO-HAS cells demonstrated uptake 
of the endothelial cell specific marker Dil-Ac-LDL (figure 3.3). Control studies showed 
Dil-Ac-LDL uptake by HuDMECs but not HDFs.  
  
 
   
 
  
Figure 3.3: Replica images of (A) ASM cells (x10 magnification), (B) ISO-HAS cells 
(x20 magnification) and (C) HuDMECs (x10 magnification), taken with white light and 
with fluorescence following incubation with the fluorescent endothelial cell marker Dil-
Ac-LDL.  
A 
B 
C 
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3.1.4 Flow cytometry 
ASM and ISO-HAS cultures showed cells with a mixed morphology, and 
immunocytochemistry studies of ASM and ISO-HAS showed cells with a range of 
staining intensity for endothelial cell markers. Cell morphology was poorly preserved on 
the glass slides used in the immunocytochemistry studies. ASM and ISO-HAS cells 
were therefore grown on Permanox multi-chamber slides to correlate cell morphology 
with endothelial cell marker expression. However, ASM and ISO-HAS cell growth were 
limited on the Permanox multi-chamber slides. Flow cytometry studies were therefore 
performed using fluorescent labelled CD31, VEGF, VEGFR1 and VEGFR2 antibodies 
to investigate for sub-populations of cells within ASM and ISO-HAS cultures. 
To analyse endothelial cell marker expression, the total cell population was gated to 
select a study population by excluding non-viable cells, cell debris and cell doublets. 
Cytometric analysis of ASM and ISO-HAS study populations demonstrated a shift in 
fluorescence intensity consistent with endothelial cell marker expression, with no 
evidence of distinct sub-populations of cells that over or under expressed endothelial 
cell markers (figure 3.4 and 3.5).  
3.1.5 Characterisation of angiosarcoma cell lines summary 
The characterisation studies confirmed ASM and ISO-HAS cells expressed CD31, 
vWF, VEGFR2, and uptook Dil-Ac-LDL, consistent with cells of endothelial origin. The 
morphology and immunocytochemistry studies suggested ASM and ISO-HAS 
consisted of a mixed population of cells, however the flow cytometry studies were 
consistent with cells of a single population that expressed endothelial cell markers with 
differing intensities. 
 
  
 73 
 
 
 
 
Median Fluorescence Intensity 
Unstained Stained 
CD31 (PECy7) 381 924 
VEGF (PerCp Cy5.5) 293 551 
VEGFR1 (R-PE) 158 275 
VEGFR2 (APC) 280 353 
 
  
  
Figure 3.4: Flow cytometry results for ASM: (A) Plot by forward and side scatter of total 
and gated study population. (B) Median shift in fluorescence intensity for each antibody 
compared to measurements in the unstained population. (C)-(F) Plot of fluorescence 
intensity for each antibody in the gated population. 
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Median Fluorescence Intensity 
Unstained Stained 
CD31 (PECy7) 548 1329 
VEGF (PerCp Cy5.5) 409 748 
VEGFR1 (R-PE) 214 261 
VEGFR2 (APC) 373 615 
 
 
  
  
Figure 3.5: Flow cytometry results for ISO-HAS: (A) Plot by forward and side scatter of 
total and gated study population. (B) Median shift in fluorescence intensity for each 
antibody compared to measurements in the unstained population. (C)-(F) Plot of 
fluorescence intensity for each antibody in the gated population.  
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3.2 Protein Expression 
ASM and ISO-HAS cells were studied using R&D Systems Proteome Profiler Antibody 
Arrays, to establish a profile of the proteins they expressed, and to identify putative 
drug targets for the treatment of angiosarcoma. The protein expression profiles of 
HuDMEC and HDF cells were used for comparison.  
3.2.1 Protein arrays 
Protein array studies determined the expression of 55 angiogenesis related proteins, 
46 phosphorylated intracellular kinases, and 42 phosphorylated receptor tyrosine 
kinases in ASM, ISO-HAS, HuDMEC and HDF cell lysates in normoxic conditions. 
Array studies were also performed to compare angiogenesis related proteins secreted 
by ASM and ISO-HAS cells into the supernatant. As hypoxia stimulates angiogenesis 
and tumours in vivo are typically hypoxic, additional array studies were performed to 
compare the expression of angiogenesis related proteins in ASM, ISO-HAS and 
HuDMEC cell lysates in hypoxic conditions. Duplicate studies were performed using 
different cell passages; however protein array costs limited the number of replicates.    
3.2.1.1 Angiogenesis related proteins 
In normoxic conditions the expression profile of angiogenesis related proteins derived 
from HuDMEC cells were distinct from HDFs (figure 3.6). The expression of a number 
of proteins were increased more than two-fold in HuDMEC cells compared to HDFs; 
significantly increased proteins included Ang-2 (p=0.022), endostatin (p=0.002), 
endothelin-1 (p=0.021), heparin-binding EGF-like growth factor (HB-EGF) (p=0.019), 
insulin growth factor binding protein-2 (IGFBP-2) (p=0.018), interleukin-8 (IL-8) 
(p=0.013), PDGF-AA (p=0.031) and PDGF-BB (p=0.027). HuDMEC expression of 
coagulation factor III, FGF-7, glial cell-derived neurotrophic factor (GDNF) and VEGF 
were less than half that of HDFs, but differences were not statistically signifcant. The 
distinct profiles of HuDMEC and HDF cells suggested the angiogenesis related protein 
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array was a useful tool for studying the expression of these proteins in ASM and ISO-
HAS cells.   
In normoxic conditions the angiogenesis related protein expression profiles of ASM and 
ISO-HAS were broadly similar to HuDMECs (figure 3.6). ASM and ISO-HAS protein 
expressions were calculated as a ratio of HuDMEC values to identify proteins with a 
greater than two-fold difference in expression (figure 3.7). ASM and ISO-HAS 
expression of coagulation factor III, TIMP-4 (tissue inhibitor of metalloproteinase-4) and 
VEGF were increased compared to HuDMECs, whilst Ang-2, MCP-1 (monocyte 
chemotactic protein-1) and prolactin were decreased relative to HuDMECs. A one-way 
ANOVA analysis was performed to compare the expression profiles. Only VEGF 
expression was significantly increased (p=0.029). A post-hoc Tukey’s analysis of VEGF 
expression showed mean ± SEM difference in peak density between ASM and 
HuDMECs 0.63 ± 0.12 (p=0.027), and mean ± SEM difference between ISO-HAS and 
HuDMECs 0.43 ± 0.12 (p=0.07). 
Secreted angiogenesis related proteins may promote tumour growth by stimulating 
neighbouring tumour and stromal cells within the tumour micro-environment. However, 
proteins expressed in cell lysates may not reflect proteins secreted into the cell 
supernatant, and a comparison may suggest different drug targets. The expression of 
angiogenesis related proteins in ASM and ISO-HAS cell supernatant was therefore 
studied, and contrasted with cell lysate data (figure 3.8). Cell supernatant was collected 
from semi-confluent cells incubated overnight in normoxia and concentrated [x20] prior 
to study. These arrays showed differences in the expression of a number of proteins: 
Activin A, angiogenin, GDNF, GM-CSF (granulocyte macrophage colony-stimulating 
factor), HGF, IGFBP-1 and -3, MCP-1 and PDGF-AA were increased in cell 
supernatant compared to the lysates, whilst coagulation factor III, aFGF, bFGF and 
TSP-1 (thrombospondin-1) were decreased.  
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As hypoxia stimulates angiogenesis, the expression of angiogenesis related proteins 
was studied in lysates from ASM, ISO-HAS and HuDMEC cells incubated overnight in 
hypoxic conditions (1% O2) (figure 3.9). The profile of angiogenesis related proteins 
obtained from HuDMECs cultured in normoxic conditions was broadly similar to the 
expression profile of HuDMECs in hypoxic conditions. However, the relative peak 
density of some of the proteins expressed by HuDMECs in hypoxia, including Ang-1, 
EGF, HGF, MMP-9, PDGF-AA and VEGF, were less than half that of HuDMECs in 
normoxia.  
A comparison of the expression profiles from ASM and ISO-HAS cells in hypoxia with 
HuDMECs identified a number of proteins with a greater than two-fold difference in 
expression (figure 3.10). Angiogenin, Ang-1, aFGF, HGF and VEGF showed increased 
expression in ASM and ISO-HAS cells compared to HuDMECs. ASM and ISO-HAS 
expression of Ang-2, CXCL16 (chemokine ligand 16), GDNF, IL-1β, MCP-1 and 
prolactin were decreased relative to HuDMECs. The difference in VEGF expression in 
hypoxia was especially pronounced; VEGF expression was twenty-five times greater in 
ASM and ISO-HAS lysates than in HuDMECs. This finding supported further study of 
VEGF expression, and the subsequent study of ASM and ISO-HAS cell response to 
agents targeting VEGF. 
If resources had permitted, additional protein array studies to assess the expression of 
angiogenesis related proteins in supernatant collected from cells incubated under 
hypoxic conditions would have been of interest, and also supernatant from HuDMECs 
in normoxic conditions.   
3.2.1.2 Phosphorylated protein kinases 
Phosphorylated tyrosine, serine and threonine residues on intracellular protein kinases 
regulate cell function, and are drug targets of small molecule kinase inhibitors. Basal 
phosphorylation of 46 protein kinases were assessed in lysates from semi-confluent 
ASM, ISO-HAS, HuDMEC and HDF cells starved overnight (figure 3.11). There were 
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few objective differences between the phosphorylated protein kinase profiles of 
HuDMEC and HDF cells, and the phosphorylated protein kinase profiles were broadly 
similar across all four studied cell lines. HuDMEC levels of phosphorylated endothelial 
nitric oxide synthase (eNOS) was more than double HDF levels (p=0.009), and 
HuDMEC levels of phosphorylated ERK were less than half that of HDFs (p=0.07), but 
other differences between HuDMEC and HDF cells were not significant. 
Only phosphorylated checkpoint II (ChkII) differed more than two-fold between both 
ASM, ISO-HAS and HuDMEC cells (p=0.15) (figure 3.12). A one-way ANOVA analysis 
identified a statistically significant difference in p53 phosphorylation at serine 15 
(p=0.010). The difference measured was small (mean ± SEM difference in relative 
peak density of phosphorylated p53S15 between ASM and HuDMECs 0.14 ± 0.02 
(p=0.009), and between ISO-HAS and HuDMECs 0.09 ± 0.02 (p=0.034)), however as 
both ChkII and p53S15 are activated by ATM (ataxia telangiectasia mutant) in response 
to DNA double strand breaks this finding may be biologically relevant. 
3.2.1.3 Phosphorylated receptor tyrosine kinases 
Ligand binding to receptor tyrosine kinases induces receptor dimerisation and 
phosphorylation of tyrosine residues on the receptor’s intracellular domain, which in 
turn activate downstream intracellular signalling networks leading to a cellular 
response. Phosphorylated receptor tyrosine kinases were profiled to identify key cell 
signalling pathways stimulated in basal conditions, and to identify potential drug 
targets. Basal phosphorylation of 42 receptor tyrosine kinases (RTKs) in lysates from 
semi-confluent ASM, ISO-HAS, HuDMEC and HDF cells starved overnight was also 
assessed (figure 3.13). Compared to ASM and ISO-HAS, both HuDMEC and HDFs 
had a broader profile of phosphorylated RTKs. Basal phosphorylation of VEGFR1, 
VEGFR2, VEGFR3, Tie2 and EphrinB1 and B2 were identified in HuDMECs. Basal 
phosphorylation of EGFR, PDGFRs, IGF-1R (insulin-like growth factor-1 receptor), Ret, 
Axl and ROR1 and 2 (receptor tyrosine kinase-like orphan receptor) were identified in 
HDFs. Only basal phosphorylation of EGFR (epidermal growth factor receptor) and 
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VEGFR2 were observed in ASM, and VEGFR1, VEGFR2, Tie2, EphrinA7, IGF-1R and 
ROR2 in ISO-HAS.  
3.2.1.4 Protein array summary 
A table summarising key findings from the array studies is shown below (table 3.2). 
 
 
Array 
HuDMEC protein 
expression compared 
to HDFs 
ASM and ISO-HAS 
protein expression 
compared to HuDMECs 
Angiogenesis related proteins 
(normoxia) 
↑Ang-2 
↑Endostatin 
↑Endothelin-1 
↑HB-EGF 
↑IGFBP-2 
↑IL-8 
↑PDGF-AA 
↑PDGF-BB 
↑Coagulation Factor III 
↑TIMP-4 
↑VEGF 
 ↓Coagulation Factor III 
↓FGF-7 
↓GDNF 
↓VEGF 
↓Ang-2 
↓MCP1 
↓Prolactin 
Angiogenesis related proteins 
(hypoxia) 
 ↑Angiogenin 
↑Ang-1 
↑aFGF 
↑HGF 
↑VEGF 
  ↓Ang-2 
↓CXCL16 
↓GDNF 
↓IL-1β 
↓MCP-1 
↓Prolactin 
Phosphorylated kinases   ↑eNOS ↑p70 S6 kinase 
↑p53 
↑ChkII 
 ↓ERK1/2  
Phosphorylated RTKs ↑VEGFR1-3 
↑Tie2 
 
  ↔VEGFR2 
 ↓EGFR 
↓IGF-1R 
↓PDGFRs 
↓Tie2 
↓VEGFR3 
Table 3.2: Key findings from protein array studies.  
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Figure 3.6: Expression profiles of angiogenesis related proteins from HuDMEC, ASM, ISO-HAS and HDF cell lysates. Data shown represents mean 
peak densities standardised relative to internal positive controls; n=2. 
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Figure 3.7: Expression profiles of angiogenesis related proteins from ASM and ISO-HAS cell lysates. Data shown represents relative peak densities 
expressed as a ratio of HuDMEC values. Gridlines identify proteins with a greater than two-fold difference in expression. 
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Figure 3.8: Expression profiles of angiogenesis related proteins in ASM and ISO-HAS supernatants (concentrated x20), and comparison with 
expression profiles from cell lysates. Data shown represents peak densities standardised relative to internal positive controls; n=1. 
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Figure 3.9: Expression profiles of angiogenesis related proteins from HuDMEC, ASM and ISO-HAS cells incubated overnight in hypoxic conditions 
(1% O2). Data shown represents peak density values standardised relative to internal positive controls; n=1. 
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Figure 3.10: Expression profiles of angiogenesis related proteins from cells incubated overnight in hypoxic conditions (1% O2). Data shown 
represents ASM and ISO-HAS peak density values expressed as a ratio of HuDMEC values. Gridlines identify proteins with a greater than two-fold 
difference in expression. Comparison of amphiregulin, artemin and vasohibin has not been included in this graph as expression in HuDMECs was 
undetected, prohibiting a direct comparison as a ratio. † VEGF data censored – ASM value 26.4; ISO-HAS value 24.9. 
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Figure 3.11: Expression profile of phosphorylated intracellular kinases in HuDMEC, ASM, ISO-HAS and HDF cell lysates. Data shown represents 
mean peak densities standardised relative to internal positive controls; n=2. 
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Figure 3.12: Expression profiles of phosphorylated intracellular kinases from ASM and ISO-HAS cell lysates. Data shown represents ASM and ISO-
HAS peak density values expressed as a ratio of HuDMEC values. Gridlines identify proteins with a greater than two-fold difference in expression. 
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Figure 3.13: Expression profiles of basal receptor tyrosine kinase (RTK) 
phosphorylation in HuDMEC, ASM, ISO-HAS and HDF cell lysates. Data shown 
represents mean peak density standardised relative to internal positive controls; n=2. 
Levels of 42 RTKs were studied in total, with a summary of the positive and important 
negative findings shown here. 
  
0 
0.05 
0.1 
0.15 
0.2 
0.25 
M
e
an
 P
e
ak
 D
e
n
si
ty
 
HuDMEC ASM ISO-HAS HDF 
 88 
 
3.2.2 VEGF ELISA 
The angiogenesis related protein array studies demonstrated increased VEGF in ASM 
and ISO-HAS cell lysates compared to HuDMECs in both normoxia and hypoxia. The 
secretion of VEGF into supernatant from cells incubated overnight in normoxic and 
hypoxic conditions (21% versus 1% O2) was therefore quantified by ELISA (figure 
3.14). These studies showed VEGF released into cell supernatant increased in hypoxic 
compared to normoxic conditions, but was statistically significant for ISO-HAS only 
(mean ± SEM VEGF secretion in pg/ml of ISO-HAS cells in normoxia vs hypoxia 149.9 
± 57.5 vs 829.4 ± 176.0 (p=0.025)). VEGF secretion in supernatant collected from ASM 
and ISO-HAS cells in normoxic conditions was higher than HuDMECs (mean ± SEM 
VEGF pg/ml HuDMEC vs ISO-HAS vs ASM cells, 23.8 ± 9.0 vs 149.9 ± 57.5 vs 179.5 ± 
58.1 (p=0.07 and 0.038 respectively)). VEGF expression was significantly higher in 
supernatant from ASM and ISO-HAS cells incubated overnight in hypoxic conditions 
compared to HuDMECs (mean ± SEM VEGF pg/ml HuDMEC vs ISO-HAS vs ASM 
cells, 64.9 ± 31.9 vs 829.4 ± 176.0 vs 855.5 ± 309.0 (p=0.005 and 0.044 respectively)). 
All data was adjusted to show VEGF concentration secreted per mg of total protein in 
the corresponding cell lysates, as determined by the BSA assay (see section 2.4.1). 
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Figure 3.14: VEGF expression in ASM, ISO-HAS and HuDMEC supernatant, collected 
from cells incubated overnight in normoxic and hypoxic conditions. Data shown 
represents mean VEGF expression (pg/ml) adjusted per mg of total protein content 
measured in the cell lysates ± SEM; n=4. 
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3.2.3 Western blot studies 
ASM and ISO-HAS expression of VEGF and VEGFRs was assessed by western blot.  
3.2.3.1 VEGF 
Cleavage of VEGFA mRNA results in different VEGFA isoforms with distinct biological 
characteristics: VEGFA121, VEGFA165 and VEGFA189. VEGFA165, the most biologically 
active isoform, is expressed as a glycosylated homodimer with a molecular weight of 
42kDa; however monomers and heterodimers with other VEGFA isoforms may also 
occur. The expression of VEGFA in ASM and ISO-HAS cell lysates and cell 
supernatant was investigated by western blotting (figure 3.15). Multiple protein bands 
of different molecular weights were detected around 25 and 42kDa which may 
represent the expression of multiple VEGFA isoforms. 
ASM 
lysate 
ASM 
supernatant 
ISO-HAS 
Lysate 
ISO-HAS 
supernatant 
    
Figure 3.15: Images of western blots probing for VEGFA in ASM and ISO-HAS cell 
lysates and cell supernatant (concentrated x10). Blots were performed 3 times, and 
representative images are shown. 
3.2.3.2 VEGFR2 
VEGFR2 is the main receptor mediating the pro-angiogenic effects of VEGFA. 
Phosphorylation of VEGFR2 in ASM and ISO-HAS lysates from semi-confluent cells 
starved overnight in normoxia and hypoxia were investigated by western blotting (figure 
3.16). These studies showed low or absent VEGFR2 phosphorylation in cells in 
50kDa 
37kDa 
25kDa 
20kDa 
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normoxic conditions without the addition of exogenous VEGF stimulation. VEGFR2 
phosphorylation was seen in normoxic conditions following the addition of exogenous 
VEGF (50ng/ml). In contrast in hypoxic conditions, VEGFR2 phosphorylation was 
observed in ASM and ISO-HAS cells even in the absence of exogenous VEGF 
stimulation. 
 Normoxia (21% O2)  Hypoxia (1% O2)  
       ASM       ISO-HAS  ASM           ISO-HAS  
     -       +         -       +     -        +        -       + VEGF 50ng/ml 
220kDa 
 
 
 
pVEGFR2 
Figure 3.16: Images of western blots probing for phosphorylated VEGFR2 in ASM and 
ISO-HAS cells incubated overnight in normoxic or hypoxic conditions +/- stimulation 
with exogenous VEGF 50ng/ml 3 minutes before lysate preparation. 
 
Despite adjustments to the working protocol described in section 2.4.3, western blot 
studies did not demonstrate expression of VEGFR1 in ASM, ISO-HAS or HuDMEC 
lysates. 
3.2.4 Protein expression summary 
Compared to HuDMECs, VEGF was significantly over-expressed by ASM and ISO-
HAS cells, in both normoxic and hypoxic conditions. There was no evidence of 
autophosphorylation of VEGFR2 in ASM or ISO-HAS cells in normoxic conditions, but 
VEGFR2 was autophosphorylated in hypoxic conditions.  
 92 
 
3.3 Functional Assays 
Functional assays were performed to contrast the biological characteristics of ASM, 
ISO-HAS and HuDMEC cells. Assays were performed to compare endothelial cell 
proliferation using the semi-automated Vi-CELL to measure viable cell counts over 
time, endothelial cell differentiation by studying tubule formation on the extracellular 
matrix Matrigel, and cell migration using the Boyden chamber (see section 2.3).  
3.3.1 Growth kinetics 
The growth curves of ASM, ISO-HAS and HuDMEC cells plated in full growth media 
were compared at an initial seeding density of 5 x 104 viable cells per ml. There was a 
lag phase of 48 hours after seeding before mean viable cell counts increased from 
baseline (figure 3.17). At 72 hours after seeding, ASM and ISO-HAS growth curves 
separated from HuDMECs and showed an exponential growth phase, whilst HuDMEC 
proliferation became variable.    
 
Figure 3.17: Growth curves from cells plated in full media, with an initial seeding 
density of 5 x 104 cells per ml. Viable cell counts were measured every 24 hours from 
seeding. Data shown represents mean viable cell count ± SEM; n=3. 
3.3.2 Differentiation (tubule formation) assay 
The differentiation assay, used to model angiogenesis in vitro, assessed endothelial 
tubule formation on an extracellular matrix (see section 2.3.2). Baseline studies 
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compared the number of tubules formed at 6 hours by HuDMEC, ASM and ISO-HAS 
cells on growth factor reduced basement membrane extract (Matrigel) in the presence 
or absence of exogenous VEGF (50ng/ml). The morphology of tubule structure was 
very different between cell lines. HuDMECs formed an elegant network of tubules, ISO-
HAS formed numerous short tubules and ASM formed fewer, short tubules (figure 3.18 
and 3.19).  ASM and ISO-HAS formed significantly shorter tubules than HuDMECs 
(mean ± SEM difference in tubule length (arbitrary units) between HuDMECs and ASM 
2.0 ± 0.3 (p<0.001), and between HuDMECs and ISO-HAS 1.8 ± 0.3 (p<0.001)). ISO-
HAS and HuDMEC formed significantly more tubules than ASM cells (mean ± SEM 
number of tubules ASM vs ISO-HAS vs HuDMECs, 31 ± 9.5 vs 108 ± 17.2 vs 106 ± 
11.7 (p=0.006 and 0.008 respectively)). In these studies no increase was seen in the 
number of tubules formed following stimulation with exogenous VEGF. The total length 
of the tubule network formed by ASM, ISO-HAS and HuDMECs strongly correlated with 
the number of tubules formed, and therefore in subsequent drug studies only the 
number of tubules formed was measured. 
 
   
ASM ISO-HAS HuDMECs 
Figure 3.18: Images of tubule formation by ASM, ISO-HAS and HuDMEC cells on 
Matrigel (x4 magnification).  
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Figure 3.19: Number of tubules formed by ASM, ISO-HAS and HuDMEC cells on 
growth factor reduced basement membrane extract ± exogenous VEGF (50ng/ml); 
* increased compared to ASM (p<0.01), p value calculated using the independent t 
test. Data shown represents mean number of tubules ± SEM; n=4. 
3.3.3 Migration 
The Boyden chamber was used to compare the migration of endothelial cells across a 
porous membrane (see section 2.3.3). Studies compared the number of migrated ASM, 
ISO-HAS and HuDMEC cells at 4 hours, in the presence or absence of VEGF 20ng/ml 
added to lower chambers (figure 3.20). In the absence of VEGF, an increased number 
of ASM and ISO-HAS cells migrated compared to HuDMECs (mean ± SEM number 
per x20hpf of migrated HuDMEC vs ASM vs ISO-HAS cells, 19.6 ± 3.2 vs 91.0 ± 9.8 vs 
60.7 ± 13.4 (p=0.001 and 0.025 respectively)). Cell migration did not increase in 
response to the addition of VEGF chemotractant to lower chambers in studies of ASM 
and ISO-HAS cell lines. In contrast, a tendency towards increased migration was 
observed in studies with HuDMECs (mean ± SEM number per x20hpf of migrated 
HuDMECs with and without VEGF 20ng/ml, 22.3 ± 2.1 and 19.6 ± 3.2 (p=0.056)). 
Comparisons between cell lines in the presence of VEGF 20ng/ml showed significantly 
increased ASM cells migrated, and a tendency towards increased ISO-HAS cells 
migrated, compared to HuDMECs (mean ± SEM number per x20hpf of migrated cells 
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in the presence of VEGF 20ng/ml HuDMECs vs ASM vs ISO-HAS, 22.3 ± 2.1 vs 86.2 ± 
3.0 vs 57.1 ± 10.3 (p<0.001 and 0.075 respectively)).  
 
 
Figure 3.20: ASM, ISO-HAS and HuDMEC cell migration in Boyden chamber studies, 
in the presence or absence of VEGF 20ng/ml; * increased cell migration compared to 
HuDMECs (p<0.05), calculated using the independent t test. Data shown represents 
mean number of migrated cells per high power field (hpf) x20 magnification ± SEM; 
n≥3. 
 
3.3.4 Functional assays summary 
These studies demonstrated ASM and ISO-HAS cells had biological characteristics 
distinct from HuDMEC cells and were consistent with a malignant phenotype, including 
increased growth kinetics, chaotic tubule formation, and increased cell migration. 
These characteristics were measureable in a series of in vitro functional assays, which 
were subsequently used to quantify and compare ASM, ISO-HAS and HuDMEC cell 
response to vascular targeted agents.   
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3.4 Drug Studies 
Drug studies were performed to compare the response of ASM, ISO-HAS and 
HuDMECs to vascular targeted agents. Baseline cell viability assays were performed to 
demonstrate chemosensitivity of ASM and ISO-HAS cells to doxorubicin and paclitaxel 
chemotherapy, which are used as first and second line agents for the treatment of 
advanced angiosarcoma. The effects of VEGF targeted agents were selected for study 
as protein array and ELISA studies identified that ASM and ISO-HAS cells expressed 
significantly more VEGF compared to HuDMECs. Bevacizumab, the humanised 
monoclonal antibody to VEGF, and the tyrosine kinase inhibitors (TKIs) axitinib and 
sunitinib were studied as examples of drugs targeting the VEGF signalling pathway. 
The MEK inhibitor selumetinib was studied after western blot studies showed persistent 
phosphorylation of downstream ERK in ASM and ISO-HAS cells despite the inhibition 
of VEGFR2 phosphorylation by VEGF targeted agents. Response to the Akt inhibitor 
MK2206 and mTOR inhibitor everolimus in ASM and ISO-HAS cells was investigated 
following results from an immunohistochemistry study by Lahat et al showing increased 
expression of pAkt, p4EBP1 and eIF4E in angiosarcoma tumour samples[168], 
although the phosphorylated kinase protein array studies presented here suggested 
only a modest increase in pAkt expression by ASM or ISO-HAS cells compared to 
HuDMECs, and increased p70 S6 kinase in ASM cells only. In contrast, the 
phosphorylated kinase array demonstrated increased phosphorylation of ChkII in ASM 
and ISO-HAS cells and therefore response to the ChkII inhibitor C3742 was studied. 
Finally, as an example of a direct vascular targeting agent, the vascular disrupting 
agent DMXAA was studied, with mechanisms of action distinct from the other agents 
selected for study. 
3.4.1 Chemotherapeutic agents 
Preliminary viability studies were performed to assess response of ASM cells to 
doxorubicin or paclitaxel chemotherapy (0 - 50ng/ml) (figure 3.21). 1 x 105 viable cells 
were seeded in full growth media and allowed 60 hours to establish before 
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chemotherapy agents were added. Viable cell counts were then measured using the 
Vi-CELL at 0, 48, 72 and 96 hours following the addition of chemotherapy. Viable cell 
counts 96 hours after treatment were expressed as a percentage of cell counts at 96 
hours in the absence of drug (0ng/ml; Figure 3.22). From the trendlines, the half 
maximal inhibitory concentrations (IC50) were estimated at 12.5ng/ml and 31.5ng/ml for 
paclitaxel and doxorubicin respectively.  
All drug studies performed subsequently used the protocol described in section 2.5.1.1. 
1x 105 viable cells were plated in full growth media and allowed 48 hours to establish. 
Therapeutic agents were then added and cell counts performed 120 hours later using 
the Vi-CELL. Further viability studies with doxorubicin and paclitaxel using this protocol 
confirmed a chemotherapy dose response at 120 hours of decreasing ASM and ISO-
HAS % viability and viable cell counts with increasing chemotherapy dose. Estimated 
IC50 from these studies were similar to the preliminary estimates, with an IC50 for 
paclitaxel of 7.5ng/ml for both ASM and ISO-HAS and IC50 for doxorubicin of 22.5ng/ml 
and 20ng/ml for ASM and ISO-HAS respectively (figure 3.23). 
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Figure 3.21: ASM viability and viable cell count at 0, 48, 72 and 96 hours after the 
addition of (A) paclitaxel and (B) doxorubicin. Data shown is the mean of 3 wells; n=1. 
 
 
Figure 3.22: ASM viable cell count at 96 hours. Log dose response to paclitaxel and 
doxorubicin chemotherapy shown with trendlines fitted; n=1. 
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Figure 3.23: (A) ASM and (B) ISO-HAS viability and viable cell counts in response to 
paclitaxel and doxorubicin chemotherapy. Data shown represents mean ± SEM; n≥3.   
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3.4.2 VEGF targeted agents 
The angiogenesis protein array and VEGF ELISA studies provided a clear rationale for 
studying the effects of VEGF targeted therapy.  
3.4.2.1 Tyrosine kinase inhibitors 
3.4.2.1.1 Cell viability studies in the presence of TKI 
Response to the broad spectrum TKI sunitinib (0 - 250ng/ml) and the more selective 
VEGFR TKI axitinib (0 - 250ng/ml) was studied. Drug response was studied across a 
range of doses based on published data from phase I trials reporting a Cmax of 72ng/ml 
and 63ng/ml for sunitinib and axitinib with recommended treatment doses (50mg daily 
and 5mg twice daily respectively)[169, 170]. Minimal responses were seen at 120 
hours in ASM or ISO-HAS % viability or viable cell counts with either agent (figure 
3.24A and B). Comparison studies investigated HuDMEC response to axitinib at 24 
and 48 hours using the MTS assay (see section 2.5.1.2). These studies showed 
modest effects on HuDMEC cell viability (figure 3.25) with a trend towards decreased 
absorbance with increased axitinib concentrations (Kendall’s tau b=-0.35, p=0.14), 
whilst parallel studies confirmed minimal response in ASM and ISO-HAS cells (figure 
3.26). HuDMEC response to sunitinib was not studied. 
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Figure 3.24: (A) ASM and (B) ISO-HAS viability and viable cell counts in response to 
axitinib (0 - 250ng/ml) and sunitinib (0 - 250ng/ml). Data shown represents mean ± 
SEM; n≥3. 
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Figure 3.25: MTS assay of HuDMECs with axitinib (0 - 250ng/ml). Absorbance was 
measured at 24 and 48 hours. Data shown represents mean relative absorbance 
expressed as a % of baseline (0ng/ml at 24 hours) ± SEM; n=3. 
 
 
Figure 3.26: MTS assay of ASM and ISO-HAS with axitinib (0 - 250ng/ml). Data shown 
represents mean relative absorbance at 48 hours expressed as a % of baseline 
(0ng/ml at 24 hours) ± SEM; n≥2. 
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As minimal response in viable cell counts were observed in TKI studies (0 - 250ng/ml) 
with ASM and ISO-HAS, studies were performed using extended drug doses (up to 
10,000ng/ml). Significantly reduced viable cell counts were observed at doses over 
500ng/ml suggesting off target effects (figure 3.27).  
  
  
Figure 3.27: (A) ASM and (B) ISO-HAS viability and viable cell counts in extended 
dose studies (0 - 10,000ng/ml) with axitinib and sunitinib. Data shown represents mean 
± SEM; n=3. TKI dose is shown on a logarithmic scale. 
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Studies were then performed to investigate any changes in ASM and ISO-HAS viable 
cell counts with TKI and chemotherapy drug combinations. In order to explore these 
effects, the dose of paclitaxel used (5ng/ml) was below the estimated IC50 and this was 
combined with axitinib (0 - 50ng/ml) and sunitinib (0 - 50ng/ml). Although responses to 
single agent TKI were demonstrated using higher doses, it was decided more clinically 
relevant doses should be used when testing in combination with chemotherapy. These 
studies suggested the effect of combining TKI with cytotoxic chemotherapy was 
additive rather than synergistic (figure 3.28). 
 
  
  
Figure 3.28: (A) ASM and (B) ISO-HAS viability and viable cell counts in response to 
combination therapy with TKI (0 - 50ng/m) and paclitaxel chemotherapy (5ng/ml). Data 
shown represents mean ± SEM; n=3.   
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3.4.2.1.2 Cell differentiation studies in the presence of TKI 
Studies were then performed to compare the biological effects of TKIs on endothelial 
cell function in differentiation (tubule formation), migration and invasion assays. 
Axitinib, as a selective and more potent inhibitor of VEGFR phosphorylation than 
sunitinib, was chosen for further study using these assays. Response to axitinib 
0ng/ml, 50ng/ml and 250ng/ml were compared; 0ng/ml as a control, 50ng/ml as a 
clinically relevant dose, and 250ng/ml as a dose that demonstrated modest evidence of 
efficacy in cell viability assays with ASM and HUDMEC cells.   
The number of tubules formed by ASM, ISO-HAS and HuDMEC cells on growth factor 
reduced Matrigel, in response to axitinib (0 – 250ng/ml) with or without the addition of 
exogenous VEGF (50ng/ml), were compared to assess drug response in vitro (see 
section 2.3.2). Consistent with the baseline differentiation studies previously described 
(see section 3.3.2), the endothelial cell lines developed distinct patterns of tubule 
formation, and exogenous VEGF did not affect these.  
Axitinib, in the presence and absence of exogenous VEGF 50ng/ml, did not 
significantly reduce the number of tubules formed by ASM cells at the doses studied 
(figure 3.29).  
Axitinib 50ng/ml significantly reduced the number of tubules formed by ISO-HAS cells 
(mean ± SEM difference between the number of tubules formed by ISO-HAS cells with 
axitinib 0ng/ml and 50ng/ml, 44.2 ± 12.4 (p=0.038)). This inhibition was not reversed by 
adding VEGF, with a trend towards fewer tubules with increasing axitinib 
concentrations in the presence of exogenous VEGF 50ng/ml (Kendall’s tau b=-0.64, 
p=0.008). Other paired comparisons of the number of ISO-HAS tubules formed 
however were not statistically significant.  
Compared to axitinib 0ng/ml, fewer tubules were formed by HuDMECs with axitinib 
50ng/ml (p=0.058) and 250ng/ml (p=0.071) (Kendall’s tau b=-0.45, p=0.07). A trend 
towards fewer HuDMEC tubules with increasing axitinib concentration was also seen in 
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the presence of exogenous VEGF 50ng/ml (Kendall’s tau b=-0.36, p=0.14), with 
significantly fewer HuDMEC tubules formed with axitinib 250ng/ml compared with 
axitinib 0ng/ml (mean ± SEM difference in the number of HuDMEC tubules formed with 
axitinib 0ng/ml and axitinib 250ng/ml in the presence of exogenous VEGF 50ng/ml, 
23.4 ± 5.1 (p=0.019)).  
 
 
Figure 3.29: Number of tubules formed in the differentiation assay with axitinib (0 - 
250ng/ml) ± VEGF (50ng/ml); * decreased tubule formation (p<0.05), calculated using 
the paired t test; comparisons between ISO-HAS cells with axitinib 0ng/ml and 50ng/ml, 
and between HuDMEC cells with axitinib 0ng/ml and 250ng/ml in the presence of 
exogenous VEGF are shown. Data shown represents mean ± SEM; n=4. 
3.4.2.1.3 Cell migration studies in the presence of TKI 
Endothelial cell migration was assessed using the Boyden chamber assay (see section 
2.5.2.2). Consistent with the baseline migration studies previously described (see 
section 3.3.3), ASM, ISO-HAS and HuDMECs demonstrated distinct patterns of 
migration (figure 3.30). Cell migration was not significantly altered in the presence of 
exogenous VEGF 20ng/ml; HuDMEC cell migration was increased but not significantly 
(p=0.11)  
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A dose dependent inhibition of HuDMEC migration was seen with increasing axitinib 
dose, but results were not significant (Kendall’s tau b=-0.55, p=0.059). In the presence 
of exogenous VEGF, a significant dose dependent inhibition of HuDMEC migration was 
observed (Kendall’s tau b=-0.72, p=0.014) (mean ± SEM number per hpf of migrated 
HuDMECs in the presence of exogenous VEGF 20ng/ml with axitinib 0ng/ml vs axitinib 
50ng/ml vs axitinib 250ng/ml, 22.8 ± 2.1 vs 16.0 ± 3.7 vs 8.3 ± 1.2 (p=0.085 and 0.013 
respectively)). In contrast, axitinib at 50ng/ml or 250ng/ml did not significantly inhibit 
ASM or ISO-HAS cell migration, either in the presence or absence of exogenous 
VEGF. 
 
 
Figure 3.30: Number of migrated ASM, ISO-HAS and HuDMEC cells seen per x20 hpf 
with the addition of axitinib 0ng, 50ng and 250ng/ml ± the chemoattractant VEGF 
20ng/ml; * decreased HuDMEC migration (p<0.05), calculated using the paired t test. 
Data shown represents mean ± SEM; n=3.  
3.4.2.1.4 Cell invasion studies in the presence of TKI 
Invasion was assessed using a modified trans-well assay in a 96-well plate format (see 
section 2.5.2.3). A plate reader was used to quantify the cellular conversion of Calcein-
AM to fluorescent Calcein in lower wells, to estimate the number of viable endothelial 
cells that invaded through from upper chambers across a porous membrane coated in 
a basement membrane extract.  
0 
20 
40 
60 
80 
100 
M
e
an
 m
ig
ra
te
d
 c
e
ll 
 C
o
u
n
t 
(p
e
r 
2
0
xh
p
f)
 
ASM 
IsoHas 
HuDMEC 
* 
 108 
 
Control studies with ASM, ISO-HAS and HuDMEC cells in axitinib 0ng/ml contrasted 
with results from the Boyden chamber migration assays (figure 3.31). Results showed 
a similar number of ASM and HuDMEC cells invaded across the basement membrane 
extract, but significantly fewer ISO-HAS cells (mean ± SEM number of invaded ISO-
HAS vs ASM vs HuDMEC cells, 598 ± 120 vs 1739 ± 229 vs 1583 ± 311 (p=0.012 and 
0.042 respectively)). Furthermore no significant increase in cell invasion was seen by 
either cell line in response to the chemotractant VEGF (20ng/ml).  
No significant differences were seen in fluorescent readings in response to axitinib 
50ng/ml or 250mg/ml, with or without the addition of exogenous VEGF (20ng/ml), and 
correspondingly therefore there were also no significant differences in the estimated 
number of invaded cells (figure 3.). Fluorescent readings with ASM cells decreased 
with the addition of axitinib 50ng/ml, however these differences were not significant 
(mean ± SEM difference in fluorescence between ASM cells with axitinib 0ng/ml and 
axitinib 50ng/ml 22.6 ± 12.1 (p=0.20)). 
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Figure 3.31: Invasion assay results comparing baseline studies with the addition of 
axitinib 50ng/ml or 250ng/ml, ± VEGF 20ng/ml. (A) mean fluorescence (raw data) and 
(B) fluorescence readings expressed as estimated cell numbers (using the equations 
shown in section 2.5.2.3); * increased ASM and HuDMEC cell invasion compared to 
ISO-HAS (p<0.05), calculated using the independent t test. Data shown represents 
mean ± SEM; n=3. 
 
3.4.2.2 Bevacizumab 
Preliminary studies were performed to assess endothelial cell response to the 
humanised monoclonal antibody to VEGF bevacizumab 5mg/ml, however in control 
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Tween[164]; see section 2.5). A Boyden chamber migration study was performed to 
assess endothelial cell response to serial dilutions of the bevacizumab control vehicle. 
This study identified 0.25mg/ml of vehicle as the maximum dose with no significant 
effect on cell migration compared to vehicle free. Response to bevacizumab 0.25mg/ml 
has previously been studied in vitro in assays with retinal microvascular endothelial 
cells[171], and was therefore selected as an appropriate dose for further study. Only 
modest responses were seen in these subsequent studies, and therefore the effects of 
bevacizumab at doses lower than 0.25mg/ml were not assessed. 
3.4.2.2.1 Cell viability studies in the presence of bevacizumab 
The effects of bevacizumab (0.25mg/ml) on ASM and ISO-HAS cell viability were 
measured with the trypan blue dye exclusion assays using the Vi-CELL (see section 
2.5.1.1) in both single agent and drug combination studies with paclitaxel (5ng/ml). No 
significant differences were seen in viable cell counts compared to control vehicle in 
either monotherapy or combination studies with chemotherapy (figure 3.32). In these 
studies the response to paclitaxel chemotherapy by ISO-HAS was less than that 
observed in the initial chemotherapy studies previously described (figure 3.23). This 
was repeated using cells recovered from a different vial of ISO-HAS cells stored in 
liquid nitrogen, but similar results were found.  
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Figure 3.32: Viable cell counts for ASM and ISO-HAS in response to bevacizumab 
(Bz) 0.25mg/ml ± paclitaxel 5ng/ml. No significant differences were seen in response to 
bevacizumab. Data shown represents mean ± SEM; n=3.   
Comparison studies were performed to investigate the effects of bevacizumab on 
HuDMEC viability using the MTS assay (see section 2.5.1.2). These studies 
demonstrated no significant changes in viability or proliferation at 24 and 48 hours 
(figure 3.33). Parallel studies confirmed minimal response to bevacizumab in ASM and 
ISO-HAS cells (figure 3.34). 
 
Figure 3.33: MTS assay of HuDMECs with bevacizumab (Bz) 0.25mg/ml. Absorbance 
was measured at 24 and 48 hours. Data shown represents mean relative absorbance 
expressed as a % of baseline (control vehicle at 24 hours) ± SEM; n=4. 
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Figure 3.34: MTS assay of ASM and ISO-HAS with bevacizumab (Bz) 0.25mg/ml. 
Data shown represents mean relative absorbance at 48 hours expressed as a % of 
baseline (control vehicle at 24 hours) ± SEM; n≥2. 
3.4.2.2.2 Cell differentiation studies in the presence of bevacizumab 
ASM, ISO-HAS and HuDMEC cell response to bevacizumab 0.25mg/ml was studied in 
differentiation assays at 6 hours (see section 2.5.2.1). Endothelial cell tubule formation 
was similar to baseline studies. In the bevacizumab studies the number of tubules 
formed by ASM and ISO-HAS cells did not differ significantly with the addition of VEGF 
(50ng/ml), however the number of tubules formed by HuDMEC cells significantly 
increased in response to VEGF (mean ± SEM number of HuDMEC tubules formed in 
control vehicle vs control vehicle plus VEGF 50ng/ml, 57 ± 5.1 vs 75 ± 7.4 (p=0.019)) 
(figure 3.35). 
No significant change was observed in the number of ASM or ISO-HAS tubules formed 
in response to bevacizumab 0.25mg/ml, either in the presence or absence of 
exogenous VEGF (figure 3.35). In contrast, bevacizumab 0.25mg/ml inhibited 
HuDMEC tubule formation stimulated by VEGF 50ng/ml (mean ± SEM number of 
HuDMEC tubules formed in control vehicle vs bevacizumab 0.25mg/ml + VEGF 
50ng/ml, 57 ± 5.1 vs 51 ± 8.1 (p=0.67)).  
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Figure 3.35: Number of tubules formed in the differentiation assay with bevacizumab 
(Bz) 0.25mg/ml ± VEGF 50ng/ml; * increased number of tubules formed by HuDMEC 
cells in response to VEGF stimulation (p<0.05), calculated using the paired t test. Data 
shown represents mean ± SEM; n≥3.  
3.4.2.2.3 Cell migration studies in the presence of bevacizumab 
Cell migration was assessed using the Boyden chamber (see section 2.3.3). Cell 
migration was similar to baseline studies. The number of migrated ASM or ISO-HAS 
cells did not significantly increase with the addition of VEGF (20ng/ml) however, the 
number of migrated HuDMEC cells significantly increased in response to stimulation 
with VEGF (mean ± SEM number per 20x hpf of migrated HuDMEC cells with 
bevacizumab 0ng/ml vs bevacizumab 0ng/ml plus VEGF 20ng/ml, 14 ± 2.2 vs 23 ± 2.6 
(p=0.022)) (figure 3.36). 
No significant change was observed in the number of migrated ASM or ISO-HAS cells 
in response to bevacizumab 0.25mg/ml (figure 3.36). In contrast Bevacizumab 
0.25mg/ml significantly inhibited VEGF stimulated HuDMEC cell migration, and 
reduced HuDMEC migration to levels below the established baseline (mean number of 
migrated HuDMEC cells per 20x hpf with control vehicle vs bevacizumab 0.25mg/ml 
plus VEGF 20ng/ml 14 +/- 2.2 vs 10 +/- 1.6 (p=0.028)). 
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Figure 3.36: Number of migrated ASM, ISO-HAS and HuDMEC cells per x20 hpf with 
bevacizumab (Bz) 0.25 mg/ml ± the chemotractant VEGF 20ng/ml; * significant 
difference in HuDMEC cell migration compared to control (p<0.05), calculated using 
the paired t test. Data shown represents mean ± SEM; n≥3.  
3.4.2.3 VEGF targeted agents in hypoxia 
Tumours are typically hypoxic. Hypoxia stimulates the expression of VEGF and thus 
tumour angiogenesis. The VEGF ELISA studies showed a dramatic increase in ASM 
and ISO-HAS expression of VEGF in hypoxia (1% O2) compared to HuDMECs (figure 
3.14). Drug studies were therefore performed to assess the response of ASM and ISO-
HAS to VEGF targeted therapy in hypoxic conditions. HuDMECs did not tolerate 
hypoxic conditions of 1% O2 well, and their response to VEGF targeted therapy was 
therefore not assessed.  
3.4.2.3.1 Cell viability in hypoxia  
Cell viability was assessed using the trypan blue dye exclusion assay with viable cell 
counts measured 120 hours after the addition of drugs (see section 2.5.1.1). ASM and 
ISO-HAS % viability and viable cell counts were lower in hypoxia (1% O2) than 
normoxia (21% O2) (table 3.3).  
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  Normoxia 
(21% O2) 
Hypoxia 
(1% O2) 
p 
ASM Viability (%) 91.8 ± 1.6 78.7 ± 6.0 0.054 
 Viable cell count (x106) 0.36 ± 0.04 0.15 ± 0.01 0.004 
ISO-HAS % viability 92.1 ± 1.1 66.8 ± 8.3 0.09 
 Viable cell count (x106) 0.24 ± 0.05 0.15 ± 0.07 0.31 
 
Table 3.3: ASM and ISO-HAS % viability and viable cell counts in normoxia (21% O2) 
and hypoxia (1% O2); p values calculated using the independent t test. Data shown 
represents mean ± SEM; n=3.  
 
As shown in figure 3.37 axitinib 50ng and 250ng/ml, and bevacizumab 0.25mg/ml did 
not significantly alter ASM or ISO-HAS viable cell counts in hypoxia (1% O2). 
  
Figure 3.37: ASM and ISO-HAS viable cell counts in hypoxia (1% O2) without VEGF 
targeted agents, and with the addition of axitinib 50ng/ml, 250ng/ml, and bevacizumab 
0.25mg/ml. Data represents mean ± SEM; n=3. 
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3.4.2.3.2 Cell differentiation in hypoxia 
Studies were performed to quantify changes in the number of tubules formed by ASM 
and ISO-HAS cells in hypoxia (1% O2). Both ASM and ISO-HAS cells formed fewer 
tubules in hypoxia than normoxia but these differences were not significant, and as in 
normoxia, ASM cells formed fewer tubules than ISO-HAS. No significant differences 
were observed between the numbers of tubules formed by ASM or ISO-HAS cells in 
hypoxia in baseline studies, with exogenous VEGF (50ng/ml), or with the addition of 
axitinib 50ng or 250ng/ml, or bevacizumab 0.25mg/ml (figure 3.38A and B).  
 
 
Figure 3.38A: Number of tubules formed by ASM and ISO-HAS cells in hypoxia (1% 
O2) with axitinib 50ng/ml and 250ng/ml ± VEGF 50ng/ml. Data shown represents mean 
± SEM; n=3.  
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Figure 3.38B: Number of tubules formed by ASM and ISO-HAS cells in hypoxia (1% 
O2) with bevacizumab 0.25mg/ml ± VEGF 50ng/ml. Data shown represents mean ± 
SEM; n=3.  
3.4.2.4 Endothelial cell differentiation with ASM and ISO-HAS conditioned media 
The protein expression studies demonstrated ASM and ISO-HAS cells secreted a 
broad panel of pro-angiogenic growth factors (figure 3.8), and increased VEGF 
secretion under hypoxic conditions (figure 3.14). Malignant endothelial cell secretion of 
pro-angiogenic growth factors may promote tumour growth through autocrine or 
paracrine stimulation of malignant endothelial cells. However, these growth factors may 
also stimulate other cells within the tumour microenvironment including non-neoplastic 
endothelial cells. An exploratory study was performed to investigate whether growth 
factors secreted by ASM and ISO-HAS would stimulate a response in non-malignant 
endothelial cells. The cell differentiation assay was used to assess the response of 
HuVECs to ASM or ISO-HAS cell conditioned media at 6 hours, and to assess whether 
VEGF targeted therapy (axitinib or bevacizumab) would inhibit any response. HuVECs 
rather than HuDMECs were used for this study, as HuDMECs were not available within 
the laboratory at that time.  
A small reduction was observed in the number of HuVEC tubules formed in response 
to exogenous VEGF (20ng/ml). In contrast, an increase in the number of HuVEC 
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tubules was seen with both ASM and ISO-HAS cell conditioned media. This increase 
was reduced by the addition of axitinib 50ng/ml or 250ng/ml, and to a lesser extent by 
bevacizumab 0.25mg/ml. 
 
 
Figure 3.39: Number of tubules formed by HuVECs in control studies (baseline and in 
response to exogenous VEGF 20ng/ml), and following the addition of ASM or ISO-HAS 
conditioned media, and with conditioned media plus axitinib 50ng/ml, 250ng/ml and 
bevacizumab 0.25mg/ml. Data shown represents mean number of tubules from 3 wells; 
n=1.  
3.4.2.5 VEGFR2 phosphorylation status 
As the observed responses to axitinib and bevacizumab in functional assays with ASM 
and ISO-HAS cells were minimal, a series of western blots were performed to assess 
change in VEGFR2 phosphorylation status (pVEGFR2) following stimulation with 
VEGF in cells pre-incubated in axitinib and bevacizumab (figure 3.40). These studies 
demonstrated pVEGFR2 was undetectable in the absence of exogenous VEGF 
stimulation. VEGFR2 phosphorylation was observed following stimulation with VEGF 
50ng/ml, which was reduced following treatment with axitinib 50ng/ml, 250ng/ml, and 
with bevacizumab 0.25mg/ml, indicating a biological effect of VEGF targeted agents on 
these cells.   
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A    0       0            50   50         250  250 Axitinib dose (ng/ml) 
 -    +             -      +            -       + VEGF (50ng/ml) 
ASM  pVEGFR2 
  VEGFR2 
ISO-HAS  pVEGFR2 
  VEGFR2 
HuDMECs  pVEGFR2 
  VEGFR2 
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     -        + 
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      +       + VEGF (50ng/ml) 
ASM  pVEGFR2 
  VEGFR2 
ISO-HAS  pVEGFR2 
  VEGFR2 
HuDMECs  pVEGFR2 
  VEGFR2 
Figure 3.40: Representative western blot studies comparing ASM, ISO-HAS and 
HuDMEC levels of total and pVEGFR2 (220 kDa) in response to exogenous VEGF 
stimulation, following pre-incubation with (A) axitinib and (B) bevacizumab. Blots were 
repeated on at least three occasions. 
3.4.2.6 Downstream signalling - phosphoERK 
Studies were performed to assess levels of the phosphorylated downstream signalling 
intermediary protein ERK (pERK) (figure 3.41a and b). Baseline levels of pERK were 
established in control studies, and a transient increase in pERK observed five minutes 
after stimulation with exogenous VEGF (50ng/ml). Baseline and peak pERK levels 
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were reduced, but not absent, in the presence of axitinib 50ng/ml, 250ng/ml and 
bevacizumab 0.25mg/ml (figure 3.42a and b).  
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Figure 3.41: Representative western blot studies of pERK in ASM and ISO-HAS cells 
pre-incubated in (A) axitinib or (B) bevacizumab for 1 hour prior to stimulation with 
VEGF 50ng/ml. pERK probed in lysates collected at 0, 5, 10 and 20 minutes after 
stimulation. Blots were repeated on two occasions. 
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Figure 3.42: Summary data from western blot studies of pERK expression in (A) ASM 
and (B) ISO-HAS cells pre-incubated in axitinib or bevacizumab before and after 
stimulation with VEGF 50ng/ml. Data shown represents mean relative density ± SEM; 
n=2. 
3.4.3 MEK inhibition 
Western blot studies of pERK expression (see section 3.4.2.6) identified basal pERK 
levels in ASM and ISO-HAS cells, and demonstrated persistent ERK phosphorylation 
despite treatment with axitinib or bevacizumab. Consistent with results from the 
phosphorylated kinase protein array, pERK expression by western blot was higher in 
ASM than ISO-HAS cells (figures 3.12 and 3.42). The array also showed increased 
levels of phosphorylated MEK in ASM and ISO-HAS cells relative to HuDMECs (figure 
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3.12). Together, these results provided a strong rationale for studying the effects of a 
MEK inhibitor. Response to selumetinib, a selective inhibitor of MEK1/2, was studied 
across a dose range of 0 - 2000ng/ml as results from a phase I trial reported mean 
plasma Cmax of 1436 ng/ml at the recommended selumetinib treatment dose of 75mg 
bd[172].  
3.4.3.1 Cell viability studies MEK inhibition 
The effect of selumetinib on ASM and ISO-HAS cell viability were studied using the 
trypan blue dye exclusion assay (see section 2.5.1.1). Selumetinib significantly reduced 
ASM viable cell counts with an estimated IC50 of 1750ng/ml, but had minimal effects on 
ISO-HAS cell viability (figure 3.43).  
  
Figure 3.43: ASM and ISO-HAS viability and viable cell counts in response to the MEK 
inhibitor selumetinib. Data shown represents mean ± SEM; n≥3.  
3.4.3.2 Cell differentiation studies with MEK inhibition 
ASM and ISO-HAS response to selumetinib were studied using the cell differentiation 
assay (see section 2.5.2.1). Endothelial cell differentiation was similar to baseline 
studies. In these studies exogenous VEGF (50ng/ml) increased ISO-HAS tubule 
formation, though not significantly (p=0.08) (figure 3.43).  
Selumetinib reduced ISO-HAS tubule formation in studies with the addition of 
exogenous VEGF 50ng/ml, but not in studies without it (mean ± SEM number of ISO-
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HAS tubules with exogenous VEGF 50ng/ml, selumetinib 0ng/ml vs 750ng/ml vs 
1500ng/ml, 108.6 ± 11.0 vs 84.6 ± 7.0 vs 82.6 ± 8.1 (p=0.021 and p=0.006 
respectively)) (figure 3.43). Selumetinib significantly reduced the number of tubules 
formed by ASM cells, both in the presence and absence of exogenous VEGF 50ng/ml 
(mean ± SEM number of ASM tubules with VEGF 50ng/ml and selumetinib 0ng/ml vs 
1500ng/ml, 10.7 ± 1.2 vs 3.2 ± 0.5 (p=0.015), and mean ± SEM number of ASM 
tubules without additional VEGF and selumetinib 0ng/ml vs 1500ng/ml, 12.1 ± 1.3 vs 
5.7 ± 1.3 (p=0.050)).  
 
 
 
Figure 3.44: Number of tubules formed in the differentiation assay in response to the 
MEK inhibitor (MEKi) selumetinib at 0ng/ml, 750ng/ml and 1500ng/ml ± VEGF 50ng/ml; 
* decreased tubule formation (p<0.05), calculated using the paired t test, comparisons 
between ISO-HAS cells with exogenous VEGF and selumetinib 0ng/ml and 1500ng/ml, 
and ASM cells with selumetinib 0ng/ml and 1500ng/ml in the presence and absence of 
exogenous VEGF are shown. Data shown represents mean ± SEM; n≥3.  
3.4.4 mTOR inhibition 
ASM and ISO-HAS cell responses to the mTOR inhibitor everolimus, and the Akt 
inhibitor MK2206, were studied in cell viability assays using the trypan blue dye 
exclusion assay (see section 2.5.1.1). mTOR inhibitors reduce VEGF synthesis through 
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reduced production of HIF-1α[173]. Akt was also identified as a potential drug target, 
as a key intra-cellular signalling molecule upstream of mTOR. Results from the 
phosphorylated kinase protein array provided supporting evidence for studying ASM 
and ISO-HAS response to these agents, with increased Akt and S6 kinase 
phosphorylation observed in ASM cells relative to HuDMECs, and increased 
phosphorylation of AMPKα, an intra-cellular inhibitor of mTOR, in HuDMEC cells 
relative to ASM and ISO-HAS.  
A phase I study reported mean plasma Cmax of 61ng/ml with an everolimus dosing 
schedule of 10mg per day, and mean plasma Cmax of 174ng/ml with a dosing schedule 
of 70mg per week[174]. The effects of everolimus were therefore studied over a dose 
range of 0 – 250ng/ml. MK2206 was also studied over a dose range of 0 – 250ng/ml, 
supported by a phase I study that reported mean MK2206 plasma Cmax of 36ng/ml with 
the recommended dosing schedule of 60mg alternate days[175].  
3.4.4.1 Cell viability with mTOR inhibition 
Neither everolimus nor MK2206 affected % viability (figure 3.45). Minor effects to viable 
cell counts were observed with the pAkt inhibitor. Modest responses were seen with 
exposure to everolimus, with maximal inhibition achieved by doses of 50ng/ml. 
Response to everolimus was subsequently studied in combination with doxorubicin 
chemotherapy (10ng/ml), as mTOR inhibitors would likely be used clinically in 
combination with chemotherapeutics. These combination studies suggested an additive 
rather than synergistic effect (figure 3.46). Effects in functional assays were not studied 
due to time constraints and indications that these agents were unlikely to have a 
profound effect. 
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Figure 3.45: (A) ASM and (B) ISO-HAS viability and viable cell counts in response to 
everolimus (0 – 250ng/ml) and MK2206 (0 – 250ng/ml). Data shown represents mean 
± SEM; n=3.   
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Figure 3.46: (A) ASM and (B) ISO-HAS viable cell counts in response to combination 
therapy with everolimus (0 – 250ng/ml) and doxorubicin chemotherapy 10ng/ml. Data 
shown represents mean ± SEM; n=3. 
3.4.5 Summary of studies with VEGF targeted agents 
Only minor responses to the VEGF targeted agents axitinib and bevacizumab were 
observed in functional assays of ASM and ISO-HAS cells, despite western blot studies 
that demonstrated target inhibition of VEGFR2 phosphorylation. Increased cell 
responses were observed to the mTOR inhibitor everolimus, and to targeting the cell 
signalling pathway downstream of VEGFR2 with the MEK inhibitor selumetinib.    
3.4.6 Checkpoint II inhibition 
The phosphorylated kinase protein array identified checkpoint II (ChkII) as a potential 
drug target. ChkII is phosphorylated in response to double strand DNA breaks, 
including double strand breaks caused by treatment with radiotherapy or 
chemotherapeutic agents such as doxorubicin[176]. A variety of checkpoint II inhibitors 
are currently in pre-clinical development. C3742 (0 – 250ng/ml) was selected for study 
(IC50 15nM) as a selective ChkII inhibitor[176].  
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3.4.6.1 Cell viability with checkpoint II inhibition 
ASM and ISO-HAS cell response to the ChkII inhibitor C3742 were studied in cell 
viability assays using the trypan blue dye exclusion assay (2.5.1.1). No response to 
C3742 was observed in ASM cells (figure 3.47), whilst in ISO-HAS the single agent 
ChkII inhibitor had a significant protective effect (mean ± SEM ISO-HAS viable cell 
count (x106) 0ng/ml vs 100ng/ml, 0.31 ± 0.02 vs 0.37 ± 0.01 (p=0.040). The ChkII 
inhibitor also protected ISO-HAS cells from response to doxorubicin (mean ± SEM ISO-
HAS cell count (x106) with doxorubicin 10ng/ml and ChkII inhibitor 0ng/ml vs 100ng/ml, 
0.24 ± 0.01 vs 0.29 ± 0.002 (p=0.006)) (figure 3.48). 
 
  
  
Figure 3.47: (A) ASM and (B) ISO-HAS viability and viable cell counts in response to 
the ChkII inhibitor C3742 (0 – 250ng/ml). Data shown represents mean ± SEM; n=3.   
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Figure 3.48: (A) ASM and (B) ISO-HAS viable cell counts in response to combination 
therapy with ChkII inhibitor (0 – 250ng/ml) and doxorubicin chemotherapy 10ng/ml. 
Data shown represents mean ± SEM; n=3.   
3.4.7 Vascular disrupting agent 
The anti-angiogenic agents studied thus far target tumour angiogenesis through 
inhibition of the cell signalling pathways stimulated by pro-angiogenic growth factors 
such as VEGF. In contrast, DMXAA is a vascular disrupting agent that induces 
apoptosis in tumour endothelial cells, resulting in collapse of the tumour vasculature 
and thus tumour hypoxia and necrosis[177]. With DMXAA treatment at 1800mg/m2, the 
dose used in phase III clinical trials in combination with chemotherapy[178],  a phase I 
trial of single agent DMXAA reported an estimated plasma Cmax of 1000µM[179]. A 
DMXAA dose range of 0 – 300µg/ml was therefore initially studied. However after a 
preliminary study, the DMXAA re-constituted in distilled water crystallised out of 
solution following storage at 40C. Thereafter DMXAA was re-constituted in DMSO, 
however this limited the maximum dose studied to 100µg/ml, as DMXAA doses beyond 
this used DMSO volumes above 1% which were toxic to cells.      
3.4.7.1 Cell viability with vascular disrupting agent 
ASM and ISO-HAS cell response to DMXAA was studied in cell viability assays using 
the trypan blue dye exclusion assay (2.5.1.1). DMXAA significantly reduced viable cell 
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counts in both ASM and ISO-HAS with an IC50 of 90 and 150 µg/ml respectively (figure 
3.49). Modest decreases in % viability were also observed. Comparison studies were 
performed to investigate the effects of DMXAA on HuDMEC viability using the MTS 
assay (see section 2.5.1.2). DMXAA significantly reduced HuDMEC viability and 
proliferation (mean ± SEM HuDMEC relative absorbance at 48 hours with DMXAA 
0µg/ml vs 30µg/ml vs 100µg/ml, 151.4 ± 14.7 vs 95.8 ± 14.1 and 76.7 ± 9.0 (p=0.053 
and 0.012 respectively)) (figure 3.50). Parallel studies of ASM and ISO-HAS cell 
viability confirmed response to DMXAA at 48 hours using the MTS assay (figure 3.51).  
 
  
Figure 3.49: ASM and ISO-HAS viability and viable cell counts in response to the 
vascular disrupting agent DMXAA (0 - 300µg/ml). Data shown represents mean ± SEM; 
n=3.   
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Figure 3.50: Results from the MTS assay of HuDMECs with DMXAA (0 – 100µg/ml). 
Absorbance was measured at 24 and 48 hours. Data shown represents mean relative 
absorbance expressed as % of baseline (0µg/ml at 24 hours) ± SEM; n=3. 
 
 
Figure 3.51: Results from the MTS assay of ASM and ISO-HAS cells with DMXAA (0 – 
100µg/ml). Data shown represents mean relative absorbance at 48 hours expressed as 
% of baseline (0µg/ml at 24 hours); n=1. 
3.4.7.2 Cell differentiation with vascular disrupting agent 
Endothelial cell response to DMXAA (0 - 100µg/ml) was studied using the cell 
differentiation assay (see section 2.5.2.1). The number of tubules formed by ASM, ISO-
HAS and HuDMEC cells in these assays were consistent with previous studies. 
DMXAA significantly reduced endothelial cell tubule formation in a dose dependent 
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manner (mean ± SEM number of ASM tubules in DMXAA 0µg/ml vs 100µg/ml, 21.1 ± 
7.2 vs 5.8 ± 2.4 (p=0.086), mean ± SEM number of ISO-HAS tubules in DMXAA 0µg/ml 
vs 100µg/ml, 108.2 ± 8.3 vs 61.0 ± 8.8 (p=0.009), and mean ± SEM number of 
HuDMEC tubules in DMXAA 0µg/ml vs 100µg/ml, 79.4 ± 19.1 vs 46.8 ± 18.8 (p=0.025)) 
(figure 3.52).  
 
 
Figure 3.52: Number of tubules formed in the differentiation assay in response to 
DMXAA at 0, 30 and 100µg/ml; * decreased tubule formation compared to 0µg/ml 
(p<0.05), calculated using the paired t test, comparisons between ISO-HAS cells with 
DMXAA 0µg and 100µg/ml, and between HuDMEC cells with DMXAA 0µg and 
100µg/ml are shown. Data shown represents mean ± SEM; n≥3.  
3.4.7.3 DMXAA drug mechanisms 
Studies were performed to investigate the mechanisms of drug response seen in the 
angiosarcoma cell lines. The precise methods by which DMXAA exerts its anti-vascular 
effect are unknown, however it has been postulated that DMXAA stimulates apoptosis 
in endothelial cells via nuclear factor kappa B (NF-κB) and induces tumour expression 
of tumour necrosis factor α (TNFα) within 24 hours of exposure[177].  
3.4.7.3.1 TNFα 
ASM cells were incubated for 4 and 24 hours with DMXAA 0µg/ml or 100µg/ml, and the 
levels of TNFα in lysates and cell conditioned media quantified by ELISA. TNFα levels 
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were similar in lysates and conditioned media, and TNFα expression was similar at 4 
and 24 hours of drug exposure (figure 3.53). Compared to control samples, TNFα 
expression was slightly higher in cells treated with DMXAA 100µg/ml but this was not 
significant.   
 
Figure 3.53: Graph comparing the expression of TNFα in ASM cell lysates following 4 
and 24 hours incubation with 0 or 100µg/ml DMXAA. Data shown represents mean 
TNFα values per mg of total protein content in the cell lysates ± SEM; n=4.  
3.4.7.3.2 Apoptosis 
ASM cells were incubated for 1, 2, 4, 6, 12 and 24 hours with DMXAA 0µg/ml or 
100µg/ml. Cell death was assessed by flow cytometry using annexin V antibody and 
propidium iodide (PI) staining to measure the proportion of apoptotic and necrotic cells 
respectively. Results showed an increase over time in the proportion of apoptosis and 
necrosis with both DMXAA 0µg/ml and 100µg/ml (mean ± SEM apoptotic plus necrotic 
cells (%) with DMXAA 0µg/ml at 1 hour vs 12 hours, 10.3 ± 2.2 vs 19.0 ± 2.5 (p=0.060), 
and mean ± SEM apoptotic plus necrotic cells (%) with DMXAA 100µg/ml at 1 hour vs 
12 hours, 12.2 ± 2.4 vs 19.8 ± 0.8 (p=0.040)) (figure 3.54). However, there was no 
significant difference in the proportion of apoptosis and necrosis between cells treated 
with DMXAA 0µg/ml and DMXAA 100µg/ml (table 3.4).   
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Figure 3.54: Plots from flow cytometry studies to measure the proportion of viable, 
apoptotc and necrotic cells using annexin V antibody (Red 660/20-A) and propidium 
iodide staining (Blue 610/20-A). Plots compare ASM cells incubated in DMXAA 0µg/ml 
and 100µg/ml for 1 hour (A and B) and 12 hours (C and D) respectively. Cells were 
gated into: a - apoptotic; n - necrotic; v - viable.   
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Time (hours) DMXAA (µg/ml) % Viable % Apoptotic % Necrotic p 
1 0 89.6 3.3 7.1 0.60 
 100 87.8 4.5 7.7  
      
2 0 85.4 2.2 12.4 0.62 
 100 88.0 3.5 8.5  
      
4 0 85.4 2.8 11.8 0.24 
 100 83.6 3.3 13.1  
      
6 0 83.6 5.3 11.1 0.49 
 100 86.7 3.5 9.8  
      
12 0 81.0 3.6 15.4 0.77 
 100 80.2 4.4 15.4  
      
24 0 81.5 5.6 12.9 0.86 
 100 82.9 5.4 11.7  
       
 
Table 3.4: The proportion of viable, apoptotic and necrotic ASM cells, as measured by 
flow cytometry using annexin V and propidium iodide staining. ASM cells were 
incubated with DMXAA 0µg/ml or 100µg/ml for 1 – 24 hours. p values were calculated 
using the independent t test to compare the proportion of apoptotic plus necrotic cells 
between DMXAA 0µg/ml and DMXAA 100µg/ml. Data shown represents mean cell 
count (%); n=3. 
3.4.7.4 Vascular disrupting agent summary 
Striking responses to the vascular disrupting agent DMXAA were observed in 
functional assays of ASM, ISO-HAS and HuDMEC cells. The mechanism of this 
response is uncertain. It has been postulated that DMXAA causes tumour endothelial 
cell apoptosis, perhaps through induction of TNFα. However, the studies presented 
here showed DMXAA did not induce TNFα expression, nor increase cell apoptosis, in 
ASM cells. Further studies in a wider panel of angiosarcoma tumour samples, including 
in vivo studies, are required to support the progression of DMXAA for angiosarcoma to 
clinical trials, however human angiosarcoma tumour samples are limited.  
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3.5 Human Angiosarcoma Tumour Samples 
Angiosarcoma tumour samples were collected intra-operatively from four patients 
following informed consent (REC number: 09/H1313/52; STH project number: 15394) 
(table 3.5). These samples were collected with the aim of isolating viable angiosarcoma 
tumour cells for in vitro study. 
 
Sample 
number 
Patient 
Age 
Patient 
Sex 
Tumour site Tumour details Additional notes 
STS0510 69 F Breast - 
secondary 
angiosarcoma 
70mm well 
differentiated 
angiosarcoma 
Wide local excision 
and post operative 
radiotherapy for 
primary breast 
cancer 12 yrs 
previously 
STS2110 69 M Soft tissue 
(leg) - 
secondary 
angiosarcoma 
Large (>50mm) 
fungating, 
necrotic tumour 
Chronic 
lymphoedema 
secondary to an 
angiogram 
procedure 
complicated by 
aneurysm and 
chronic infection 12 
yrs previously 
STS2210 58 F Breast - 
secondary 
angiosarcoma 
2mm tumour 
excised  
Mastectomy and 
post operative 
radiotherapy for 
primary breast 
cancer 8 yrs 
previously 
STS1011 48 F Breast - 
primary 
angiosarcoma  
52mm tumour No known risk 
factors 
Table 3.5: Details of patients donating angiosarcoma tumour tissue. 
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3.5.1 Tumour cell isolates 
Fragments from fresh tumour biopsies were homogenised and plated in T25 flasks in 
full growth media (see section 2.6.1). Once established, adherent proliferating cell 
populations were re-plated to form a monolayer in T75 flasks. Immunocytochemistry 
studies of early cell passages were performed to assess expression of endothelial cell 
markers including CD31, VEGF and VEGFRs, and the fibroblast marker αSMA. 
3.5.1.1 STS0510 
Once cultured, STS0510 tumour cell isolates were separated to select CD31+ cells 
using MACS micro beads coated with antibody for CD31 (see section 2.6.1). The 
extracted CD31+ cells were then re-plated and re-cultured. These cells had a spindle 
morphology (figure 3.55), and immunocytochemistry studies showed they were CD31, 
CD34 and vWF negative, VEGFR2 weakly positive, and αSMA, VEGF and VEGFR1 
strongly positive (figure 3.56). This profile was consistent with cells of a fibroblastic 
rather than endothelial lineage. A similar immunocytochemistry profile was also seen in 
STS0510 cell isolates which underwent a repeat CD31 separation. Growth of the 
STS0510 tumour cell isolates arrested at passage 6. Aliquots of cell isolates were 
stored in liquid nitrogen in 10% DMSO for later study in functional assays, but 
unfortunately did not survive this process.  
 
Figure 3.55: Cells isolated by CD31+ MACS micro beads from STS0510, passage 2 
(x4 magnification).  
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CD31 αSMA VEGF VEGFR1 
Figure 3.56: Immunocytochemistry studies of STS0510 passage 2 tumour cell isolates 
which had previously undergone CD31 separation (x20 magnification). Cells did not 
stain for CD31 but did stain for αSMA, VEGF and VEGFR1. A similar staining profile 
was seen with isolates that underwent a secondary CD31 separation. 
3.5.1.2 STS2110, STS2210 
Insufficient cells settled and grew in culture from these tumour specimens, prohibiting 
further study.  
3.5.1.3 STS1011 
Unlike with STS0510, cell separation of STS1011 cell isolates using CD31 antibody 
coated MACS micro beads was not performed. STS1011 tumour cell isolates had a 
spindle morphology (figure 3.57), and in immunocytochemistry studies passage 4 cells 
were CD31 and αSMA negative, but VEGF, VEGFR1 and VEGFR2 positive (figure 
3.58). STS1011 cell growth arrested at passage 8. 
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Figure 3.57: Image of cells isolated from STS1011, passage 2 (x4 magnification).  
 
    
CD31 αSMA VEGF VEGFR1 
Figure 3.58: Immunocytochemistry studies of passage 4 cells isolated from STS1011 
(x20 magnification). Cells were CD31, αSMA negative, VEGF and VEGFR1 positive. 
3.5.1.3.1 Functional in vitro studies 
The response of STS1011 cell isolates to VEGF targeted agents was studied in 
functional assays. Response to axitinib (50ng/ml and 250ng/ml) and bevacizumb 
(0.25mg/m) was assessed. These studies preceded the assays investigating ASM and 
ISO-HAS response to the MEK inhibitor selumetinib and the vascular disrupting agent 
DMXAA, and thus STS1011 response to these agents was not studied.  
3.5.1.3.1.1 STS1011 cell viability 
Cell viability in response to paclitaxel chemotherapy (5ng/ml), and VEGF targeted 
agents was assessed using the trypan blue dye exclusion assay (see section 2.5.1.1). 
STS1011 passage 4 cell isolates showed a striking response to single agent paclitaxel 
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5ng/ml, a modest response to axitinib 250ng/ml, and no response to bevacizumab 
0.25mg/ml. In contrast, only minor drug responses were seen with passage 7 cells. No 
increased response was observed to combinations of paclitaxel with VEGF targeted 
agents with passage 4 or 7 cells (figure 3.59a and b).  
 
 
Figure 3.59: Comparison of STS1011 passage 4 and 7 viable cell counts (A) in 
response to single agent axitinib (50ng/ml, 250ng/ml) or bevacizumab (0.25mg/ml) and 
(B) in response to single agent paclitaxel (5ng/ml) and in combination with VEGF 
targeted agents. Data shown represents the mean viable cell count of 2 wells 
expressed as a percentage of the STS1011 viable cell count without any drug; n=1.  
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3.5.1.3.1.2 STS1011 cell differentiation 
The response of STS1011 tumour cell isolates to VEGF targeted agents was studied in 
cell differentiation assays (see section 2.5.2.1). Tubule formation by passage 2 
STS1011 cells was similar to that observed with ISO-HAS cells. Passage 4 STS1011 
cells pre-dominantly formed islands of proliferating cells interconnected by webs of 
tubules and by passage 7 only a few tubules were seen (figure 3.60).  
Overall, no increase was seen in the number of tubules formed by STS1011 passage 2 
and 4 cells in response to VEGF 50ng/ml stimulation (mean ± SEM number of tubules 
formed by passage 2 and 4 cells, with vs without VEGF 50ng/ml, 103.5 ± 5.1 vs 104.9 
± 4.9 (p=0.853)). Axitinib 50ng/ml and 250ng/ml tended to reduce the number of 
tubules formed, both in the presence and absence of exogenous VEGF 50ng/ml 
stimulation (in the absence of VEGF mean ± SEM number of tubules with axitinib 
0ng/ml vs 50ng/ml vs 250ng/ml, 113.0 ± 2.0 vs 75.4 ± 5.9 vs 79.8 ± 6.8 (p=0.07 and 
0.09 respectively); in the presence of VEGF 50ng/ml mean ± SEM number of tubules 
with axitinib 0ng/ml vs 50ng/ml vs 250ng/ml, 100.3 ± 9.8 vs 77.7 ± 6.0 vs 63.8 ± 26.2 
(p=0.39 and 0.27 respectively)) (figure 3.61A). The number of tubules formed did not 
differ in response to bevacizumab 0.25mg/ml, either in the presence or absence of 
VEGF 50ng/ml stimulation (figure 3.61B).  
 
   
P2 P4 P7 
Figure 3.60: Tubule formation on growth factor reduced Matrigel in differentiation 
assays with cell isolates from STS1011, passage 2, 4 and 7 (x4 magnification). 
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Figure 3.61: Number of tubules formed by STS1011 cell passages (P2, P4 and P7) in 
cell differentiation assays in response to (A) axitinib (0 – 250ng/ml) and (B) 
bevacizumab (0.25mg/ml) in the presence or absence of VEGF 50ng/ml stimulation. 
Data shown represents mean number of tubules from 3 wells; n=1. 
3.5.1.4 Tumour cell isolates summary 
These studies illustrated some of the difficulties of isolating tumour cells from 
angiosarcoma samples for in vitro study, including the rarity of human angiosarcomas 
and the rapid adaptation of cells to in vitro culture. Protocol 3 (see section 2.6.1) was 
the most efficient method of isolating cells from tumour samples.     
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3.5.2 Angiogenesis related protein array of tumour samples 
Array studies were performed using the R&D Systems protein array to investigate the 
expression of angiogenesis related proteins in freshly frozen tumour samples from five 
human cutaneous angiosarcomas (see section 2.6.2). STS2110 and STS1011 tumour 
samples were collected intra-operatively from patients with localised disease (REC 
number: 09/H1313/52; STH project number: 15394). Three other tumour samples were 
collected pre-treatment from patients with advanced angiosarcoma enrolled on the 
clinical phase II study of axitinib for soft tissue sarcoma (Axi-STS study; REC number: 
09/H1208/42; STH project number: 15195).  
The expression profiles of the five tumour samples were generally similar to each 
other, although factors such as coagulation factor III, bFGF and IL-8 showed a range of 
expression (figure 3.62). The profiles were also broadly consistent with the expression 
profiles obtained from ASM and ISO-HAS cells in hypoxia (see figure 3.9). Particular 
differences of note include increased expression of matrixmetalloproteases (MMP-8 
and -9), and decreased expression of HGF, TGF-β, TSP-1 and VEGF in the tumour 
tissue compared to the cell lines (table 3.6). 
 
Tumour expression increased 
compared to cell lines 
Tumour expression decreased 
compared to cell lines 
Angiogenin  Coagulation factor III  
IGFBP-3  HB-EGF  
MMP-8 and -9  HGF  
Platelet factor 4  TGF-β  
Serpin F1  PDGF-BB  
  TSP-1  
  uPA  
  VEGF  
Table 3.6: Summary of angiosarcoma tumour expression of angiogenesis related 
proteins compared with ASM and ISO-HAS cell lines.  
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Samples from two de-differentiated liposarcoma tumours collected intra-operatively 
(STS1711 and STS1810) were also analysed using the angiogenesis related protein 
array (figure 3.63). The liposarcoma expression profiles were distinct from the 
angiosarcoma samples. The expression of angiogenin, dipeptidyl peptidase IV 
(DPPIV), endoglin, serpin F1 and TIMP-1 were similar, but compared to the 
angiosarcoma specimens the expression of Ang-2, endostatin, IL-8, TGF-β, PlGF, uPA 
and VEGFC were low or absent in the two liposarcoma samples.    
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Figure 3.62: Expression profiles of angiogenesis related proteins from freshly frozen angiosarcoma tumour samples (a - STS21010; b - STS1011; c 
to e - samples collected from Axi-STS study). Data shown represents mean peak density from paired antibody spots (n=1). 
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Figure 3.63: Expression profiles of angiogenesis related proteins from two de-differentiated liposarcoma tumour samples (f - STS1711; g - STS1810). 
Data shown represents mean peak density from paired antibody spots (n=1). 
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3.5.3 Immunohistochemistry studies of tumour samples 
FFPE vascular tumour samples were identified from the pathology archives of Sheffield 
Teaching Hospitals NHS Trust (REC number: 09/H1313/30; STH project number: 
15355). Histology and sample adequacy were confirmed by Dr David Hughes 
collaborating histopathologist, and 6µm tumour sections cut for immunohistochemistry 
study (see section 2.6.3). Details of the 39 tissue blocks used for these studies are 
summarised in table 3.7. Slides of placental tissue were used as a positive control. 
Tumour slides processed with the primary antibody substituted with PBS were used as 
a negative control. Staining of normal tissue adjacent to the vascular tumour was 
examined to identify endothelial specific staining. 
Two haemangioendotheliomas were included in the group of malignant vascular 
tumours. Haemangioendotheliomas are rare vascular tumours of intermediate 
malignant potential. They typically present as a painful solitary mass in superficial or 
deep soft tissue and have a low risk for metastasis[180]. Haemangiomas are benign 
vascular tumours. Capillary haemangiomas are common, typically superficial lesions, 
whilst cavernous haemangiomas often involve deeper structures[181]. Pyogenic 
granulomas are rapidly growing exophytic vascular tumours of skin or oral mucosa. 
They are inflammatory lesions which often bleed and ulcerate. Their aetiology is 
unknown but may be of traumatic or infective origin. They commonly present in the first 
trimester of pregnancy (granuloma gravidarum) indicating hormonal influences on 
tumour growth[181]. 
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  Tissue          Histology Tumour Site Date Patient 
Age 
Patient 
Sex 
Malignant 
Vascular 
Lesions 
16 Angiosarcoma
†
 
2 Haemangioendothelioma 
8 Breast 
6 Cutaneous 
4 Soft tissue 
2000 - 
2011 
71 
(41 - 83) 
5M: 13F 
Benign 
Vascular 
Lesions 
11 Benign Haemangioma - 2010 - - 
Inflammatory 
Vascular 
Lesions 
6 Pyogenic Granuloma 
3 Granulation Tissue 
- 2010 - - 
Table 3.7: Summary of the vascular tumour blocks analysed by immunohistochemistry. 
†17 angiosarcoma specimens were included, 1 breast angiosarcoma was represented 
twice – as an excision biopsy and a surgical resection specimen. 
3.5.3.1 Histological features 
Angiosarcomas are infiltrative tumours of malignant endothelial cells that form irregular 
vascular channels (figure 3.64). Haemangioendotheliomas consist of nests of rounded 
endothelial cells containing intracytoplasmic vacuoles that sit embedded within a 
myxoid or hyaline matrix[180]. Capillary haemangiomas consist of a profusion of small 
blood vessels which in cavernous haemangiomas form large, thin walled vascular 
spaces lined by flattened endothelial cells. Pyogenic granulomatous lesions in contrast 
are highly cellular lesions with packed with proliferating endothelial cells arranged in a 
lobular pattern[181].    
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Angiosarcoma: Poorly differentiated 
vascular channels (V) formed by large 
malignant endothelial cells (A) 
Angiosarcoma: Malignant endothelial 
cells (A) and dissecting collagen fibres (C) 
  
Benign haemangioma: Large vascular 
spaces (V) lined by endothelial cells with 
thin cytoplasm (EC) 
Pyogenic granuloma: Highly cellular 
tumour of benign endothelial cells 
bordered by collagen fibres (arrowed) 
 
Figure 3.64: Tumour samples stained with haematoxylin and eosin, comparing the key 
morphological features of angiosarcomas with benign haemangiomas and pyogenic 
granulomas (x20 magnification). 
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3.5.3.2 Tumour expression of angiogenesis related proteins 
Tumour expression of VEGF, VEGFR1, VEGFR2, NRP1, bFGF, FGFR1, Ang-1, Ang-
2, Tie2, HGF and Met was assessed by immunohistochemistry (see section 2.6.3.1). 
The immunohistochemistry staining was semi-quantified by adding a score for the 
proportion of cells staining (0: <1%; 1: 1 – 10%; 2: 10 – 50%; 3: >50%) to a score for 
the staining intensity (0 – absent; 1 – weak; 2 – moderate; 3 – strong). Slides of 
placental tissue were used as a positive control. Tumour slides processed with the 
primary antibody substituted with PBS were used as a negative control. Staining of 
normal tissue adjacent to the vascular tumour was used to assess endothelial specific 
staining. 
The semi-quantitative analysis of all specimens is summarised in figure 3.65. The 
inflammatory vascular lesions formed a distinct block with high expression of all the 
angiogenic growth factors. The angiosarcoma and benign haemangiomas in contrast, 
showed a range of staining intensities. An inter-group comparison of the ranked 
immunohistochemistry scores showed angiosarcoma had a lower expression of 
angiogenic growth factors and their receptors than the benign haemangiomas or 
inflammatory vascular lesions (table 3.8), with the expression of VEGFR1, NRP1 and 
bFGF statistically significant (p=0.010, 0.001 and <0.001 respectively). The expression 
of FGFR1, Tie2 and Met were not statistically different. Analysis using the Mann-
Whitney test to directly compare angiosarcomas with benign haemangiomas showed 
VEGF expression was significantly lower in angiosarcomas (p=0.028). VEGFR2 
expression was not significantly different (p-0.08), and neither was Ang-2 (p=0.19). 
HGF expression was lower in benign haemangiomas than angiosarcomas but this was 
not statistically significant. Analysis using the Mann-Whitney test to compare 
angiosarcomas with the inflammatory vascular lesions showed VEGFR2, Ang-1, Ang-2 
and HGF expression was significantly lower in angiosarcomas (p=0.006, 0.032, 0.010 
and 0.029 respectively). VEGF expression was not significantly different (p=0.060). 
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The benign haemangiomas and inflammatory vascular lesions studied were selected 
from cases presenting in 2010. In contrast, the angiosarcoma tumour blocks were from 
cases presenting in 2000 – 2011. Angiosarcoma immunohistochemistry score 
significantly correlated with age of the tumour block (table 3.9). The strongest 
correlation with tumour block age was with the VEGFR1 score (correlation coefficient 
0.810; p=<0.001). When angiosarcoma cases pre-2007 were excluded, VEGFR1 did 
not correlate significantly with tumour block age (correlation coefficient 0.546; 
p=0.205).  
A repeat comparison of the ranked immunohistochemistry scores using the Kruskall-
Wallis test, selecting out the angiosarcoma cases pre-2007 showed similar 
immunohistochemistry scores across the tumour groups (table 3.10). Only the 
expression of bFGF was significantly lower in angiosarcoma (p=0.014). 
The expression of angiogenic growth factors and their receptors were compared 
between benign haemangiomas and the inflammatory vascular lesions (table 3.11). 
The inflammatory lesions had a higher expression of angiogenic factors with VEGFR2, 
Ang-2 and HGF statistically significant (p=0.039, 0.014 and 0.021 respectively). 
The co-expression of angiogenic growth factors and their receptors were compared 
within tumour groups using Spearman’s correlation coefficient. Analysis involved 
multiple testing of each angiogenic factor. To avoid over interpretation of the data, only 
results with a significance of <0.01 are presented. As angiogenic factor co-expression 
by the angiosarcoma tumours was biased by the age of the tumour block, this analysis 
was performed on cases from 2007 onwards. Only HGF and Met expression correlated 
(r=0.891; p=0.007). In the benign haemangioma group, VEGFR1 and Tie2 expression 
correlated (r=0.744; p=0.009). Angiogenic factor co-expression was not investigated in 
the inflammatory vascular lesions, as expression was high across all the factors.  
VEGFR2, Ang-1, Ang-2 and Tie2 immunohistochemistry scoring was quantified 
separately by Dr Malee Fernando (collaborating histopathologist). There was good 
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inter-observer agreement between immunohistochemistry scores, which did not differ 
by more than one grade (r=0.846, 0.826, 0.681 and 0.705 for VEGFR2, Ang-1, Ang-2 
and Tie2 respectively, calculated using Kendall’s tau-b test). Representative images 
from the immunohistochemistry comparing angiosarcomas with benign haemangiomas 
and pyogenic granulomas are shown in figures 3.66 – 3.76. 
3.5.3.3 Immunohistochemistry studies of tumour samples summary 
The immunohistochemistry studies of human tumour samples demonstrated vascular 
tumours expressed a range of angiogenic growth factors and their receptors. 
Inflammatory vascular lesions were distinguished from benign haemangiomas by 
increased expression of VEGFR2, Ang-2 and HGF; however, the angiogenic growth 
factors studied did not distinguish between benign and malignant groups.    
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 A A A A A A A A A A A A A A A† A† Aa A Ab H H H H H H H H H H H I I I I I I I I I 
VEGF                                        
VEGFR1                                        
VEGFR2                           X             
NRP1                                        
bFGF                                     X   
FGFR1                                     X   
Ang-1                    U U U U U U U U U U U          
Ang-2                                        
Tie2                                     X   
HGF                                        
Met                                     X   
Key: 
      
0 2 3 4 5 6 
 
A - angiosarcoma 
H - haemangioma 
 I - inflammatory vascular lesions 
† - paired biopsy and excision specimens 
a - STS2110 
b - STS1011 
X - tissue not available for analysis 
U - unable to accurately score - difficult to distinguish angiopoieitin-1 staining of endothelial cells from surrounding collagen  
 
Figure 3.65: Heat map summarising the semi-quantitative analysis from the immunohistochemistry studies. The angiosarcoma tumours are grouped 
together in chronological order (2000 to 2011), followed by the benign haemangiomas and then the inflammatory vascular lesions. 
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Mean Rank N VEGF VEGFR1 VEGFR2 NRP1` bFGF FGFR1 Ang-1 Ang-2 Tie2 HGF Met 
Angiosarcoma 19 15.8 14.7 14.7 13.1 12.3 17.6 12.3 15.7 17.8 18.0 16.8 
Haemangioma 11 24.3 22.9 21.0 26.1 24.3 18.3 - 20.0 18.5 16.9 22.4 
Inflammatory 9 23.6 27.6 28.1 27.2 30.1 25.8 19.2 29.0 25.0 28.0 21.9 
p value  0.033 0.010 0.007 0.001 <0.001 0.18 0.032 0.013 0.23 0.043 0.273 
Table 3.8: Ranked immunohistochemistry scores, grouped by tumour type (angiosarcoma, benign haemangioma or inflammatory vascular lesion). 
Data shown represents the mean rank and p value, calculated using the Kruskall-Wallis test. 
 
 N VEGF VEGFR1 VEGFR2 NRP1` bFGF FGFR1 Ang-1 Ang-2 Tie2 HGF Met 
Spearman 
Correlation 
Coefficient (r) 
19 0.662 0.810 0.720 0.703 - 0.566 0.484 0.488 0.654 - - 
p value  0.002 <0.001 0.001 0.001 0.60 0.012 0.036 0.034 0.002 0.18 0.29 
Table 3.9: Immunohistochemistry scores correlated with age of the angiosarcoma tumour blocks. Data shown represents the spearman correlation 
coefficient and p value. 
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Mean Rank N VEGF VEGFR1 VEGFR2 NRP1` bFGF FGFR1 Ang-1 Ang-2 Tie2 HGF Met 
Angiosarcoma 7 14.6 13.2 12.9 10.4 7.4 14.4 7.3 14.0 14.7 13.2 11.7 
Haemangioma 11 14.1 12.6 10.7 14.9 13.7 10.8 - 10.5 11.3 10.7 14.3 
Inflammatory 9 13.5 16.4 17.1 15.7 18.5 16.4 9.4 18.3 15.5 18.7 13.9 
p value  0.92 0.51 0.13 0.30 0.014 0.25 0.34 0.07 0.38 0.06 0.73 
Table 3.10: Ranked immunohistochemistry scores, grouped by tumour type excluding angiosarcoma cases pre-2007. Data shown represents the 
mean rank and p value, calculated using the Kruskall-Wallis test. 
 
Mean Rank N VEGF VEGFR1 VEGFR2 NRP1` bFGF FGFR1 Ang-1 Ang-2 Tie2 HGF Met 
Haemangioma 11 10.7 9.3 7.8 10.3 8.4 8.2 - 7.8 8.7 7.9 10.1 
Inflammatory 9 10.3 12.0 12.5 10.8 12.3 12.5 - 13.8 11.8 13.7 9.8 
p value  0.83 0.29 0.039 0.83 0.11 0.08 - 0.014 0.22 0.021 0.89 
Table 3.11: Ranked immunohistochemistry scores, grouped by tumour type (benign haemangioma versus inflammatory vascular lesion). Data shown 
represents the mean rank and p value, calculated using the Mann-Whitney test
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Angiosarcoma: Diffuse, strong VEGF 
expression 
 
Angiosarcoma: Diffuse, moderately 
intense VEGF expression, with collagen 
fibres dissecting through the tumour 
(arrowed) 
  
Benign haemangioma: Strong 
expression of VEGF seen in the thin 
endothelial cells (arrowed) that surround 
the large vascular spaces. 
Pyogenic granuloma: Diffuse, strong 
expression of VEGF (arrowed) 
 
Figure 3.66: Immunohistochemistry studies showing the diffuse expression of VEGF 
across all tumour groups (x20 magnification). 
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: 
  
Angiosarcoma: Diffuse, moderately 
intense expression of VEGFR1 (arrowed) 
Angiosarcoma: Weak expression of 
VEGFR1 (arrowed) 
  
Benign haemangioma: Strong 
expression of VEGFR1 in the endothelial 
cells lining vascular spaces 
Pyogenic granuloma: Diffuse, strong 
VEGFR1 expression 
 
Figure 3.67: Immunohistochemistry studies comparing the expression of VEGFR1 
across all tumour groups (x20 magnification). 
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Angiosarcoma: Moderately intense 
nuclear and cytoplasmic VEGFR2 staining 
(arrowed)  
Angiosarcoma: Weak VEGFR2 staining 
(arrowed) 
  
Benign haemangioma: Compact, nuclear 
staining (arrowed) 
Pyogenic granuloma: Compact, strong 
nuclear VEGFR2 staining (arrowed) 
 
Figure 3.68: Immunohistochemistry studies comparing the expression of VEGFR2 
across all tumour groups (x20 magnification). 
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Angiosarcoma: Diffuse, strong NRP1  
staining of tumour cells, dissected by 
collagen fibres (arrowed) 
Angiosarcoma: Weak NRP1 staining of 
tumour cells, with intense staining focally 
around vascular channels (arrowed) 
  
Benign haemangioma: Strong NRP1 
staining of endothelial cells lining vascular 
spaces (arrowed) 
Pyogenic granuloma: Diffuse, strong 
NRP1 staining 
 
Figure 3.69: Immunohistochemistry studies comparing the expression of NRP1 across 
all tumour groups (x20 magnification). 
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Angiosarcoma: Weak cytoplasmic bFGF 
staining in <50% of tumour cells (arrowed) 
Angiosarcoma: Strong cytoplasmic bFGF 
staining in the majority of tumour cells 
  
Benign haemangioma: Strong 
cytoplasmic bFGF staining in the 
endothelial cells lining the vascular 
spaces (arrowed) 
Pyogenic granuloma: Diffuse, strong 
cytoplasmic bFGF staining 
 
Figure 3.70: Immunohistochemistry studies comparing the expression of bFGF across 
all tumour groups (x20 magnification). 
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Angiosarcoma: Strong FGFR1 staining in 
epithelioid tumour cells (arrowed) 
Angiosarcoma: Weak FGFR1 staining 
(arrowed) from the same tumour sample 
shown in the left hand panel 
  
Benign haemangioma:FGFR1 staining of 
the endothelial cells lining the vascular 
spaces (arrowed) adjacent to a normal 
blood vessel 
Pyogenic granuloma: Strong, diffuse 
FGFR1 staining 
 
Figure 3.71: Immunohistochemistry studies comparing the expression of FGFR1 
across all tumour groups (x20 magnification). 
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Angiosarcoma: Very weak, diffuse Ang-1 
cytoplasmic staining of the tumour cells 
Angiosarcoma: Strong, diffuse Ang-1 
staining 
  
Benign haemangioma: Intense staining 
of the matrix surround the vascular 
spaces making accurate scoring of Ang-1 
staining of the endothelial cells (arrowed) 
very difficult  
Pyogenic granuloma: Moderately 
intense Ang-1 staining (arrowed) 
 
Figure 3.72: Immunohistochemistry studies comparing the expression of Ang-1 across 
all tumour groups (x20 magnification). 
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Angiosarcoma: Strong staining of Ang-2 
around the vascular spaces (arrowed) 
Angiosarcoma: Weak Ang-2 staining 
  
Benign haemangioma: Focal staining of 
endothelial cells lining the vascular 
spaces 
Pyogenic granuloma: Diffuse, 
moderately intense staining of Ang-2 
(arrowed) 
 
Figure 3.73: Immunohistochemistry studies comparing the expression of Ang-2 across 
all tumour groups (x20 magnification). 
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Angiosarcoma: Strong, diffuse Tie2 
staining of epithelioid angiosarcoma cells 
Angiosarcoma: Weaker Tie 2 staining in 
the same tumour, showing more spindle 
shaped tumour cells  
  
Benign haemangioma: Tie2 staining of 
endothelial cells lining the vascular 
spaces (arrowed) 
Pyogenic granuloma: Intense 
Tie2staining of endothelial cells lining 
vascular channels (arrowed) 
 
Figure 3.74: Immunohistochemistry studies comparing the expression of Tie2 across 
all tumour groups (x20 magnification). 
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Angiosarcoma: Diffuse, strong HGF 
staining 
Angiosarcoma: Weak HGF staining 
(arrowed) 
  
Benign haemangioma: Absent HGF 
staining 
Pyogenic granuloma: Diffuse, strong 
HGF staining 
 
Figure 3.75: Immunohistochemistry studies comparing the expression of HGF across 
all tumour groups (x20 magnification). 
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Angiosarcoma: Diffuse, strong 
expression of Met 
Angiosarcoma: Diffuse, weak expression 
of Met 
  
Benign haemangioma: Strong Met 
staining of endothelial cells lining the 
vascular spaces (arrowed) 
Pyogenic granuloma: Intense Met 
staining of vascular channels (arrowed) 
 
Figure 3.76: Immunohistochemistry studies comparing the expression of Met across all 
tumour groups (x20 magnification). 
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3.5.4 Immunohistochemistry studies of canine vascular tumours 
In contrast with humans, angiosarcomas are common in dogs. Through collaboration 
with the Animal Health Trust (Cambridge, UK), formalin fixed paraffin embedded 
tumour samples of canine angiosarcomas and benign haemangiomas were obtained 
for comparative immunohistochemistry studies to determine whether canine 
angiosarcoma could be used as a model for human angiosarcoma. Details of the 
tumour blocks studied are summarised in table 3.12.  
 
 Histology         Tumour site                     Date 
Malignant 
vascular tumours 
19 angiosarcomas 12 skin or subcutaneous 
7 splenic 
2004 - 2008 
Benign vascular 
tumours 
5 haemangiomas Skin or subcutaneous 2004 - 2005 
    
Table 3.12: Summary of the canine vascular tumours analysed 
Canine angiosarcomas demonstrated similar morphological features to human 
angiosarcomas, including abnormal vascular channel formation by malignant 
endothelial cells, and dissecting bundles of collagen fibres (figure 3.77). Preliminary 
studies were performed to compare the pattern of VEGF and VEGFR2 expression in 
canine vascular tumours with human vascular tumours. Canine specific antibodies 
were not available commercially, and therefore the immunohistochemistry protocols 
used for the study of human tumours were utilised without modification (see section 
2.6.4).  
The canine angiosarcoma tumour cells showed a strong, diffuse staining pattern with 
antibody to VEGF, whilst the haemangiomas showed weak, compact staining (figure 
3.78). Similarly, the canine angiosarcoma tumours showed moderately intense staining 
for antibody to VEGFR2, whilst the haemangiomas showed weak staining (figure 3.79). 
VEGFR2 staining of the canine tumour blocks was less intense than that seen with the 
human tumours. This difference in VEGFR2 staining compared to human samples may 
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reflect the age of the canine tumour blocks, or differences in antigen-antibody binding. 
Immunohistochemistry scores for canine haemangiomas and angiosarcomas were 
compared using the Mann-Whitney test. In contrast to the human samples, VEGF and 
VEGFR2 immunohistochemistry scores were significantly higher in the angiosarcomas 
than in the benign lesions (mean VEGF rank in haemangiomas 3.4 compared to 14.9 in 
angiosarcomas (p=0.001); mean VEGFR2 rank in haemangiomas 4.1, compared to 
14.2 in angiosarcomas (p=0.002)). 
 
  
Canine angiosarcoma: Abnormal 
vascular channels (V), with malignant 
angiosarcoma tumour cells (A) and 
dissecting collagen fibres (C)  
Canine angiosarcoma: Abnormal 
vascular channels (V) with malignant 
angiosarcoma tumour cells (A) 
  
Canine haemangioma: Vascular spaces 
lined by benign endothelial cells (arrowed) 
Canine haemangioma: Vascular spaces 
lined by benign endothelial cells (arrowed) 
 
A 
A 
C 
C 
V 
V 
A 
A 
V 
V 
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Figure 3.77: Haematoxylin & eosin stained canine vascular tumour (x20 magnification). 
 
  
Canine angiosarcoma: Strong, diffuse 
VEGF staining of malignant endothelial 
cells 
Canine angiosarcoma: Strong, diffuse 
VEGF staining of malignant endothelial 
cells, with dissecting collagen fibres 
(arrowed) 
  
Canine angiosarcoma: Moderately 
intense VEGF staining of malignant 
endothelial cells 
Canine haemangioma: Compact, nuclear 
VEGF staining of benign endothelial cells 
(arrowed) 
 
Figure 3.78: Immunohistochemistry studies comparing the expression of VEGF in 
canine vascular tumours (x20 magnification). 
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Canine angiosarcoma: Moderately 
intense VEGFR2 staining of malignant 
endothelial cells (arrowed) 
Canine angiosarcoma: Moderately 
intense VEGFR2 staining of malignant 
endothelial cells (arrowed) 
  
Canine angiosarcoma: Moderately 
intense VEGFR2 staining of malignant 
endothelial cells (arrowed) 
Canine haemangioma: No VEGFR2 
staining of benign endothelial cells 
 
Figure 3.79: Immunohistochemistry studies comparing the expression of VEGF2 in 
canine vascular tumours (x20 magnification). 
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4 Discussion 
4.1 Characterisation Studies 
ASM and ISO-HAS cell lines were separately developed from two patients with 
cutaneous angiosarcoma of the scalp. Similar to previously published reports[154, 
158], ASM and ISO-HAS demonstrated Dil-Ac-LDL uptake and expressed CD31, vWF, 
VEGFR1 and VEGFR2, consistent with cells of endothelial origin. Cell morphology and 
immunocytochemistry studies suggested ASM and ISO-HAS consisted of a 
heterogeneous population of cells. However, flow cytometry studies showed that the 
cells were derived from a single population but expressed endothelial cell markers over 
a range of intensities. 
In contrast to HuDMEC primary cell cultures, ASM and ISO-HAS showed accelerated 
growth kinetics and apparent limitless replicative potential in vitro. Functional assays 
also showed biological characteristics distinct from HuDMECs, with ASM and ISO-HAS 
demonstrating chaotic tubule formation on Matrigel, and significantly increased cell 
migration in Boyden chamber studies. Cytogenetic analysis had previously identified 
chromosomal abnormalities in ASM cells including the loss of whole chromosomes 
from homologues 4, 7, 8, 13, 15 and 16[154], and gene sequencing of ISO-HAS had 
shown the presence of a p53 mutation[156]. Neither ASM nor ISO-HAS cells formed 
tumours in vivo in CD1 nude mice. Krump-Konvalinkova et al were also unable to 
demonstrate ASM or ISO-HAS tumour formation in CD1 nude mice[154], though 
Masuzawa et al eported ISO-HAS tumourigenesis in profoundly immuno-compromised 
SCID mice pre-treated with anti-IL2 antibody[156].  
Other angiosarcoma models considered included HAEND, EAhy926, SVR and ISOS-1 
cells. HAEND cells were isolated from a human angiosarcoma of the liver[182]. It was 
not possible to source these cells, but it has previously been reported these cells were 
CD31, CD34 and vWF negative, and did not take up Dil-Ac-LDL, suggesting these cells 
were not of endothelial origin[158]. Both EAhy926 and SVR were synthetic cell lines. 
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EAhy926 was a hybrid cell line artificially formed by fusion of the lung cancer cell line 
A549 with an endothelial cell line (HuVECs)[157]. SVR was created by transfection of a 
primary murine endothelial cell line with retroviruses encoding for SV40 large T-antigen 
and activated H-ras[128], and in vivo form vascular tumours morphologically consistent 
with well differentiated angiosarcomas[128]. ISOS-1 cells were developed from the 
same cutaneous angiosarcoma as ISO-HAS, by subcutaneous transplantation of 
tumour fragments into SCID mice[155]. Cytogenetic analysis of ISOS-1 cells however 
demonstrated these cells had a murine rather than human phenotype[155].  
ASM and ISO-HAS cells were derived from human cutaneous angiosarcomas, and the 
characterisation studies, together with the previously reported data, identified these 
cells as abnormal, potentially malignant, endothelial cells. ASM and ISO-HAS were 
therefore selected for further study as in vitro models most representative of human 
angiosarcoma. 
4.2 Protein Expression 
A targeted proteomic approach was used to compare ASM and ISO-HAS cell 
expression of angiogenic growth factors with that of HuDMECs and HDFs. The R&D 
Systems Proteome arrays enabled the simultaneous comparison of 55 angiogenesis 
related proteins. The levels of 42 phosphorylated receptor tyrosine kinases were also 
compared, including VEGFRs, Tie1 and 2, FGFRs and PDGFRs, and the levels of 46 
phosphorylated protein kinases, including the signalling intermediaries promoting 
cellular response to VEGFR2 activation: cell proliferation (PLCy-1, MEK, ERK), cell 
growth (Akt, TOR, GSK-3, AMPK, p70 S6 kinase) cell migration (p38 MAPK, HSP27, 
Src, FAK, paxillin) and vascular permeability (eNOS) (figure 4.1)[38, 183]. 
These arrays were used as a tool to generate hypotheses for further study. Of note, the 
arrays did not measure absolute protein levels. Protein spot densities were dependent 
on antigen-antibody binding efficiency, which might not be equivalent across different 
proteins. The relative expression of individual proteins was therefore compared across 
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cell lines and culture conditions (e.g. to compare the expression of VEGF between 
ASM, ISO-HAS and HuDMECs, and between normoxia and hypoxia), but were not 
used to compare expression between different proteins within the same cell line (e.g. a 
direct comparison of Ang-1 with Ang-2 expression would in part be influenced by 
differences in antigen-antibody binding efficiencies). Comparisons of a large number of 
proteins across a small number of cell lines also increased the risk of declaring false 
positive associations. A two-fold difference in protein expression was initially used as a 
filter to identify proteins of interest. However, biological responses may not be linearly 
related to protein expression, and more subtle changes could also have profound 
biological effects. Patterns of expression across related proteins in cell signalling 
pathways were therefore also considered. 
Other methods of comparing expression profiles between cell lines were considered. 
RNA studies are quantitative, but may not reflect actual protein expression levels, and 
an advantage of the R&D Systems Proteome arrays is that they enabled comparison of 
phosphorylated (active) protein kinases rather than total protein levels, which may be 
more biologically relevant. Unselected methods of measuring protein expression, such 
as iTRAQ, were also considered but differences between cell lines were likely to be lost 
within the general protein expression profiles.  
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Figure 4.1: Signalling cascades recruited in response to VEGF activation of VEGFR2 
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Protein expression was principally studied in cell lysates. However, secreted 
angiogenesis related proteins in the cell supernatant may promote cell growth through 
autocrine or paracrine stimulation. Analysis of ASM and ISO-HAS cell supernatant was 
therefore also performed. This demonstrated quantitative differences with the proteins 
expressed in cell lysates. For example, bFGF was relatively high in ASM and ISO-HAS 
cell lysates, but the levels secreted into the cell supernatant were low. In contrast, 
levels of inflammatory cell chemoattractants including MCP-1 and GM-CSF were low in 
the cell lysates, but high in the cell supernatant. These studies highlighted the 
limitations of extrapolating from expression profiles based on cell lysate derived data 
only. If resources had permitted it would have been interesting to have studied the 
expression of angiogenesis related proteins in cell supernatant collected from 
HuDMEC cells, and to compare how levels in cell supernatant changed with incubation 
in hypoxic conditions. 
Hypoxia is more representative of physiological conditions and therefore array studies 
were performed to assess the expression of angiogenesis related proteins in lysates of 
cells incubated in hypoxia. Compared to the studies in 21% O2, greater differences 
were seen between the cell lines in expression of angiogenesis related proteins in 1% 
O2, with increased expression of angiogenin, Ang-1, aFGF, HGF and VEGF by ASM 
and ISO-HAS cells compared to HuDMECs.  
Despite studies demonstrating that ASM and ISO-HAS cells expressed a wide range of 
pro-angiogenic growth factors, phosphorylation of receptor tyrosine kinases in ASM 
and ISO-HAS cell lysates was restricted to a small number of receptors, suggesting 
limited autocrine or paracrine stimulation of ASM and ISO-HAS cells. The panel of 
phosphorylated receptor tyrosine kinases identified in studies of HuDMECs were 
predictable, including phosphorylation of VEGFR1, VEGFR2, VEGFR3 and Tie2, 
suggesting these array results were reliable. Under the same culture conditions, 
western blot studies suggested VEGFR2 was not phosphorylated at baseline in either 
ASM, ISO-HAS or HuDMEC cells, perhaps due to probing with a different primary 
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antibody from that used in the protein arrays. VEGFR2 phosphorylation was identified 
by western blot following stimulation of the cells with exogenous VEGF (50ng/ml), and 
following cell culture in hypoxic conditions (1% O2). If further resources had permitted, it 
would have been interesting to explore whether the expression profiles of other 
phosphorylated kinases and receptor tyrosine kinases altered in hypoxic conditions.  
Overall, few distinct differences emerged between the protein expression profiles of 
ASM, ISO-HAS and HuDMECs.  This may reflect the use of semi-confluent, 
proliferating HuDMECs as a comparison group, rather than confluent, senescent cells, 
which more closely reflects endothelial cells of the normal vasculature, although re-
creating these conditions in vitro would be difficult. Proteins of interest identified by the 
protein arrays for further study included VEGF/VEGFRs, mTOR/S6 kinase, MEK/ERK 
and ChkII. 
4.2.1 VEGF 
VEGF was significantly over expressed in ASM and ISO-HAS cell lysates compared to 
HuDMECs, and dramatically increased in hypoxic conditions. The increased VEGF 
expression was quantified and confirmed by ELISA. Western blot studies were 
performed to investigate the expression of VEGFA isoforms in ASM and ISO-HAS cell 
lysates and supernatants. Multiple protein bands were seen between 25 and 42 kDa 
which could reflect the concurrent expression of different VEGFA isofoms such as 
VEGFA121, VEGFA165 and VEGFA189. The expression of PlGF, which is not bound by 
antibodies to VEGF including the anti-VEGFA antibody bevacizumab, was included in 
the angiogenesis related protein array. ASM and ISO-HAS expression of PlGF was not 
significantly different from HuDMECs. Expression of VEGFB and D were not 
investigated. 
4.3 Drug Studies 
Initial studies performed with doxorubicin and paclitaxel, current first and second line 
chemotherapy options for patients with advanced angiosarcoma, confirmed putative 
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ASM and ISO-HAS cell sensitivity to chemotherapy in cell viability assays. 
Angiosarcoma response to paclitaxel has not been directly compared with doxorubicin 
in clinical trials, but a retrospective analysis suggested similar overall response 
rates[104]. There has been particular interest in paclitaxel as a chemotherapy option 
for the treatment of angiosarcoma. Paclitaxel is classified alongside other anti-
microtubule chemotherapy agents including vinca alkaloids[184]. However, in contrast 
to vinca alkaloids which inhibit microtubule formation, paclitaxel accelerates 
microtubule assembly and fixates mitotic spindle formation. Paclitaxel has anti-
angiogenic properties, and inhibits endothelial cell differentiation and migration at sub-
lethal doses[185].  
4.3.1 VEGF targeted agents 
Results from the angiogenesis related protein arrays and VEGF ELISA studies 
supported the study of VEGF targeted agents. Potential methods of targeting VEGF 
included: 
 targeting the ligand, through antibodies against VEGF (e.g. bevacizumab) 
 targeting the receptor, through tyrosine kinase inhibitors to inhibit VEGFR 
phosphorylation following ligand binding (e.g sunitinib or axitinib) 
 inhibition of downstream signalling components including mTOR inhibitors (e.g. 
everolimus) or inhibitors of the MAPK pathway (e.g. the MEK inhibitor 
selumetinib) 
Bevacizumab is a humanised monoclonal antibody to VEGF. In vitro studies with 
HUVECs have demonstrated bevacizumab binds to VEGF to inhibit receptor mediated 
functions including endothelial cell proliferation, survival and migration, without 
evidence of antibody-dependent cell-mediated cytotoxicity (ADCC)[186]. Clinical trials 
exploring the efficacy of bevacizumab have been summarised previously in table 1.1. 
Tyrosine kinase inhibitors (TKIs) inhibit receptor and intracellular tyrosine kinases, and 
thus inhibit signal transduction pathways. There are numerous TKIs in clinical 
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development each with a different profile of kinase inhibition[39]. Sunitinib is a broad 
spectrum TKI[40]. A screening array of 242 kinases showed 0.3µmol/l sunitinib 
inhibited the activity of 49 kinases by more than 50% including VEGFR1-3, PDGFRs, 
KIT, FLT3, CSF-1R and RET[187]. Axitinib is more selective, principally inhibiting 
VEGFR1-3, PDGFR and KIT (table 4.1)[41]. At doses above 1µmol/l however axitinib 
also inhibits Abl, Aurora B, Arg, AMPK, Axl and MST2[41]. In vitro, axitinib reduced 
HUVEC survival and inhibited tubule formation by HuDMEC spheroids[41]. Axitinib is 
currently under study in a phase II clinical trial for advanced soft tissue sarcoma, 
including a cohort for angiosarcoma (ISRCTN:60791336). Clinical trials exploring the 
efficacy of bevacizumab have been summarised previously in table 1.2. 
 Axitinib 
(nmol/l)  
Sunitinib 
(nmol/l) 
VEGFR1 0.1 NA 
VEGFR2 0.2 5 
VEGFR3 0.2 NA 
KIT 1.7 0.3 
PDGFRα 1.6 NA 
PDGFRβ 5 2 
FGFR1 215 180 
Flt-3 >1000 1 
Table 4.1: RTK inhibition profile of axitinib and sunitinib. Data shown represents the 
IC50 estimated from cellular inhibition studies[41, 187]. NA – not available 
 
mTOR inhibitors inhibit formation of the mTOR1 complex, formed following activation of 
the PI3K/Akt signalling cascade. They thus inhibit phosphorylation of downstream S6 
kinase and the release of eIF4E (eukaryotic translation initiation factor) following 
phosphorylation and inactivation of 4EBP1 (eIF4E binding protein) consequently 
modulating protein synthesis, cell proliferation and cell growth[188]. mTOR inhibitors 
have demonstrated clinical benefit in the treatment of advanced renal cell 
carcinoma[189], and in a recent phase III study of maintenance ridaforolimus after 
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chemotherapy for advanced soft tissue sarcoma, showed a small but statistically 
significant increase in progression free survival – angiosarcoma specific responses 
were unreported[190]. 
MEK is a central intermediary of the MAPK signalling cascade, and is phosphorylated 
in response to growth factor initiated activation of tyrosine kinase receptors, or through 
constitutive activation of upstream kinases including Ras or Raf. In contrast to other 
kinase inhibitors MEK inhibitors, including selumetinib, do not compete with ATP 
binding to inhibit MEK phosphorylation, but rather interfere with MEK binding and the 
subsequent activation of downstream ERK[191]. Evidence of clinical efficacy for 
selumetinib monotherapy has been demonstrated in studies of patients with advanced 
colorectal cancer[192] and melanoma[193]. 
4.3.2 VEGFR inhibition 
Despite increased VEGF expression only minor responses to VEGFR inhibitors were 
observed in studies of ASM and ISO-HAS, with a modest response seen in assays with 
HuDMECs. ASM and ISO-HAS cell viability were significantly reduced using supra-
pharmacological doses of TKI, possibly due to off target inhibitory effects involving 
other kinases such as Aurora B. Drug responses were not substantially enhanced by 
combining VEGF targeted agents with paclitaxel chemotherapy.  
The functional assays may not have been sufficiently sensitive to detect biological 
responses to VEGFR inhibition. For example, the trypan blue dye exclusion assay to 
measure cell viability assessed response 120 hours after the addition of drug. This may 
not have been the optimum time point at which to measure response, however results 
from these assays were consistent with findings from the MTS assay which measured 
cell viability at 24 and 48 hours. Cell viability with the dye exclusion assay was 
measured at 120 hours to enable direct comparison with response to the other targeted 
agents.  
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Other studies measuring endothelial cell response to bevacizumab in vitro have often 
used large vessel endothelial cells (e.g. HuVECs) rather than microvascular endothelial 
cells (e.g. HuDMECs). However, different endothelial cell types are functionally and 
genetically distinct, and their response to vascular targeted agents may not be the 
same (Chi, 2003). As both ASM and ISO-HAS were derived from superficial cutanous 
angiosarcomas, comparison of drug response with dermal microvascular endothelial 
cells (HuDMECs) was considered most appropriate. Luthra et al showed bevacizumab 
(0.125mg/ml – 1.0mg/ml) had no significant effect on human microvascular endothelial 
cell viability[194], and a study by Deissler et al showed no effect of bevacizumab 
(0.25mg/ml) on retinal microvascular endothelial cell proliferation, although endothelial 
cell migration was inhibited[195]. Importantly, the study by Deissler et al also 
suggested bevacizumab stored at 40C for more than 2 weeks was significantly less 
potent than fresh aliquots of the drug. However repeated studies of ASM, ISO-HAS and 
HuDMEC using fresh aliquots of bevacizumab and axitinib produced similar results.  
In other studies, tumour cell responses to bevacizumab have not been seen in 
vitro[33], but responses have been demonstrated in vivo, including reduction in tumour 
micro-vessel density in patients receiving neo-adjuvant bevacizumab for advanced 
colorectal cancer[196]. In vivo studies may therefore be required to determine 
angiosarcoma response to VEGFR inhibitors. Consistent with the in vitro data however, 
phase II clinical studies of single agent bevacizumab, sunitinib and sorafenib for the 
treatment of advanced angiosarcoma have proved disappointing with overall response 
rates less than 15% (see table 1.4). It has been proposed that angiosarcomas 
harbouring mutations of VEGFR2 may respond to VEGFR kinase inhibitors[72]. A 
previous molecular study of tumour samples from 22 angiosarcomas reported four 
cases with VEGFR2 mutations. In vitro these mutations induced VEGFR2 
autophosphorylation sensitive to inhibition with sorafenib and sunitinib[72]. However, a 
recently published phase II study found no activating mutations of VEGFR2 in 41 
patients with advanced angiosarcoma, and no evidence for efficacy of single agent 
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sorafenib in these patients, suggesting angiosarcomas harbouring VEGFR2 mutations 
are a rare sub-group[107]. 
Biological responses to stimulation with exogenous VEGF were not seen in functional 
assays with the malignant ASM and ISO-HAS cells, whilst increased tubule formation 
and cell migration were seen in response to stimulation with exogenous VEGF in 
studies with HuDMECs. The absence of ASM and ISO-HAS response to stimulation 
with exogenous VEGF could be ascribed to VEGFR saturation by excess endogenous 
VEGF, and this could partly explain their insensitivity to VEGF targeted therapy. 
However, the western blot studies of ASM, ISO-HAS and HuDMECs suggested 
VEGFR2 was not phosphorylated by the levels of endogenous VEGF expressed in 
normoxia. In contrast VEGFR2 was phosphorylated by the levels of endogenous VEGF 
expressed in hypoxia, and in response to exogenous VEGF (50ng/ml). Induced 
VEGFR2 phosphorylation was inhibited by VEGF targeted agents (bevacizumab and 
axitinib) but this did not translate into a response in functional assays.  
Western blot studies may not have been sufficiently sensitive to detect all 
phosphorylated VEGFR2. VEGFR2 activates the MAPK signalling cascade through 
tyrosine1175[38], and therefore the principal antibody used in these studies probed for 
pVEGFR2Y1175. VEGF binding to VEGFR2 also induces phosphorylation of other 
tyrosine residues including tyrosine951, which stimulates cell migration through 
activation of Src[38]. Western blot studies were not performed to confirm that axitinib 
and bevacizumab inhibited all the phosphorylation sites on VEGFR2, nor to assess 
phosphorylation status of other VEGFRs (1 and 3), nor to assess signalling mediated 
through VEGFR2 interaction with the non-tyrosine kinase co-receptors NRP1 and 
NRP2. Interestingly, recent data from studies using an in vitro model for infantile 
haemangioma suggested downstream ERK phosphorylation was initiated by VEGFA 
and VEGFB signalling through VEGFR1 rather than through VEGFR2[197], supporting 
further study of VEGFR1 activity in ASM and ISO-HAS. 
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Intrinsic activation of down-stream signalling cascades including the MAPK pathway 
may have muted ASM and ISO-HAS cell response to stimulation with exogenous 
VEGF. ERK, a central signalling intermediary of the MAPK pathway, may be 
phosphorylated as a consequence of mutated Ras or Raf upstream, or through 
autocrine or paracrine stimulation of the MAPK pathway by other secreted growth 
factors. Western blot studies of ASM and ISO-HAS cells showed basal activation of 
ERK. ERK phosphorylation increased in response to stimulation with exogenous 
VEGF, and decreased in the presence of VEGF targeted agents, conflicting with the 
lack of response seen in functional assays. Residual ERK phosphorylation following 
treatment with axitinib and bevacizumab however may have been sufficient to maintain 
biological response  
The functional assays used to assess drug response were not specific to VEGF. The 
angiogenesis related protein array studies demonstrated ASM, ISO-HAS and 
HuDMECs expressed a broad panel of pro-angiogenic growth factors, which were not 
targets of VEGFR inhibitors. Whilst the protein expression studies suggested VEGF 
was a key growth factor, these other pro-angiogenic cytokines may have compensated 
for any attenuation in VEGF signalling. Consistent with this, resistance to VEGF 
targeted agents in the treatment of other malignancies, is mediated through other 
signalling pathways, including FGF, PDGF and Notch[198]. 
4.3.3 mTOR inhibition 
The phosphorylated protein kinase array studies provided evidence to support 
investigating response to mTOR inhibitors, with increased levels of pAkt, pTOR, p70 
S6 kinases, and decreased pAMPK in ASM and ISO-HAS cell lysates. Furthermore, an 
immunohistochemistry study reported high expression of pAkt and peIF4E in 
angiosarcomas[168], and another recent study by Italiano et al reported expression of 
pS6K and p4EBP1 in 17/40 (42%) angiosarcomas[119].  
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Compared to axitinib and bevacziumab, increased responses were seen to the mTOR 
inhibitor everolimus in cell viability assays with ASM and ISO-HAS. The biological 
effects of mTOR inhibitors include inhibition of angiogenesis, partly through decreased 
synthesis of VEGF by reduced expression of HIF-1α[173]. mTOR inhibitors have other 
effects, including reduced cell growth and cell proliferation. ASM and ISO-HAS 
response to everolimus cannot be solely attributed therefore to decreased VEGF 
synthesis. Furthermore, an immunohistochemistry study showed angiosarcoma 
expression of VEGF was not dependent on HIF-1α expression[199].  
The contribution of endogenous VEGF to angiosarcoma biology remains unclear. This 
could be further explored in vitro using short interfering RNA (siRNA) to VEGF to 
decrease the synthesis of endogenous VEGF. However, an efficient methodology 
would be required to reduce the high VEGF expression levels in ASM and ISO-HAS to 
be comparable with those measured in HuDMECs.  
4.3.4 MEK inhibition 
The phosphorylated kinase array studies demonstrated intrinsic activation of the MAPK 
pathway, with elevated pMEK and pERK in ASM cells compared to HuDMECs, though 
these were not elevated in ISO-HAS cells. As previously discussed, the MAPK 
signalling cascade may be stimulated by endogenous growth factors, or through 
constitutive activation of MEK by mutated Ras or Raf.  
A recent immunohistochemistry study identified expression of pERK in 12/39 (31%) 
angiosarcomas[119]. However another immunohistochemistry study of benign and 
malignant vascular tumours suggested pERK was significantly lower in malignant 
endothelial lesions[200]. There was also evidence to support the study of MEK 
inhibitors from pre-clinical studies of other malignant vascular tumours, specifically 
Kaposi’s sarcoma. Kaposi’s sarcoma lesions develop as a consequence of lymphatic 
endothelial cell infection with human herpes virus-8 (HHV-8). Viral interleukin-6 (vIL-6) 
and viral G protein coupled receptor (vGCPR) stimulate the MAPK signalling cascade, 
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and increase the secretion of pro-angiogenic growth factors, including Ang-2, reduced 
in vitro by MEK inhibition[201].  
Consistent with the protein expression studies, the MEK inhibitor selumetinib inhibited 
both ASM cell viability and tubule formation. ISO-HAS response to selumetinib was 
seen in cell differentiation assays, but not in cell viability studies. The absence of an 
ISO-HAS response to MEK inhibition in the cell viability assays suggest the 
Raf/MEK/ERK pathway did not drive proliferation in these cells. Alternatively, as drug 
response was assessed at 6 hours in cell differentiation assays compared to 120 hours 
in cell viability assays, the difference in drug response could be due to adaptive 
changes in cell signalling pathways. A study of MEK inhibition in a panel of different cell 
lines, including non small cell lung cancer and melanoma cell lines, showed cell 
sensitivity to MEK inhibitiors required the presence of mutated Ras or Raf. In cell lines 
with wild type Ras or Raf, MEK inhibitors were associated with loss of pERK mediated 
feedback loops and consequently drug resistance[202]. A separate study of MEK 
inhibition showed drug efficacy was dependent upon the mutation status of the PI3K 
pathway[203], suggesting compensatory signalling through the PI3K/Akt/mTOR 
pathway may have limited the effects of MEK inhibition in ISO-HAS cells. Drug studies 
to assess ASM and ISO-HAS cell response to combination therapy with MEK inhibitor 
and Akt or mTOR inhibitor were not performed. No response was observed however to 
single agent MK2206, an Akt inhibitor, in ISO-HAS or ASM cell viability studies. If 
resources had permitted, studies to investigate changes in the phosphorylation status 
of key kinases in the PI3K/Akt/mTOR and Raf/MEK/ERK pathways in response to MEK 
inhibition would have been of interest.  
4.3.5 Checkpoint II inhibition 
Phosphorylated ChkIIT68 and p53S15 were significantly elevated in ASM and ISO-HAS 
cells relative to HuDMECs. ChkII may be required to manage genomic instability, and 
both ChkII and p53 are activated by at these phosphorylation sites by ATM in response 
to DNA double strand breaks[204]. Phosphorylated ChkII induces cell cycle arrest, 
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promotes DNA repair and activates apoptosis[204]. The clinical utility of ChkII inhibitors 
is uncertain. It has been postulated that, in combination with anti-cancer therapies that 
induce double strand DNA breaks, including radiotherapy and chemotherapy agents 
such as topoisomerase inhibitors, ChkII inhibitors may be of benefit to patients with 
concurrent DNA repair pathway abnormalities[204]. However, the main effect of ChkII 
activation may be to induce apoptosis in response to DNA damage. Therefore, the 
clinical potential of ChkII inhibitors may reside in protecting normal tissue with 
functioning DNA repair pathways from undergoing apoptosis in response to exposure 
to radiotherapy. 
ASM and ISO-HAS cell response to ChkII inhibition was investigated in monotherapy 
studies and in combination with the topoisomerase II inhibitor doxorubicin. C3742 
(ChkII inhibitor II) was selected for study as it is specific for ChkII, whilst other ChkII 
inhibitors identified also inhibit ChkI, required for the repair of  single strand DNA 
breaks. The results from the cell viability assays demonstrated no benefit of ChkII 
inhibition at the doses studied, and in ISO-HAS cells C3742 showed a protective effect, 
potentially through inhibition of pro-apoptotic signals.  
4.3.6 DMXAA 
DMXAA is a flavonic acid derivative vascular disrupting agent that reduces tumour 
blood flow and induces tumour necrosis. A recent phase III trial of DMXAA in 
combination with carboplatin-paclitaxel chemotherapy for advanced non small cell lung 
cancer showed no improvement in progression free survival compared to 
chemotherapy alone, although DMXAA was well tolerated[178]. 
DMXAA’s anti-tumour properties are not fully understood. Within 30 minutes of 
administration in vivo, DMXAA induces apoptosis of tumour endothelial cells leading to 
reduction in tumour blood flow[205]. Endothelial cell death exposes the underlying 
basement membrane, inducing platelet activation, and leading to a localised increase 
in 5-HIAA (5-hydroxyindole-3-acetic acid), resulting in vascular constriction, and thus 
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tumour hypoxia and necrosis[206]. Within 4 hours of administration, through activation 
of nuclear factor kappa B (NF-B), DMXAA induces tumour production of a number of 
cytokines including TNFα, interferon-γ (IFNγ) and IFNγ-inducible protein-10 (IP-
10)[206]. Systemic administration of TNFα is highly toxic, but localised administration 
by isolated limb perfusion, in combination with melphalan chemotherapy, is used in the 
treatment of soft tissue sarcoma of the distal extremities[207]. TNFα appears important 
for mediating the response to DMXAA in vivo, with treatment less effective in TNF 
receptor-1 knockout mice[208]. In contrast to mouse tumour models, evidence from 
phase I clinical studies suggested minimal TNFα production in human tumours, 
potentially explaining the subsequent lack of efficacy seen in the phase III NSCLC 
trial[179]. However, the phase I clinical studies measured TNFα in plasma rather than 
assessment of intratumoural levels, and thus may have missed any focal TNFα 
expression. In any case, production of TNFα may not be necessary for tumour 
response. Thalidomide inhibits the synthesis of TNFα but, intriguingly, studies of 
DMXAA in combination with thalidomide showed an increased anti-tumour response, 
despite evidence of modulated TNFα expression[209]. 
At clinically relevant doses DMXAA profoundly inhibited ASM, ISO-HAS and HuDMEC 
cell viability and tubule formation. The mechanisms by which DMXAA exerted its effect 
were unclear. ELISA studies showed no significant increase in TNFα expression in 
ASM cells after 4 and 24 hours of exposure to DMXAA 100µg/ml. Assays to measure 
AnnexinV showed no increase in apoptotic ASM cells after exposure to 100µg/ml 
DMXAA for up to 24 hours. Previously reported in vitro studies with HUVECs showed a 
modest reduction in cell viability 24 hours after treatment with 100µg/ml DMXAA, with 
an estimated IC50 of 300µg/ml[210]. Compared to untreated HUVEC cells, apoptosis 
was not significantly increased at 100µg/ml DMXAA, but was increased at doses 
beyond 300µg/ml[210]. Other in vitro studies with mouse endothelial cells (HECCP) 
showed apoptosis was induced after 3 hours of exposure to 400µg/ml DMXAA, and 
increased substantially after exposure for 24 hours[211]. No significant increase in 
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HECCP cell apoptosis was observed after 24 hours of exposure to 100µg/ml DMXAA, 
and a dose of 500µg/ml DMXAA was required to induce apoptosis in 50% of cells at 24 
hours. These studies illustrate differences seen between the effects of DMXAA on 
endothelial cells in vitro with tumour response in vivo.  
Overall, the results from studies with ASM cells suggested the method by which 
DMXAA exerted its effect did not involve TNFα expression or induction of apoptosis. 
Interestingly, a recent report proposed DMXAA as a multi-kinase inhibitor including, 
and most prominently, an inhibitor of VEGFR2[212]. VEGFR2 phosphorylation status 
was not studied in ASM, ISO-HAS or HuDMEC cells in response to treatment with 
DMXAA. The western blot studies previously described however demonstrated basal 
VEGFR2 phosphorylation levels in these cells were low or absent, suggesting VEGFR2 
inhibition as an unlikely mechanism of response. Tubule formation was significantly 
inhibited in assays with ASM, ISO-HAS and HuDMEC cells, but these responses could 
have been mediated through a direct cytotoxic effect, rather than through a response 
involving the inhibition of VEGFRs. DMXAA inhibits a number of other kinases 
including the aurora kinases. As previously described, axitinib inhibits aurora B kinase 
at doses that reduced ASM and ISO-HAS cell viability in the extended dose studies, 
suggesting a common mechanism requiring further study. 
 
In summary the in vitro drug studies show targeting ASM or ISO-HAS cells with 
inhibitors of a single pro-angiogenic growth factor such as VEGF was less efficacious 
than either targeting a common signalling intermediary such as MEK, or using less 
directed therapy such as the vascular disrupting agent DMXAA, or the 
chemotherapeutic agents doxorubicin or paclitaxel. Ideally, additional in vitro studies 
would investigate response to MEK inhibitiors or vascular disrupting agents in a wider 
panel of angiosarcoma samples, and subsequently investigate drug response within an 
in vivo system. However, angiosarcomas are rare, and suitable material for further 
study is limited. In vivo studies are needed to fully evaluate angiosarcoma response to 
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anti-angiogenic agents, as their target may be the tumour micro-environment rather 
than the tumour cells. ASM and ISO-HAS cells did not form tumours in vivo, and there 
are currently no animal models for angiosarcoma. 
4.4 Human Angiosarcoma Tumour Samples 
Fresh angiosarcoma tumour samples were collected intra-operatively following the 
patient’s consent. After resection the tumour was transported on ice for immediate 
sampling by the collaborating histopathologist. Multiple biopsies were taken under 
macroscopic inspection of the tumour to identify suitable lesional tissue. The presence 
of viable, neoplastic cells within the study samples was inferred, and the precise 
architecture of the samples used in the protein array study and for tumour cell isolation 
was unknown. In addition to fresh angiosarcoma tumour samples, historical samples 
were retrieved from the pathology archives of Sheffield Teaching Hospitals NHS Trust 
for immunohistochemistry study. 
4.4.1 Tumour cell isolates 
Fresh angiosarcoma tumour samples were collected in order to isolate and study 
tumour cells in vitro. As angiosarcomas are rare the opportunity to collect samples 
occurred sporadically, which hampered any systematic study. Cell isolates were 
successfully established in two of four cases (STS0510 and STS1011), although 
immunocytochemistry study suggested these cell isolates were not of endothelial 
origin. Drug studies with VEGF targeted agents were performed using cell isolates from 
one case (STS1011). Results were consistent with the studies of ASM and ISO-HAS 
cells, demonstrating the feasibility of this approach. Paclitaxel profoundly reduced 
STS1011 cell viability. A modest response was observed to axitinib in cell viability and 
cell differentiation assays, but no response was seen to bevacizumab. The window for 
performing in vitro studies with the tumour isolates was short as the characteristics of 
the cell isolates evolved rapidly during culture. Few tubules were formed by passage 7 
cells, in contrast to earlier passages, and passage 7 cells were also drug resistant. 
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4.4.2 Angiogenesis related protein array study of tumour samples 
The expression profiles of angiogenesis related proteins derived from the human 
angiosarcoma tumour samples were broadly consistent with ASM and ISO-HAS 
expression profiles, supporting the study of these cell lines as an in vitro model of 
angiosarcoma. Differences, such as higher expression of matrix metalloproteinases 
(MMP-8 and MMP-9) by tumour tissue samples may reflect analysis of more complex 
samples. The immunohistochemistry studies of angiosarcoma tumour samples, and the 
protein expression studies of ASM and ISO-HAS, showed high expression of VEGF by 
malignant endothelial cells. The angiogenesis related protein array study of 
angiosarcoma tumour samples however showed low tumour expression of VEGF. An 
mRNA analysis of angiosarcoma samples also reported low tumour expression of 
VEGF[72]. The quantitative differences in expression likely reflect differences in 
methodology. Tumour architecture was not assessed by array studies, in contrast to 
immunohistochemistry, which quantifies both intensity and location of protein 
expression. 
The expression profiles of the two de-differentiated liposarcomas were distinct from the 
angiosarcoma samples, with lower levels of expression of angiogenesis related 
proteins by the liposarcomas compared to the angiosarcomas. The expression of 
proteins such as angiogenin and TIMP-4 were similar across all samples. This finding 
may be genuine, but probably illustrates the semi-quantitative nature of these arrays 
and suggests the use of sensitive but not specific primary antibodies to detect these 
proteins. Macroscopically, in contrast to the angiosarcoma tumour samples, the 
lipoosarcoma specimens appeared gelatinous and were relatively avascular. The 
differences in protein expression may therefore reflect the proportion of endothelial 
cells in the samples. It would be of interest to compare angiogenesis related protein 
expression profiles of benign vascular tumours, including capillary haemangiomas and 
pyogenic granulomas, with angiosarcomas. The subsequent immunohistochemistry 
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studies of benign and malignant vascular tumours would predict however that any 
differences would be small.  
4.4.3 Immunohistochemistry studies 
Immunohistochemistry studies were performed to compare benign and malignant 
vascular tumour expression of angiogenic growth factors and their receptors. Two 
haemangioendotheliomas were included in the group of malignant vascular tumours. 
Haemangioendotheliomas are rare vascular tumours of intermediate malignant 
potential, with a low risk of metastasis compared to angiosarcomas[180]. Capillary and 
cavernous haemangiomas were included as examples of benign quiescent vascular 
tumours, and pyogenic granulomas and granulation tissue were included as examples 
of benign inflammatory lesions[181]. 
Results from the immunohistochemistry studies of angiosarcoma tumour samples were 
biased by a strong correlation between the immunohistochemistry score and the age of 
the tumour block, with staining intensity reduced or absent in older specimens. On 
average two or three patients with angiosarcoma presented annually to Sheffield 
Teaching Hospitals, and therefore to collect the cohort size used in these studies it was 
necessary to use tissue blocks from a ten year period. The age of the benign vascular 
tumour blocks was not matched with the age of the malignant vascular tumour blocks, 
but this should be considered for future studies.     
4.4.3.1 VEGF and VEGFRs 
The expression of VEGF and its receptors in angiosarcomas and haemangiomas has 
been reported previously in several immunohistochemistry studies. Tokuyama et al 
identified increased expression of VEGF and VEGFR2 in angiosarcomas compared to 
capillary and cavernous haemangiomas[213]. A comparison of VEGF expression by 
Dim et al also suggested VEGF expression was increased in angiosarcomas compared 
to haemangiomas[142]. However, cytoplasmic VEGF staining only was scored in this 
study. The tumour endothelial cells of benign vascular lesions have a compact nucleus 
 190 
 
with a thin rim of cytoplasm, compared to the tumour endothelial cells of angiosarcoma 
which demonstrate prominent cytoplasm, and this difference may have biased their 
results. Zietz et al also demonstrated increased expression of VEGF in angiosarcomas 
compared to benign controls[144]. The controls used covered a range of conditions 
including normal skin, an angiofibroma, a lymphangioma and granulation tissue. 
Notably the two haemangioma cases included in this series scored moderate and 
strong expression of VEGF. In contrast, a small study by Brown et al found strong 
expression of VEGFR2 by angiosarcoma tumour cells, but weak expression of 
VEGFR1 and VEGF, whilst capillary haemangiomas showed strong expression of 
VEGFR2 and R1, and weak expression of VEGF[214]. Results from a large study by 
Itakura et al were comparable with the results presented here[145]. Staining intensity 
was not assessed by Itakura et al, but the proportion of cells staining positive was 
measured. In these studies VEGFA was expressed by the majority of tumour cells but 
VEGFR1 and VEGFR2 expression varied. In summary, whilst a variety of sources have 
demonstrated angiosarcomas express VEGF and their receptors, the quantity of the 
expression relative to benign vascular tumours is unproven.  
4.4.3.2 Neuropilins 
Neuropilins are transmembrane non-tyrosine kinase co-receptors first shown to bind 
class 3 semaphorins (Sema-3) to regulate neuronal development during 
embryogenesis[215]. Neuropilins are required for normal development of the 
vasculature, and are expressed by endothelial cells during physiological angiogenesis 
including wound healing. They are expressed by both endothelial cells of the tumour 
vasculature and by neoplastic cells, and increased expression is associated with 
tumour progression and a worse prognosis.  As co-receptors they complex with 
VEGFR2 and facilitate signal transduction on binding with VEGF to promote 
angiogenesis. Neuropilins do not induce phosphorylation of ERK, but through activation 
of focal adhesion kinase (FAK) they stimulate endothelial cell migration[10]. Neuropilins 
have been identified as a mechanism of resistance to VEGF targeted therapy as the 
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neuropilin binding site on VEGF, encoded by exons 7 and 8, is distal to VEGFR and 
bevacizumab binding sites. Furthermore, neuropilins have been reported to bind a wide 
range of pro-angiogenic growth factors that includes FGF, PDGF, HGF and TGF-
β[216]. Neuropilin expression in vascular tumours has not been previously studied. The 
immunohistochemistry studies reported here demonstrated expression of NRP1 in both 
benign and malignant vascular tumours. Pre-clinical studies have shown NRP1 
blocking antibody enhanced the efficacy of VEGF targeted therapy[217], suggesting a 
potential drug combination to study for the treatment of angiosarcoma. 
4.4.3.3 bFGF and FGFR1 
Angiosarcoma expression of aFGF and bFGF were suggested by protein array studies 
of ASM, ISO-HAS and the five fresh angiosarcoma tumour samples. The 
immunohistochemistry studies however showed bFGF expression was significantly 
lower in angiosarcomas than in either benign tumour group, although the expression of 
its receptor FGFR1 was similar. Angiosarcoma expression of bFGF and FGFR was 
previously reported in an immunohistochemistry study of 7 cutaneous angiosarcomas, 
but this study did not include a comparison group[150]. aFGF and bFGF promote 
angiogenesis, and increase the expression of other pro-angiogenic growth factors 
including VEGF and Ang-2[24]. Furthermore, bFGF signalling can stimulate 
angiogenesis despite effective VEGFR inhibition[218], indicating a resistance 
mechanism to VEGF targeted therapy. Axitinib inhibits FGFR1 phosphorylation, with an 
IC50 of 215nmol/l (i.e. 83ng/ml)[41]. Minor responses were seen to axitinib at doses up 
to 250ng/ml in functional assays of ASM and ISO-HAS cells, suggesting co-inhibition of 
VEGF and FGF signalling was not beneficial. The efficacy of agents specifically 
targeting FGF however was not separately studied. 
4.4.3.4 Angiopoietins 
Endothelial cell response to angiopoietins is context dependent[14]. Through the Tie2 
receptor, Ang-1 promotes endothelial cell survival and vessel integrity. Ang-2 is an 
Ang-1 antagonist that promotes vessel destabilisation. In the presence of VEGF, this 
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promotes endothelial cell proliferation, but in the absence of VEGF induces vessel 
regression. Antibodies specifically targeting Ang-2 have been shown to inhibit 
angiogenesis in pre-clinical models, and an antibody (AMG-386) was recently tested in 
a phase I trial[219]. Ang-2 expression is elevated relative to Ang-1 in the tumour 
vasculature of other malignancies[17]. Data on the expression of angiopoietins in 
angiosarcoma however is sparse. Given the functional response to Ang-2 in the 
presence of VEGF, Ang-2 expression was predicted to be high in angiosarcomas. Ang-
2 expression was observed in both malignant and benign vascular tumours, with 
highest expression in inflammatory vascular lesions, and lowest expression in 
haemangiomas. The expression of Ang-1 was difficult to characterise as the 
extracellular matrix stained heavily with Ang-1 antibody. Tie2 staining in contrast was 
highly specific for endothelial cells. Ang-1 stained slides were therefore examined in 
parallel with Tie2 stained slides to assist the quantification of Ang-1 staining of 
endothelial cells. The endothelial cells lining the dilated vascular spaces of 
haemangiomas were flattened, with only a thin rim of cytoplasm visible. Therefore, in 
the majority of haemangioma samples it was not possible to reliably distinguish 
endothelial staining for Ang-1, from staining of neighbouring pericytes or the 
extracellular matrix. Ang-1 staining was therefore not scored in this tumour group. 
Angiosarcoma and inflammatory vascular tumour expression of Ang-1 were similar. 
High Ang-2 serum levels have been reported in patients with metastatic angiosarcoma 
compared with localised disease[220]. In two cases of angiosarcoma Brown et al 
reported high expression of Tie2 and Ang-2, and low expression of Ang-1[221]. It was 
not possible to directly infer an Ang-2:Ang-1 expression ratio from the 
immunohistochemistry and protein array studies presented here. In hypoxia however, 
the Ang-2:Ang-1 expression ration increased in ASM and ISO-HAS cells compared to 
cells in normoxia.  In both normoxic and hypoxic conditions Ang-2 expression was 
lower in ASM and ISO-HAS cells than in HuDMECs. Consistent with this, a previous 
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report identified higher Ang-2 expression in HuDMECs than ISO-HAS cells, with Ang-1 
mRNA undetectable in either[220]. 
4.4.3.5  HGF and MET 
Through the receptor tyrosine kinase MET, HGF promotes cell proliferation, migration 
and invasion, and protects cells from apoptosis[222]. Hypoxia increases MET 
transcription, and it has therefore been postulated that increased tumour hypoxia, as a 
consequence of anti-angiogenic therapy, promotes MET signalling and thus increases 
tumour invasion and metastasis[223]. HGF expression in angiosarcoma has not been 
previously studied. HGF expression was increased in ASM and ISO-HAS cells 
compared to HuDMECs, in both normoxia and hypoxia. HGF expression was 
significantly elevated in the inflammatory vascular lesions compared with the 
haemangioma group. However, whilst HGF expression correlated with MET 
expression, HGF expression was not significantly increased in angiosarcomas. MET 
inhibitors are in clinical development, including agents that inhibit binding of HGF to 
MET, and small molecule tyrosine kinase inhibitors[224] including crizotinib, a dual 
inhibitor of MET and ALK, which demonstrated response in non-small cell lung cancer 
patients harbouring the echinoderm microtubule associated protein-like 4 - anaplastic 
lymphoma kinase fusion oncogene (EML4-ALK)[225], and several compounds such as 
foretinib which inhibits both MET and VEGFRs[226].   
 
In summary, and consistent with data obtained from the protein array studies, the 
immunohistochemistry analysis demonstrated angiosarcomas express a range of 
angiogenic growth factors and their receptors. This supports the conclusions drawn 
from the in vitro studies that targeting a single pro-angiogenic growth factor in the 
treatment of angiosarcoma would be less effective than targeting central signalling 
processes such as the MAPK pathway. This analysis identified other targets for future 
study to combine with inhibitors of VEGF, including NRP1 and HGF/MET.      
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4.5 Canine Angiosarcomas 
As with their human counterpart, canine angiosarcomas are aggressive, locally 
invasive tumours of proliferating malignant endothelial cells. In contrast to human 
angiosarcomas however, canine angiosarcomas are common, accounting for 10% of 
all canine malignancies[167]. Angiosarcomas are more frequent in certain breeds (e.g. 
German Shepherds, Boxers and Golden Retrievers) indicating a genetic 
predisposition[227]. A viral aetiology has been postulated, though not been 
demonstrated[167]. Canine angiosarcomas frequently develop in the skin or soft tissue, 
though most commonly arise in the spleen. Response to anthracycline based 
chemotherapy has been reported but, as with human angiosarcomas, the overall 
prognosis is poor[228].    
Similar to the immunohistochemistry results presented here, other studies have shown 
that canine angiosarcomas express increased VEGF and VEGFR2 compared to 
haemangiomas, and also express increased VEGFR1 and bFGF[229]. These findings 
contrast with those from the immunohistochemistry analysis of the human vascular 
tumours. Of note however, both the benign and malignant canine tumour blocks were 
collected over a similar period, with no relationship seen between the age of the tumour 
block and the staining intensity.  
Canine sarcomas have been studied elsewhere as a model of human sarcomas, 
including a clinical study in dogs of mifamurtide for the treatment of osteosarcoma[230]. 
The clinical and pathological features of canine angiosarcoma suggest it represents a 
model with which to study the human disease.  
4.6 Future Work 
The role of Notch signalling in the pathogenesis of angiosarcoma was not studied. 
Studies have shown inhibition of Notch1 in mouse models leads to the formation of 
vascular tumours, including hepatic angiosarcomas[152, 153], and the importance of 
Notch in branching morphogenesis and in regulating endothelial cell expression of 
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receptors such as VEGFR2 and NRP1[30], identifies an area worth further study. The 
R&D Systems protein arrays did not assess the expression of Notch, or any of its 
signalling counterparts, and Notch was also not included in the immunohistochemistry 
studies. Future studies could assess the expression of DLL-4, Notch1, and the 
negative regulator Jag-1 in vascular tumours by immunohistochemistry, and the ASM 
and ISO-HAS cell lines used to investigate the effects of modulating the Notch pathway 
in vitro.  
Through collaborations with the Animal Health Trust (Cambridge, UK) and the Van 
Andel Research Institute (VARI; Great Rapids, USA) canine angiosarcoma tumour 
samples have been obtained for future study. These samples include a large cohort of 
formalin fixed paraffin embedded tumour blocks of angiosarcoma and benign vascular 
lesions, and angiosarcoma tumour cell isolates for in vitro study.  An mRNA study is 
proposed to compare canine angiosarcoma expression of angiogenic proteins and their 
receptors with benign canine vascular lesions. The canine angiosarcoma tumour cell 
isolates will be characterised in vitro, and their response to vascular targeted agents, 
including the MEK inhibitor selumetinib and the vascular disrupting agent DMXAA, will 
be assessed in cell viability and cell differentiation assays. The data obtained from 
these studies will be compared to the findings reported here from the study of human 
angiosarcoma samples. These studies will be supported by a grant from SarcomaUK.  
It is expected that further in vitro studies will lead to the selection of a vascular targeted 
agent for a clinical trial in angiosarcoma. As angiosarcomas are rare in humans, a 
clinical trial would require national or international collaborations. The pre-clinical data 
presented here would suggest the study of a vascular disrupting agent such as 
DMXAA. Tumour response to DMXAA monotherapy could be assessed in a single arm 
phase II trial. The clinical development of DMXAA has halted however, as a 
consequence of the disappointing results observed in the phase III trials of DMXAA in 
combination with chemotherapy for advanced NSCLC. Other vascular disrupting 
agents in clinical development that could be trialled include combretastatin (CA-4-P). 
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The mechanism of action of CA-4-P is distinct from DMXAA. CA-4-P targets the 
cytoskeleton of tumour endothelial cells, causing collapse of the tumour vasculature 
and tumour necrosis[231]. Pre-clinical studies are necessary to indicate CA-4-P activity 
against the malignant endothelial cells of angiosarcoma. In vitro studies however may 
not inform tumour response, as CA-4-P does not directly induce endothelial cell death. 
The study of angiosarcoma response to CA-4-P may therefore require an in vivo 
model. Currently there are no established in vivo models for angiosarcoma. The canine 
angiosarcoma tumour cell isolates obtained from VARI form tumour xenografts with 
histological features consistent with angiosarcoma (unpublished data from VARI). 
These tumour cell isolates may therefore be used to study angiosarcoma response to 
vascular targeted agents in vivo.  
A clinical trial of vascular targeted agents could also be considered in dogs presenting 
with angiosarcoma. This would provide a unique opportunity for the study of 
angiosarcoma tumour response to vascular targeted agents, and could inform the 
selection of an agent for clinical trial in humans.   
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